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ABSTRACT
Infection with human immunodeficiency type 1 (HIV-1) is associated with a
slow irreversible impairment of the immune system eventually leading to AIDS.
Many studies have been carried out to elucidate the infection mechanisms and
pathogenicity of HIV-1 although a number of questions still remain. This study was
carried out to investigate the relationship between HIV-1 populations infecting
different tissues to determine when infection to non-lymphoid tissue occurs during
the course of infection.
The time of spread of HIV-1 to non-lymphoid tissue was investigated by
sequence comparisons of variants infecting a range of tissues from three individuals
with AIDS in the pl7gag gene, and flanking regions of V1/V2. In both regions,
phylogenetic analysis revealed several lineages in each individual that contained
sequences from lymphoid and non-lymphoid tissue, such as brain. This observation
contrasted strongly with the previously described organ-specific sequences in the
V3 region in this study population and in other investigations.
By estimating mean synonymous pairwise distances in the pl7gag region, it
was possible to calculate the time of divergence of variants infecting lymphoid and
non-lymphoid tissues. In lymphoid tissue the mean diversity of gag sequences
implied an approximate population age of 2.65 to 5.6 years, while those infecting
brain were significantly more variable, suggesting an even earlier time of
diversification (4.1 to 6.2 years). In two of the three individuals, these times of
divergence indicate that infection of the brain may have occurred as an early event
in the progression of the disease, preceding the onset of AIDS by several years.
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This is the first report in which it has been possible to estimate times of
diversification in different tissues in vivo and is of importance in understanding the
dynamics of the spread of HIV-1 into non-lymphoid tissue, and its possible
adaptation for replication in different cell types.
Phenotypic variation between different isolates of HIV-1, such as
macrophage tropism and syncytium induction have been mapped to specific regions
in the env gene, including the V3 and V1/V2 hypervariable regions. In this study I
have analysed variability in the VI and V2 regions of HIV-1 proviral sequences
amplified from lymphoid tissue, brain and other non-lymphoid tissue collected at
autopsy from three HIV-infected individuals with giant cell encephalitis. As
previously found by analysing pl7gag region I found no evidence for any tissue-
specific grouping of variants in the V1/V2 regions. Furthermore, I found no
correlation of charge, length or number of glycosylation sites with tissue origin, or
inferred phenotype.
Length polymorphism analysis is a rapid method to compare whole
populations of HIV-1 variants within a sample, and provides information on the
length and diversity of the VI and V2 hypervariable regions. Based upon a
comparison of 42 individuals with CD4 counts ranging from 802 to <1, at time of
death, I found no evidence for changes in the length of V2. Using the number of
length variants in the VI and V2 hypervariable region as a measure of the overall
degree of variability within HIV populations, I found no evidence for an increase
or a decrease in diversity between those with or without AIDS defining illness.
In summary, both analysis of the pl7gag and V1/V2 regions revealed high
levels of heterogeneity of HIV-1 in tissue such as brain producing multiple lineages
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upon phylogenetic analysis. I have therefore found no evidence for specifically
neurotropic variants of HIV-1 and question the idea that spread into the central
nervous system (CNS) or other non-lymphoid tissues requires specific adaptation.
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CHAPTER 1. INTRODUCTION: HUMAN IMMUNODEFICIENCY TYPE 1
(HIV-1).
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1.1 CLINICAL ASPECTS OF HIV-1 INFECTION.
1.1.1 IDENTIFICATION AND ISOLATION OF HIV-1.
Infection with the human immunodeficiency virus type-1 (HIV-1) is
associated with a slow, progressive and irreversible impairment of the immune
system eventually leading to severe immunodeficiency clinically known as AIDS. It
is now universally accepted that HIV-1 is the main aetiological agent of the
acquired immune deficiency syndrome (AIDS). Studies to determine how widely
disseminated the virus was eventually led to the discovery of a second related
virus, HIV-2, which was found to be capable of inducing the same clinical
symptoms in humans as HIV-1 (Clavel et al., 1986; Barin et al., 1985).
Approximately 15 years ago, Gottlieb and colleagues reported an unusually high
number of young homosexual males presenting with Pneumocystis carinii
pneumonia and other unusual opportunistic infections (Gottlieb et al., 1981).
Following this report a succession of observations involving young male
homosexuals presenting with unusual opportunistic infections and immune
deficiencies were reported (Stahl et al., 1982; Friedman Kien et al., 1982; Klein et
al., 1984; Metroka et al., 1983; Mildvan et al., 1982; Siegal et al., 1981; Drew et
al., 1981; Masur et al., 1981). Thus far, this new illness was considered by most to
be a 'gay' disease. In 1981 this issue was further confused when an increasing
number of Haitian immigrants to the United States were reported to have died with
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toxoplasmosis and cytomegalovirus in their brains (Moskowitz et al., 1983) and
was further compounded by the appearance of cases in women. The juxtaposition
of these various reports proved to be fortuitous as events following these
observations led to the conclusion that a single infectious agent was responsible for
this epidemic of immune deficiency.
Isolation of this infectious agent was finally accomplished in 1983 when the
virus was cultured in T lymphocytes, from a lymph node biopsy of a homosexual
patient with multiple lymphadenopathies (Barre-Sinoussi et al., 1983). It was
suggested that this novel virus was a member of the human T-cell leukaemia virus
(HTLV) family. Serum from this patient strongly reacted with surface antigens of
HTLV-1 and the divalent cationic requirements of the viral reverse transcriptase
(RT) were similar to that for HTLVs. However, it was thought to be a distinct
virus since core proteins of this novel virus were immunologically unrelated to
those of HTLV-1 (Barre-Sinoussi et al., 1983). This virus was further identified as
a retrovirus using a sucrose density gradient and electron microscopy illustrating
particles budding from the surface of umbilical cord lymphocytes characteristic of
retroviruses. This virus was therefore designated lymphadenopathy-associated virus
(LAV). An association of members of the HTLV family with patients with AIDS
was subsequently reported from numerous independent sources (Levy et al., 1984;
Essex et al., 1983; Gelman et al., 1983; Gallo et al., 1984). For some time there
was a certain degree of confusion regarding the nomenclature of this virus
implicated in AIDS. Initially there were three claims on the nomenclature: LAV
(Barre-Sinoussi et al., 1983), HTLV-III (Gallo et al., 1984) and AIDS related virus
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(ARV; Levy et al., 1984). However, it is now universally known as the human
immunodeficiency virus type-1 (HIV-1; Coffin et al., 1986b).
1.1.2 CLASSIFICATION OF HIV-1 DISEASE STATUS.
Infection with HIV-1 can result in a spectrum of clinical conditions, ranging
from asymptomatic infection to severe immunodeficiency and the acquisition of
numerous opportunistic infections and neoplasms. The Centres for Disease Control
(CDC) have constructed a classification system which catalogues the manifestations
of HIV-1 into four clinical stages: Group I-IV (CDC, 1986; Table 1). CDC group I
identifies those patients who have recently undergone seroconversion, shortly
following initial infection, which may be accompanied by an acute seroconversion
illness, with clinical features such as a mononucleosis-like illness, fever and
malaise (Cooper et al., 1985). CDC group II includes asymptomatic patients
showing no signs or symptoms of HIV-1 infection. This asymptomatic period can
last from a few months to a number of years before any signs of clinical disease
are apparent. Patients presenting with persistent generalized lymphadenopathy are
classified as CDC group III. CDC group IV describes a number of clinical
manifestations and has been subdivided into five subgroups A to E. Subgroup A
(constitutional disease) includes individuals with one or more of the following
afflictions: fever (> 1 month), diarrhoea (> 1 month) and/or involuntary weight loss
(> 10% of baseline). Infection must be unattributable to any infection other than
HIV infection. Subgroup B (neurological disease) includes individuals suffering
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TABLE 1: CLASSIFICATION SYSTEM FOR HIV INFECTION
CDC group Clinical manifestation
Group I Acute infection
Group II Asymptomatic infection
Group III Persistent generalized
lymphadenopathy
Group IV Other diseases
Subgroup A Constitutional disease
Subgroup B Neurological disease
Subgroup C Secondary infectious diseases
Category C-l Specified secondary infectious
diseases listed in the CDC
surveillance definition for
AIDS3
Category C-2 Other specified secondary
infectious diseasesb
Subgroup D Secondary cancers0





from one or more of the following neurological diseases: dementia, myelopathy or
peripheral neuropathy. Infection must solely be due to invasion of the nervous
system by HIV and not attributable to any other illness or condition. Subgroup C is
divided into two categories (CI and C2) and includes individuals with clinical
disease associated with secondary infectious diseases and a defect in cell-mediated
immunity. Subgroup D is associated with the development of secondary cancers
and a defect in cell mediated immunity. Subgroup E includes other clinical
disorders, previously unclassified, which may be attributable to HIV infection. The
CDC produced a revised classification system that extended the diagnosis of AIDS
to asymptomatic individuals with CD4+ T-cell counts of < 200 cells///!. Similarly,
the number of previously defined clinical categories, group IV, has been expanded
to include further clinical conditions (CDC. 1992).
1.1.3 NATURAL HISTORY OF HIV-1 INFECTION.
The natural history of HIV-1 infection can be viewed as a progression of
three distinct clinical stages: an initial acute stage associated with primary infection
(CDC stage I), a chronic stage resulting in a period of clinical, but not virological,
latency (CDC stages II and III) and finally, a crisis stage representing a period of
profound immunodeficiency manifest by the development of opportunistic
infections and neurological disorders (CDC stage IV; Fig 1).
During primary infection, plasma HIV-1 titres increase dramatically
manifested by high levels of viraemia and serum p24 antigen (Simmonds, 1990a;
24











































Fiscus et al., 1995a; Ferbas et al., 1996a; Clark et al, 1991a; Daar et al., 1991a).
This plasma viraemia is only transient (up to 103 to 104 tissue culture infective
doses (TCID) per ml have been detected in plasma; Clark et al., 1991; Daar et al.,
1991), and generally only lasts for a few weeks subsiding when a specific antibody
response is mounted. However, a cellular cytotoxic immune response almost
certainly contributes to the initial containment of primary HIV-1 infection. The
immune mechanisms responsible for this viral clearance are discussed in detail
below. In addition, the acute stage of infection may coincide with an acute
seroconversion illness characterized by fever, rash and myalgia (Clark et al., 1991;
Daar et al., 1991). CD4 cell counts fall dramatically during this stage of infection,
although it is not clear whether this is a result of a cytopathic effect by HIV-1 or
redistribution to extravascular sites (Fahey et al., 1990; Bofill et al., 1996; Ferbas
et al., 1996). Following the curtailment of acute primary infection a chronic,
clinically asymptomatic stage ensues. This is often termed the latent period and
although clinically latent recent studies have revealed HIV-1 infection as a dynamic
process in which a stable steady state hides a very high rate of viral replication and
turnover of infected cells (Wei et al., 1995; Ho et al., 1995; Ho et al., 1989;
Coombs et al., 1989; Saag et al., 1991; Michael et al., 1992). Similarly, a number
of studies have reported active replication of HIV-1 in lymphoid tissue (Pantaleo et
al., 1991; Graziosi et al., 1993; Pantaleo et al., 1993). During this chronic stage of
persistent infection only low levels of plasma viraemia can be detected (30 TCID5Q
per ml; Ho et al., 1989) and few infected CD4+ cells are present in the peripheral
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blood (1 in 10,000; Harper et al., 1986). As disease progresses the development of
clinical immunodeficiency follows the reappearance of significant levels of plasma
viraemia and an increase in the expression of HIV-1 DNA and RNA (Michael et
al., 1992), which is associated with an accelerated depletion of CD4+ cells
(MacDonell et al., 1990; Ho et al., 1989; Coombs et al., 1989; Saag et al., 1991;
Ferbas et al., 1996). As the number of CD4+ cells decreases so the percentage of
infected lymphocytes increases. Indeed, in one study of patients with clinical AIDS
the number of infected lymphocytes was found to exceed 1 in 40 (Ho et al., 1989).
Similarly, a number of studies have shown that the number of CD4+ cells
decreases as the plasma viraemia increases and may exceed 104 TCID50 per ml
(Coombs et al., 1989; Ho et al., 1989; Saag et al., 1991). Saag et al., also studied
the clinical course of infection in children infected perinatally with HIV-1 and
found that they frequently exhibited significantly high plasma levels and
accelerated disease irrespective of CD4+ cell counts (Coombs et al., 1989). This is
most likely due to the immature nature of these childrens' immune response failing
to control the initial viraemia.
The rapid decline in viraemia after primary infection suggests a potent
antiviral role for the host immunity. A number of studies suggest that HIV-1
specific cytotoxic T lymphocytes (CTL) may play an important role in the
clearance of acute infection (Rouse et al., 1988; Plata et al., 1987; Walker et al.,
1987). Following HIV-1 infection CTL precursors (CTLp) are produced in regional
lymph nodes followed by the accumulation of virus specific CD8+ CTL at sites of
virus replication. This CTL activity reaches a peak shortly after viral replication,
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and in some cases prior to a specific antibody response (Koup et al., 1994; Walker
et al., 1986; Walker et al, 1990). Koup et al., detected CTLp specific for cells
expressing HIV-1 gag, pol and env antigens within three weeks of infection and
found that they remained elevated for at least three to six months following acute
viral infection (Koup et al., 1994). The CTL response is the first virus specific
immune response detected suggesting CTL activity is responsible for viral
clearance and predict the consequences of the acute stage of infection. Neutralizing
antibodies are undetectable until several weeks after viraemia has subsided. It is
possible that CTL are not the only mechanism involved in the clearance of acute
viraemia during primary HIV-1 infection. Natural killer (NK) cells are also likely
to play a role although they have not been studied in detail. However, they are
important in the clearance of other acute viral infections such as acute infectious
mononucleosis (Tomkinson et al., 1989; Nahill et al., 1993), and transient
elevations in their numbers have been observed in acute HIV-1 infection (Koup et
al., 1994).
Following seroconversion, approximately four weeks after infection,
antibodies to different structural components of HIV-1 can be detected by enzyme
immunoassays (EIA). These do not appear simultaneously and antibodies to the
envelope glycoprotein, gpl20, are the first to be detected. Subsequently, antibodies
to the regulatory proteins, p24 from gag and p53 and p64 from pol, are produced.
Antibodies to the transmembrane glycoprotein, gp41, are often not detected until
several weeks later. Although detection of antibodies to HIV-1 structural and
regulatory proteins are indicative of infection, their role as an antiviral component
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of the immune system is less certain. The presence of anti-HIV-1 neutralizing
antibodies in infected individuals has been reported by several investigators. The
envelope glycoproteins gpl20 and gp41 are among the principal targets for the host
humoral immune response to HIV-1 (Fung et al., 1992; Matsushita et al., 1988;
Javaherian et al., 1990; Ho et al., 1991; Looney et al., 1988; Haigwood et al.,
1990; Broliden et al., 1991; Weiss et al., 1986). Virtually all neutralizing activity
in the sera of infected individuals is directed against these proteins and particularly
against regions of gpl20. The V3 hypervariable region has been found to be the
principal neutralization determinant in HIV-1 infection (Kuiken et al., 1993; Wolfs
et al., 1991; Zwart et al., 1991; Javaherian et al., 1990; Javaherian et al., 1989;
Skinner et al., 1988). V3 neutralizing antibodies can prevent HIV-1 entering target
cells, although they do not necessarily abrogate binding to the cell via the gpl20-
CD4 interaction (Linsley et al., 1988; Skinner et al., 1988). The V3 loop can
present both linear and conformational determinants for antibody recognition. A
second major neutralizing region is the CD4 binding site located in the carboxy
terminal region of gpl20 (Pinter et al., 1993; Ditzel et al., 1995; Kang et al.,
1991). This determinant is generally conformation-dependent and antibodies block
the binding of HIV-1 to the cellular receptor. Neutralizing antibodies directed
against the VI and V2 hypervariable regions of gpl20 have also been detected
(Mankowski et al., 1994; Warrier et al., 1994; McKeating et al., 1993; Gorny et
al., 1994; McKeating et al., 1993; Moore et al., 1993). As with the V3 loop, linear
and conformational determinants appear to be involved. The envelope glycoprotein
gp41 has not been analysed as extensively as gpl20 although, neutralizing
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antibodies have been detected (Purtscher et al., 1994; Sattentau et al., 1995;
Purtscher et al., 1996; Back et al., 1993). Generally neutralizing antibodies to gp41
are recognized following the gpl20-CD4 interaction suggesting that receptor
binding induces conformational changes exposing the gp41 domain (Sattentau et
al., 1993). The role of neutralizing antibodies in clearing viraemia during the acute
phase of infection remains controversial. Several studies have found the decline in
viraemia precedes the production of neutralizing antibodies, although it is possible
that antibodies are present at very low levels prior to the decline in viraemia
undetectable by current assays.
1.1.4 MONITORING THE RESPONSE TO HIV-1 INFECTION.
1.1.4.1 DIAGNOSTIC TECHNIQUES.
The diagnosis of infection with HIV-1 is dependent on the detection of
specific HIV antibodies, detection of circulating viral antigens, isolation of the
virus from clinical specimens, or detection of viral genetic material. Routine
diagnostic procedures used to identify HIV-1 infected individuals rely largely on
the presence of antibodies to viral antigens in the serum. Antibody tests combining
a screening assay and a confirmatory test have been the most widely used
techniques for establishing the presence of HIV-1 infection (Phair et al., 1992).
Most HIV antibody screening assays use the rapid and convenient EIA. Originally
EIAs used whole viral lysates obtained from cultivation of HIV in lymphocytes
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(Jackson et al., 1988; Johnson, 1992). These preparations however, resulted in false
positive results due to the reaction of serum antibodies to cellular components.
Subsequent assays have been developed that use recombinant HIV-1 proteins to
env and gag products and synthesized peptides corresponding to conserved regions
of env and p24 core proteins (Johnson, 1992). These assays have proven to be
more sensitive and specific than the original EIAs.
Diagnosis of HIV-1 infection is not always possible based on the presence
of antibodies in the serum. For example antibodies are not present in the acute
phase of infection (serological window period) and can be lost in the advanced
stages of disease. Therefore diagnostic tests for either direct detection of the virus
or its components may be important in monitoring the disease when no antibody is
present. Virus culture can provide definitive information about the presence or
absence of HIV-1 infection. However it is costly, time consuming and labour
intensive with the potential for exposure to high concentrations of infectious virus.
Therefore although it is a good reference method for identifying HIV-1 infection it
is of limited practical use for diagnosis, and is not suitable for measurement of
circulating virus load.
HIV-1 antigenaemia is thought to be significant during two periods of HIV-
1 infection, initially during the acute phase, prior to the production of antibodies,
and at the terminal stages of infection and development of AIDS when virus
production increases dramatically (Gaines et al., 1987; von Sydow et al., 1988;
Pedersen et al., 1987). During these brief periods p24 antigen can be detected in
both serum and plasma using an EIA based antigen capture technique (Goudsmit et
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al., 1986). However, direct detection of p24 antigen in infected sera is unreliable
following seroconversion in most cases because of the small amount of circulating
antigen (MacDonell et al., 1990). In general p24 antigen cannot be detected in the
serum of 85% or more asymptomatic HIV-1 seropositive individuals (Fahey et al.,
1990). The low detection rate of p24 antigen in serum from asymptomatic patients
may be due to low levels of antigen production or to the formation of immune
complexes. In order to increase the sensitivity of this diagnostic test Nishanian et
al., developed an acid dissociation procedure designed to disrupt p24 antigen-
antibody immune complexes (Nishanian et al., 1990). This method improved the
detection and quantitation of p24 antigen EIA testing allowing a more accurate
assessment of in vivo viral replication.
In more recent years, PCR-based methods have been developed to quantify
specific DNA and RNA sequences present in small amounts of biological
specimens. These methods were developed as an alternative to conventional
diagnostic molecular hybridization methods such as Southern and Northern blots,
dot hybridization and spot hybridization, as these methods show inadequate
sensitivity for HIV in vivo. PCR based applications provide a specific and efficient
method for direct detection of HIV-1 infection and can detect DNA and RNA in
plasma of HIV-1 infected individuals regardless of clinical condition (Zhang et al.,
1991; Piatak et al., 1993; Ottmann et al., 1991). This technique will therefore be
valuable for identifying HIV-1 infected individuals prior to seroconversion and
identifying infected babies born to HIV-1 infected mothers in whom maternal
antibodies can persist for 5 to 14 months (Rogers et al., 1989). Similarly, this
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technique has important advantages for resolving equivocal serologic results from
HIV-1 infected patients (Jackson et al., 1990).
1.1.4.2 PROGNOSTIC MARKERS.
Numerous markers have been studied in patients infected with HIV-1 in an
effort to monitor and predict progression to disease. Monitoring of HIV-1 infection
can be classified into three categories: the direct detection of the virus or its
antigens, methods which quantitate the immunosuppression of HIV-1 and
evaluation of the immune response to HIV-1.
Previously detection of infectious HIV-1 in plasma was carried out
following co-cultivation with phytohaemagglutinin (PHA) stimulated donor PBMCs
(Coombs et al., 1989). Quantification of plasma viraemia was carried out using
serial dilution co-culture and detection of p24 antigen production in vivo (Ho et al.,
1989; Coombs et al., 1989). These studies concluded that plasma viraemia
correlated well with progression to disease since plasma viraemia was detected
more frequently in symptomatic individuals than in asymptomatic individuals.
More recently a more sensitive quantitative approach has been developed using a
novel PCR based method. Several investigators have coupled a reverse transcriptase
(RT) reaction step to conventional RNA PCR and have detected HIV RNA in HIV-
1 cell cultures and PBMCs from infected individuals (Arrigo et al., 1989; Byrne et
al., 1988). These studies have confirmed that a low level of viral replication occurs
throughout the clinically latent stage of infection, although they do not determine
33
absolute quantities of RNA. In order to quantify actively replicating virus a number
of methods have been proposed including competitive RT-PCR (cRT-PCR) and a
limiting dilution assay (Zhang et al., 1991; Menzo et al., 1992). Both studies
provide evidence that quantitation of plasma viraemia using an RT-PCR approach
is a more accurate method for the detection and quantitation of virus production.
Therefore, these methods provide a better marker for the progression of disease, in
contrast with p24 antigen assays which are limited by the production of immune
complexes preventing the detection of p24 antigen.
During HIV-1 infection and progression to AIDS a marked decrease in
CD4+ T cells is apparent. These cells are central to the regulation of the immune
system and the sharp decline in numbers is thought to be central to the resulting
immunodeficiency. During the asymptomatic phase there appears to be an increase
in CD8+ T cells (cytotoxic) suggesting that this cell subset may contribute to the
limiting of HIV-1 replication during this phase (Giorgi et al., 1987; Lang et al.,
1989). An initial inversion of the CD4+:CD8+ T cell ratio is another prominent
feature of HIV-1 infection, although it is unclear whether this inversion is due to a
decrease in the number of CD4+ T cells or augmentation of CD8+ T cells. Many
studies have been carried out to determine the prognostic value of these
immunological markers (Miedema et al., 1990a; Giorgi et al., 1987a; Fahey et al.,
1984a; Bogner et al., 1991a; Lang et al., 1989a; Phillips et al., 1991a). Results
from these studies indicate that following seroconversion a rapid decrease in CD4+
T cells occurs as a result of the pathogenic effects of HIV-1. This is followed by a
continual fall in CD4+ T cells but at a much slower rate and for a variable period
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of time during the asymptomatic phase. Prior to the progression to AIDS
(approximately two years) CD4+ T cell counts begin to fall more rapidly again and
low counts are common just prior to progression to AIDS. There are various
methods available to monitor the CD4+ T cell count: the absolute CD4+ T cell
number in blood, the percentage of CD4+ T cells and the CD4+:CD8+ T cell ratio.
It is now widely accepted that CD4+ T cell counts are a reliable prognostic marker
to determine progression to AIDS and may be a suitable marker for monitoring the
effects of antiviral treatments.
There are various soluble products of immune activation present in the
serum that can be readily measured. Beta-2-microglobulin ((3-2-M) is a low
molecular weight protein (11,800 Da) that forms the light chain of the class I
major histocompatibility complex found on the surface of most nucleated cells
(Jacobson et al., 1989; Hofmann et al., 1990). P-2-M is normally present in the
serum and urine and normal levels reflect the balance between production and
removal of this molecule. Serum levels are generally increased in diseases
characterized by increased cell turnover including malignancies and chronic
inflammation. It is also associated with renal failure and has been reported to be
elevated in various diseases affecting lymphocytes, such as cytomegalovirus,
hepatitis and HIV infection (Hofmann et al., 1990; Fuchs et al., 1991). Due to the
immunosuppression caused as a result of HIV-1 infection and a reduction in CD4+
lymphocytes (3-2-M was considered to be a good prognostic marker during
progression to AIDS. Various investigations have been carried out to determine
how infection with HIV-1 affects the levels of (3-2-M (Mastroianni et al., 1990;
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Jacobson et al., 1989; Hofmann et al., 1990; Fuchs et al., 1991). Analysis of
asymptomatic and symptomatic individuals has shown that |3-2-M levels increase
during progression to AIDS. Similarly, analysis of HIV-1 seroconverters showed
that changes in (3-2-M levels after exposure to HIV-1 were associated with the
decline in CD4+ T cells.
Neopterin is another serum marker associated with immune cell activation, a
low molecular weight compound derived biosynthetically from
guanosinetriphosphate (Fuchs et al., 1988b). It is predominantly produced following
macrophage stimulation with interferon gamma (IFN-y) released from activated T
cells (Huber et al., 1984). Increased neopterin levels have been demonstrated in
individuals with diseases associated with or caused by cell mediated immunity
(CMI), including allograft rejections, autoimmune disorders, viral infections,
bacterial infections, parasitic infections and various malignancies (Fuchs et al.,
1991; Fuchs et al., 1988). Neopterin levels behave similarly to (3-2-M during the
course of HIV-1 infection and parallel disease progression. Various studies have
investigated the levels of neopterin in asymptomatic and symptomatic individuals
and found much higher levels of this molecule in symptomatic individuals (Fuchs
et al., 1991; Fuchs et al., 1988a; Fuchs et al., 1988b). Detection of neopterin was
found to be as sensitive a prognostic marker as the CD4+ T cell count and
increased levels of this molecule correlated with the rapid decrease in CD4+ T cell
counts. Both (3-2-M and neopterin have been found to have good predictive power,
probably on a parallel with CD4+ T cell counts, acting independently of each other
and indeed of CD4+ T cell measurements. Therefore the level of [3-2-M or
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neopterin used in conjunction with CD4+ T cell counts may provide a better
method for monitoring progression to disease than CD4+ T cell counts alone.
1.1.5 TRANSMISSION OF HIV-1.
HIV transmission can primarily be defined into three major groups
depending on the mode of transmission: (1) unprotected sexual intercourse, (2)
inoculation of infected blood or blood products and, (3) vertically from mother to
child. The risk factors involved in transmission of HIV in each of these three
groups vary depending on the nature of the activity through which transmission
occurs. However, in each case one unifying risk factor exists, that is the stage of
disease. An HIV infected individual appears to be more infectious in the very early
stages (prior to antibody production) and again in the late stages of clinical AIDS
due to higher levels of virus present in the blood during these stages of disease
than during the asymptomatic stage (European study group., 1989; Jacques et al.,
1994; Lazzarin et al., 1991).
Transmission of HIV through unprotected sexual activity can occur from
male to male, male to female and female to male (Caceres et al., 1994; European
Study Group, 1992). Female to female transmission remains extremely rare (Raiteri
et al., 1994). A number of factors influence transmission of HIV through sexual
contact. Generally the receptive partner in either homosexual or heterosexual
activity is more susceptible to HIV infection (Rodrigues et al., 1995). Anal
intercourse carries the risk of trauma to the mucosal lining and hence increased risk
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of infection. During heterosexual intercourse male to female transmission is more
effective than female to male transmission (European study group., 1989; European
study group., 1992). The frequency of sexual contacts is thought to be the most
important factor in creating the worldwide epidemic of sexually transmitted HIV
infection, although a single contact can be sufficient to transmit HIV. An important
biological factor increasing the probability of HIV transmission is the presence of
variable sexually transmitted diseases, such as genital ulcers (Rodrigues et al.,
1995).
The second mode of transmission is through blood and blood products.
Contaminated blood is highly infectious upon parenteral exposure. The primary risk
group for HIV transmission via blood is through intravenous drug abuse (Des
Jarlais et al., 1988). This route of transmission is significant due to an epidemic of
drug abuse and a change from oral to intravenous administration over the past few
decades. Also an increase in needle sharing behaviour, especially in countries
where 'shooting galleries' exist, provides a fertile field for the transmission of HIV
among a large network of drug injectors. Also exposure is often repeated due to the
addictive nature of these drugs. There is also an increased risk of transmission to
sexual partners of intravenous drug users (Ronald et al., 1993). Similarly, frequent
drug abuse is associated with other high risk behaviours such as sexual
promiscuity. For example, prostitution is frequently motivated by the cost of drug
addiction (Celentano et al., 1994).
Transmission of HIV-1 to blood transfusion recipients and haemophiliacs
receiving blood clotting factors, such as factor VIII and IX, was originally a
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significant risk of infection. However, this route of transmission is now very rare in
countries where blood is screened for HIV antibodies and viral inactivating steps,
such as heat inactivation, are routinely carried out in blood product manufacture,
such as factors VIII and IX (Lackritz et al., 1995; Mannucci, 1993). Unfortunately
contaminated blood is still a route of infection for HIV in some developing
countries where difficulties have been encountered in setting up safe blood
transfusion systems (Lackritz et al., 1993). Health care workers have been infected
after a needle stick injury from a needle containing HIV infected blood or, less
frequently, through an open cut or splashes into a mucous membrane (e.g. eyes,
inside of nose). To date there has only been one case where a health care worker
has infected patients. This involved the transmission of HIV from a dentist to a
number of patients (Ou et al., 1992). Other practices which hold a potential risk of
transmission through blood include those that involve piercing of the skin which
acts as a natural barrier to infection. For example, infection may occur through
tattooing, acupuncture or the use of other invasive instruments that may have come
in contact with contaminated blood and have not been properly disinfected.
The third mode of transmission is vertically from an infected mother to her
child. The parameters involved in this mode of transmission are not well defined. It
is thought infection may occur in utero (intrauterine or transplacental; Conaldi et
al., 1995), during delivery through the birth canal (perinatal) or after birth through
breast milk (infancy; Palasanthiran et al., 1993; Looney et al., 1988; Toniolo et al.,
1995). Transmission from mother to child ranges from 15% to 35% with the lowest
rates reported in Europe and the highest in Africa (Stlouis et al., 1993; Newell et
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al., 1993; Dabis et al., 1993; Peckham et al., 1995).
1.1.6 EPIDEMIOLOGY OF HIV-1 INFECTION.
The global pandemic of HIV infection comprises many separate epidemics
in different geographical areas and is influenced by many factors including the time
of introduction of the virus, population density and diverse cultural and social
variables. Previously HIV infection in distinct geographical areas could be
separated according to the major mode of transmission. However this distinction is
becoming less relevant as the epidemic develops. For example, in Europe the main
mode of transmission was initially through homosexual contacts. Increasingly,
however transmission through drug abuse and heterosexual routes are becoming
apparent. Similarly, in South America the initial AIDS epidemic was focused in
homosexual communities but heterosexual transmission is now considered to be a
major route of exposure to HIV infection. Spread of HIV infection has varied
considerably between developed and developing countries, depending on cultural,
social and behavioural patterns.
In Africa, HIV infection is the leading cause of adult death in many cities
and has greatly increased childhood mortality (Gregson et al., 1994). The World
Health Organization (WHO) has estimated that approximately 16 million
individuals in Africa have been infected with HIV, most of them in sub-Saharan
Africa (World Health Organization. 1995). Heterosexual transmission is the main
mode of transmission among African adults. As a result of the increasing numbers
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of women becoming infected through heterosexual transmission, the prevalence of
paediatric infections from mother to child is extremely high and expected to rise.
In most Asian countries, HIV infection was not recognised until much later
than in the USA or Africa. However over 4 million people are now thought to be
infected (Quinn, 1996). Thailand was the first Asian country in which HIV
infection was recorded. Transmission was notably through drug abuse and high risk
heterosexual activity, such as female sex workers (Morris et al., 1996). HIV
seroprevalence increased from 1.2% to 45% in intravenous drug users (IDU)
between 1988 and 1991 in Thailand (Quinn, 1996). In addition, HIV prevalences of
43% to 82% were detected in IDU in China (Cheng et al., 1994). HIV
seroprevalence among female sex workers and their contacts are also surprisingly
high with a prevalence of 30% to 65% reported among female sex workers in
Thailand and India (Bollinger et al., 1995; Kaldor et al., 1994). A similar pattern to
that observed in Thailand and India may be expected in many other countries in
Asia that share the same prevalence of female sex workers and high frequency of
IDU.
The number of infected individuals in the Pacific Islands has been estimated
to be about 75 000, with most in Australia and New Zealand (World Health
Organization. 1995). Most infections in these regions have occurred among
homosexual men. The frequency of infection among IDU is relatively low
compared to Europe and North America although this mode of transmission
remains a significant route for the dissemination of HIV infection.
HIV infection amongst individuals in the Americas has been estimated at
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three million, with over one million in North America and two million in Latin
America and the Caribbean (World Health Organization. 1995; Quinn, 1996). There
is a trend in these countries for a marked decline of HIV-1 among homosexual
individuals and a substantial increase in the heterosexual population (Heverkos et
al., 1995). For individual countries, the highest number of reported cases in the
world originate in the USA with over 500 000 cases by the end of 1995 (Centres
for Disease Control and Prevention. 1995).
Half a million individuals are thought to be infected in Western and Eastern
Europe with transmission routes differing significantly between countries. For
example, in Italy, Spain and Poland almost two thirds of infections are attributable
to IDU, whereas homosexual individuals constitute the majority of infections in
Scandinavia, Czech and Slovak republics. In Europe as a whole, the number of
cases attributable to homosexual transmission decreased significantly from 62% to
36% between 1985 and 1992 (Quinn, 1996). The opposite trend for IDU has been
reported with an increase from 16% to 40% in recent years. Similarly, transmission
through heterosexual intercourse has shown an increase and seroprevalence studies
indicate that between 14% and 18% of infected individuals may have acquired HIV
infection heterosexually.
Future predictions of the global pandemic of HIV infection are very
difficult to make with any degree of confidence. However, predictions by the WHO
are that there will be approximately 26 million HIV infected individuals by the
year 2000 (Quinn, 1996). It is suspected that the incidence of infection in younger
populations (15 to 25 years old) will increase, as is already evident in the USA and
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sub-Saharan Africa. The number of cases in sub-Saharan Africa and Asia are
expected to continue to rise although, in America and Europe the number of HIV
infected individuals are expected to remain fairly constant as the number of new
infections are likely to parallel the number of fatalities. Therefore, future efforts to
control the AIDS epidemic must be focused on educating people, to influence
change in social and cultural behaviour until an effective vaccine regime or better
therapeutic interventions are available.
1.2 VIROLOGICAL ASPECTS OF HIV-1 INFECTION.
1.2.1 CLASSIFICATION OF HIV-1.
HIV is a member of a large group of viruses known as the Retroviridae.
Retroviruses display a variety of common features specific to this virus group.
They are surrounded by a spherical envelope, which is acquired as the virion buds
from the plasma membrane. The envelope surrounds a core protein encapsidating
two copies of a positive strand ribonucleic acid (RNA) genome. The genome of
retroviruses possess a common viral structure organised into three polyprotein
genes: group specific antigens (gag), polymerase (pol) and envelope (env). The life
cycle of a retrovirus involves the insertion of the viral genome into the host genetic
material utilizing a virally encoded enzyme, integrase (IN). Replication proceeds
through a deoxyribonucleic acid (DNA) intermediate again utilizing a virally
encoded RNA-dependent DNA polymerase (RT). The Retroviridae were originally
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classified into three subfamilies: Oncovirinae (onkos-Greek word meaning
'tumour'), Lentivirinae (lenti-Latin word meaning 'slow') and Spumavirinae
(spuma-Latin word meaning 'foam'; Matthews, 1979). This family has since been
re-classified by disease, tissue tropism, host range, virion morphology and more
recently by genome relationships, and is now divided into 7 genera (Table 2). The
oncoviruses are the only genera of retroviruses that can transform target cells and
are associated with cancers and neurological disease. They are also characterised by
the morphology of their core in electron micrographs as type A, B, C and D.
HTLV-I and HTLV-II are members of this genera. Spumaviruses cause a distinct
cytopathological effect (vacuolated 'foamy' cytopathology) but do not appear to
cause clinical disease. Lentiviruses (slow viruses) characteristically display long
periods of latent infection prior to causing immunological and neurological disease.
They contain a characteristic cylindrical nucleocapsid core, obvious in electron
micrographs, tapering at one end. The genomes of this genera carry a complex
combination of regulatory genes in addition to gag, pol and env. The prototype
members were visna virus, equine infectious anemia virus and caprine arthritis-
encephalitis virus. More recently, human and simian immunodeficiency viruses
(HIV and SIV) and the more distantly related feline and bovine immunodeficiency
viruses (FIV and BIV) have been classified as members of this genera (Table 2).
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TABLE 2: CLASSIFICATION OF RETROVIRUSES
Genus Examples
Avian-leukosis-sarcoma RSV
Mammalian C-type Mo-MLV, FeLV
B-type viruses MMTV
D-type viruses MPMV
HTLV-BLV group HTLV-1 and-2,
BLV
Spumavirus group HFV, SFV
Lentivirus group HIV, SIV
RSV, Rous sarcoma virus; Mo-MLV, Moloney murine leukemia virus;
FeLV, Feline leukemia virus; MMTV, Mouse mammary tumor virus;
HTLV, Human lymphotropic virus; BLV, Bovine leukemia virus; HFV,
Human foamy virus; SFV, Simian foamy virus; HIV, Human
immunodeficiency virus; SIV, Simian immunodeficiency virus.
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1.2.2 BIOCHEMICAL STRUCTURE OF HIV-1.
The morphology of HIV has been determined by thin section electron
microscopy and by negative staining (Christie et al., 1988; Standard et al., 1987).
HIV-1 is an enveloped virion 80-100nm in diameter (Matthews, 1979). The lipid
bilayer is densely studded with 72 knob like projections (Gelderblom, 1991),
derived from a single precursor protein (gpl60) encoded by the env gene, of
approximately 8nm in diameter (Gelderblom, 1991; Matthews, 1979). Cleavage of
gpl60 produces gp41 (transmembrane protein-TM) and gpl20 (outer surface
glycoprotein-SU) which are found in close association on the surface of the virion
in the form of a heterodimer. Host cell components have been shown to be present
on the viral membrane, such as major histocompatibility complex (MHC) class I or
II depending on the infected cell from which the virus buds (Henderson et al.,
1987; Arthur et al., 1992; Frank et al., 1996; Fig 2). The morphology within the
virion is provided by the protein products of the gag polyprotein gene which form
two distinct constituents. Thin section electron micrographs have indicated an
electron dense layer underlying and in close proximity to the lipid membrane
(Gelderblom et al., 1989). This layer has since been characterised as the matrix
(MA) protein encoded by the pl7 region of gag and is vital for the structure and
integrity of the virion. The second constituent provided by the gag gene is the viral
core generated by the p24 region and has a characteristic cone shape prominent in




















encodes genetic information required for the replication of HIV. It consists of two
identical copies of RNA found in close association with the viral RNA-dependent
DNA polymerase (RT), and the nucleocapsid proteins encoded by the gag gene (p6
and p9). The association between the nucleocapsid proteins and RNA genome
forms the ribonucleo-protein complex (RNP). The core also contains two other
virally encoded enzymes required for the replication of HIV, these are protease
(PR) and integrase (IN). There is some evidence to suggest a link between the cone
shaped core and the matrix protein. Hoglund et al have proposed a core-envelope
link protein attaching the narrow end of the core to the matrix protein (Hoglund,
1990). Nomenclature for the various HIV proteins mentioned has been taken from
the revised standardized nomenclature for proteins common to all retroviruses by
Leis et al and is summarised in Table 3 (Leis et al., 1988).
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1.2.3 GENOMIC ORGANISATION OF HIV-1.
The HIV proviral genome has been well characterised through molecular
cloning and extensive sequencing (Fig 3; Hahn et al., 1984). Every HIV particle
has two identical positive strands of RNA, each of which is approximately 9.2
kilobases (Kb) long. Common to all retroviruses the HIV genome encodes the three
main protein coding genes gag, pol and env flanked by long terminal repeat (LTR)
sequences that are required for replication. However, HIV is more complex than
conventional retroviruses, such as HTLV-I and HTLV-II, encoding an additional 8
genes; tat, rev, nef, vif, vpr, vpu, vpx and tev. For convenience gag, pol and env
have been classified as structural genes, tat, rev and nef as regulatory genes, and
vif (virion infectivity factor), vpr (virion protein R), vpu (virion protein U), vpx and
tev as accessory genes. In order to facilitate the synthesis of at least 11 distinct
proteins, from a genome of less than lOkb, HIV displays great economy in its
coding potential employing a complex array of differential RNA splicing and
overlapping translational reading frames.
1.2.4 STRUCTURAL GENES OF HIV-1.
Transcription of the HIV genome is characterised by a transition from the
synthesis of short multiply spliced messenger RNAs (mRNAs; approximately 2kb),
which encode the regulatory proteins early in infection, to the production of larger




























































structural proteins of HIV. The transition from early gene expression to late gene
expression is controlled by the viral trans-activator proteins tat and rev. The
function of these two regulatory proteins will be discussed more fully in section
1.2.5.
The gag gene codes for the main non-glycosylated structural components of
the virus particle. Initially a polyprotein precursor (p55) is translated from full
length mRNA and is subsequently cleaved by the viral protease to produce four
distinct gag proteins; p17 (matrix protein), p24 (major capsid protein), p9 (nucleic
acid binding protein) and p6 (proline-rich protein). Various domains of this gene
play pivotal roles in the assembly and release of virus particles (Mervis et al.,
1988) and are discussed more fully in section 1.2.8.6.
The pol gene codes for several enzyme activities required during the life
cycle of HIV. To date the pol gene of all retroviruses have been shown to be
expressed initially as a gag:pol fusion protein (Weiss et al., 1985). In HIV the gag
and pol genes overlap by 241 nucleotides and the pol gene is in a -1 reading frame
with respect to gag (Vaishnav et al., 1991). Expression of the pol gene is
facilitated by a ribosomal frameshift which occurs at a low frequency (5%) and is
directed by a short homopolymeric sequence located in the overlap between the
gag and pol open reading frames that allows a 'slip back' of the ribosome into the
-1 position (Jacks et al., 1988). This results in the production of large quantities of
the gag structural genes and relatively small quantities of the pol gene products.
This pi60 gag:pol polyprotein precursor is cleaved by the viral protease to produce
three distinct enzymes; plO (PR), p66/p51 (RT) and p32 (IN) and four distinct gag
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proteins (mentioned above).
The env gene codes for the viral glycoproteins which are produced by
cleavage of the gpl60 polyprotein precursor by a cellular protease in the Golgi.
Two glycoproteins are produced, gpl20 and gp41, which are located on the surface
of the virion embedded into the plasma membrane. gpl20 is an external
glycoprotein (gp), whereas gp41 is a transmembrane glycoprotein anchoring the
envelope complex to the virus. Both gpl20 and gp41 are extensively glycosylated
and contain complex N-linked carbohydrates. gpl20 is thought to be associated
with tissue tropism of the virus while gp41 is thought to mediate fusion of the
virus and cellular membranes prior to entry. gpl20 and gp41 are non-covalently
associated and are thought to form tetramers composed of dimers of each
glycoprotein (Vaishnav et al., 1991). The envelope protein, gpl20, consists of five
hypervariable regions (V1-V5) interspersed with five more conserved regions (Cl-
C5; Modrow et al., 1987; Fig 4). Leonard et al., have determined the location of 9
disulphide bonds in a prototypic gpl20 and have proposed a secondary structural
model in which gpl20 is composed of five major cysteine loops (Leonard et al.,
1990).
1.2.5 REGULATORY GENES OF HIV-1.
The tat gene is encoded by two exons, one of which is found 5' of the env
gene and the other is found within the coding region of the env gene (Fig 3; Karn
et al., 1991). The tat gene encodes a 14Kd protein that is essential for viral
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Fig. 4. Secondary structural model of gpl20 (modified from Leonard et ai, 1990).
9^, high mannose or hybrid-type oligosaccharide structures. ^, complex-type
oligosaccharide structures. Hypervariable regions 1 to 5 are are indicated by
enclosed boxes.
 
replication. This nuclear protein is a transactivator of LTR-directed gene
expression and binds to a nascent RNA structure located within the LTR known as
the trans-activation response element (TAR; Sodroski et al., 1985; Vaishnav et al.,
1991). Tat can act at multiple levels in the viral life cycle although its main
function is to increase the level of transcripts from genes linked to the HIV-1 LTR.
However, it has also been shown to function at the post-transcriptional level and
has recently been shown to decrease the activity of the MHC class 1 gene
promotor (Howcraft et al., 1993; Felber et al., 1993).
The rev gene is also encoded by two exons, one is found 5' of the env gene
and the other, as with the tat gene, is found within the coding region of the env
gene (Fig 3; Karn et al., 1991). The rev gene encodes a 19Kd nuclear protein,
which binds to a specific RNA target sequence, found within the env coding
region, known as the rev responsive element (RRE; Arrigo et al., 1989). The rev
protein appears to affect the nuclear-cytoplasmic distribution of HIV RNAs post-
transcriptionally by either inhibiting spliceosome function or by activating the
export of the singly spliced (4.5Kd) and unspliced (9.2Kd) HIV RNAs from the
nucleus to the cytoplasm. This function promotes the expression of the larger
structural proteins required for virus assembly and maturation.
The nef gene is encoded by a single exon which is located at the 3' end of
the genome overlapping the 3' end of the env gene and the 3' LTR (Fig 3). The
nef gene encodes a 25-27Kd protein (Allan et al., 1985), which is found in
association with the inner membrane courtesy of post-translational myristoylation
(Kan et al., 1986). The function of this regulatory protein is somewhat uncertain. It
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was originally thought to act as a negative regulatory factor inhibiting HIV
replication (Niederman et al., 1989; Ahmad et al., 1988). However, more recently
it has been suggested that this protein may play a role in disease pathogenesis
(Schwartz et al., 1995; Miller et al., 1994; Schwartz et al., 1995; Kestler et al.,
1991). It has also been found that expression of this protein is inversely linked to
the expression of the cell surface CD4 receptor (Garcia et al., 1991) indicating it
may act to downregulate CD4 expression of infected cells.
1.2.6 ACCESSORY GENES OF HIV-1.
The vif gene is encoded by a single exon overlapping the pol gene and
encodes a 23Kd protein (Fig 3; Kan et al., 1986). The function of this protein is
uncertain although there is some evidence to indicate that it may promote
infectivity of cell free virus since vif negative mutants show a profound reduction
in their infectivity (Fisher et al., 1987). Although the exact mechanism by which
vif affects viral infectivity has not been determined it is thought this protein acts
during the late phases of viral replication (Kan et al., 1986; Fisher et al., 1987).
The vpu gene is located at the 5' end of the env gene and encodes a 15-
20Kd protein (Fig 3; Cohen et al., 1989). vpu is unique to the HIV-1/SIVCPZ group
of primate lentiviruses and is not found in either HIV-2 or other SIV isolates.
Mutational analyses using vpu negative isolates have suggested that this protein
may be involved in facilitating assembly and/or release of virus particles (Klimkait
et al., 1991; Strebel et al., 1989).
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The vpr gene is encoded by a single exon which overlaps the vif gene and
encodes a 15Kd protein (Fig 3). This protein accelerates the replication and
cytopathic effects of HIV and appears to act at an early step in the replication
cycle (Ogawa et al., 1989). Unlike onco-retroviruses HIV does not require mitosis
for entry of viral nucleic acid into the host cell nucleus (Bukrinsky et al., 1992). It
has been suggested that vpr, in association with MA protein from the gag region,
may be crucial in the translocation of the pre-integration complex into the nucleus
of a non-dividing cell (Freed et al., 1995; Heinzinger et al., 1994). A role for vpr
in the regulation of cellular functions has also been suggested. It has been
demonstrated that vpr causes terminal differentiation of rhabdomyosarcoma cells
(Levy et al., 1993), and expression of vpr in the yeast Saccharomyces cerevsiae
resulted in cell growth arrest and gross cell enlargement (Macreadie et al., 1995).
Hence, vpr may function to bring about growth arrest to enable genomic integration
to occur.
The vpx gene has, to date, only been found in HIV-2 and SIV isolates but
not in HIV-1. It encodes a 14Kd protein (SIV) and a 16Kd protein (HIV-2; Yu et
al., 1988; Franchini et al., 1988). It has been suggested that the vpx gene arose
from a duplication in the vpr gene (Tristem et al., 1992). A number of studies have
suggested that vpx is required for efficient replication in PBMCs (Guyader et al.,
1989; Kappes et al., 1991; Yu et al., 1991). One such study showed that mutant
vpx negative isolates infect primary lymphocytes with a reduced efficiency
(Guyader et al., 1989). Also mutations in two adjacent regions of this gene have
been shown to disrupt the incorporation of this protein into the mature virion (Park
57
et al., 1995).
The tev gene encodes a 28Kd protein and is a hybrid protein expressed by a
novel multiply spliced mRNA. This mRNA begins with the first exon of tat
continues through env and ends in the second exon of rev. The function of this
protein is not clear, although it has been shown to contain both tat and rev
properties. Expression is decreased in the presence of rev suggesting it is produced
early on in the virus life cycle and may play a regulatory role in the initial stages
of virus expression (Benko et al., 1990).
1.2.7 ORIGIN AND EVOLUTION OF HIV-1.
Primate lentiviruses include HIV-1, HIV-2 and a number of viruses isolated
from nonhuman primates collectively known as simian immunodeficiency viruses
(SIV). Extensive genetic analysis has been carried out on these primate lentiviruses
and they have been found to be more closely related to each other than they are to
lentiviruses of other mammals (Myers et al., 1992b). In order to further classify
these primate lentiviruses phylogenetic trees have been constructed, derived from
pol protein sequences, which have identified five distinct groups (Sharp et al.,
1994). One group contains viruses present in humans (HIV-1) and chimpanzees, a
second group contains viruses found in humans (HIV-2), macaques and sooty
mangabeys, and the final three groups consist of viruses currently found within
single species (African green monkey, the mandril and Sykes' monkey).
Theories of the origin of HIV viruses have remained extremely
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controversial. Serological studies on nonhuman primates have been carried out to
identify animals with antibodies cross-reactive with HIV or closely related viruses.
Seropositive nonhuman primates include African green monkeys, mandrills and
sooty mangabeys (Kanki et al., 1985). Similar serological studies carried out in
humans from West Africa have suggested infection with a virus closely related to
SIV (Barin et al., 1985). This virus, designated HIV-2, was isolated by Guyader et
al., who found it to be closely related to a virus isolated from a captive macaque
(SIVmac), but significantly different from HIV-1 (Guyader et al., 1987). This finding
was somewhat puzzling since the natural habitat for macaques is Asia not Africa,
and Asian macaques have not been found to be infected with SIV in the wild.
Hirsch et al., suggested that macaques could probably have been infected with SIV
through a cross species transmission from an African primate (Hirsch et al., 1989).
Epidemiological data point to sooty mangabeys as the source of SIVmac. There
would therefore appear to be good phylogenetic evidence to suggest that the sooty
mangabey is the natural reservoir for HIV-2 and that infection of man probably
represents a cross species transfer.
The natural reservoir for HIV-1 remains unclear, although it is highly likely
that known strains of HIV-1 have arisen in a similar fashion to HIV-2, namely
following a cross species transmission(s). Phylogenetic analysis has shown a close
relationship between HIV-1 and SIV infecting chimpanzees (SIVcpz), which may
indicate that the natural reservoir for HIV-1 is in fact the chimpanzee (Peeters et
al., 1992; Huet et al., 1990). However, in a seroepidemiological study of 94
chimpanzees (originating from Gabon, Zaire and Cote d'lvoire) only three animals
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were found to be infected (Peeters et al., 1992), casting doubt on these primates
being the natural host. It is therefore possible that both humans and chimpanzees
have been infected following cross species transmission from a third, yet
unidentified primate. Gojobori et al., have constructed phylogenetic trees for a
number of primate lentiviruses, comparing nucleotide sequences from five regions
of the genome (LTR, gag, pol, env, nef; Gojobori et al., 1990a). They analysed
SIVagm and SIVmnd and found that these isolates grouped with either HIV-1 or HIV-
2 depending on the gene analysed. For example, analysis of the env region suggests
SIVagm is closely related to HIV-2, while analysis of the nef region suggested
SIVagm is more closely related to the HIV-1 group. These results suggest a
recombination event may have occurred between simian viruses prior to the
emergence of HIV-1 and HIV-2. It is therefore possible that HIV-1 and HIV-2
have evolved from two separate cross species transfers from non human primates
to humans, with one occurring in Central Africa, possibly from chimpanzees giving
rise to HIV-1 and a second in Western Africa most probably from sooty
mangabeys giving rise to HIV-2.
Divergence times between HIV-1, HIV-2 and SIVs have been estimated by
a number of groups. A comparison between the complete genome of SIVagm
(isolated from an African green monkey) and known HIV and SIV sequences
suggested that HIVs and SIVs have "diverged gradually in concert with the
evolution of primates" and that HIV-1 and HIV-2 have been present in the human
population for some time, having diverged during human evolution (Fukasawa et
al., 1988). This implies a diversification time of millions of years. For more closely
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related viruses Hircsh et al., suggested that SIVsra/SIVmac may have diverged from
HIV-2 approximately 30 years ago (assuming a mutation rate for the gag gene of
0.5% per virus per year; Hirsch et al., 1989), similar to other estimates (Sharp et
al., 1988). Extension of this investigation for the divergence of HIV-1 from HIV-2
predicts a time of hundreds of years. Similarly, Yokoyama et al., estimated HIV-1
and HIV-2 diverged about 280 years ago , assuming the pol gene of lentiviruses
evolved at the same rate as viral oncogenes (0.5 x 10"3 nonsynonymous
substitutions per site per year; Yokoyama, 1988). Yet another study estimates that
HIV-1, HIV-2 and SIVagm all diverged approximately 150 years ago (Sharp et al.,
1988), although in this study the rate of evolution of the pol gene was estimated to
be 0.96 x 10"3. All these studies are inconsistent with the proposal that HIV-1 and
HIV-2 diverged from a common ancestor as recently as 40 years ago (Smith et al.,
1988). The range in estimated times of divergence illustrates the weakness of this
aspect of evolutionary analysis in reconstructing convincing histories of virus
evolution.
Attempts have been made to further classify the five groups of primate
lentiviruses. This is especially important within the two lineages containing human
viruses since development of a successful vaccine will require knowledge of the
extent of HIV genetic diversity worldwide. Phylogenetic analysis of HIV-1 strains
has produced a classification system in which different subtypes or clades have
been distinguished. The first attempt at describing HIV-1 subtypes was
accomplished by Myers et al., using env gene sequences (Myers et al., 1992a).
This analysis provided evidence of at least 6 distinct env subtypes, designated A to
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F. Subtype A is representative of sequences from Central Africa (Zaire, Uganda
and Rawanda; Myers et al., 1991). Subtype B is found most prevalent in North and
South America and Western Europe although subtype B sequences have been
detected in most continents (Pfeifer et al., 1991). Subtype C includes isolates from
South Africa (Myers et al., 1992a), India (Dietrich et al., 1993), Zambia
(McCutchan et al., 1992b) and Djibouti (Louwagie et al., 1993). Subtype D
includes isolates from Central Africa (Myers et al., 1991). Subtype E isolates are
mainly found in Thailand although isolates from Central Africa (McCutchan et al.,
1992a) and India (Grez et al., 1994) have been described. Subtype F includes
viruses from Brazil, Romania and Zaire (Louwagie et al., 1993; Dumitrescu et al.,
1994; Potts et al., 1993; Louwagie et al., 1994). Among subtypes A to F, viruses
that belong to different subtypes exhibit up to 30% variation in their env coding
sequences.
An independent study by Louwagie et al., examined the diversity of HIV-1
among 70 sequenced isolates from 15 different countries using a different region of
the genome, the gag gene (Louwagie et al., 1993). This analysis described 7
distinct subtypes originally denoted A to G. Unfortunately when Louwagie et al.,
characterised the three new subtypes, E to G, only four env subtypes had been
proposed. However by the time this gag data had been published a fifth new env
subtype had been identified and named 'E' on the basis of the established
nomenclature (Myers et al., 1992a). However, gag E and env E isolates were found
to belong to distinct viral groups (Louwagie et al., 1994), and so gag E to G had to
be renamed to gag F to H, illustrating the problems which may arise during the
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naming of new subtype sequences. The subtype of most HIV-1 isolates have been
found to be congruent for gag and env sequences, although some discrepant
sequences are apparent. For example, the African isolates (MAL, from Zaire), have
an env sequence similar to subtype D viruses but a gag sequence similar to subtype
A (Alizon et al., 1986). Also, viruses characterized from Thailand (CM238 and
CM243), have a subtype E env sequence but a subtype A gag sequence (Louwagie
et al., 1993). This switching of subtype between different regions of the genome
suggests that some subtypes may have arisen through recombination between two
divergent viruses. More recently, four additional sequence subtypes have been
assigned on the basis of their env sequences, termed G, H, I and J. These include
viruses from Gabon, Cameroon and Zaire (Jansens et al., 1994). Collectively
subtypes A to J are classified as group M (major subtypes).
Recently much more diverse variants of HIV-1 have been identified. Two
independent studies have isolated HIV-1 isolates which, although they are more
closely related to HIV-1 than any of the other four groups of primate lentiviruses,
are considerably more diverse than the previously described subtypes of HIV-1. De
Leys et al., report a novel isolate obtained from two individuals, originally from
Cameroon, which exhibit major differences in immunological and biological
properties and in the U3 region of the viral LTR. This isolate has been designated
ANT 70 (Deleys et al., 1990). Gurtler et al., also report a novel isolate from a
Cameroonian AIDS patient with a V3 configuration which has not yet been
described for other HIV strains. This isolate has been designated MVP-1580
(Gurtler et al., 1994). Both novel isolates, ANT-70 and MVP-1580, are considered
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to constitute a new subtype, group O (meaning outlier; Peeters et al., 1996).
Although these two isolates have been grouped together they are as divergent from
each other as subtypes A and B and could therefore represent separate subtypes
themselves. No doubt as more novel isolates are recovered this may be resolved.
A highly divergent HIV-1 related virus (SIVcpz.ant) was isolated from a wild
captured chimpanzee originating from Zaire (Vanden-Haesevelde et al., 1996).
Phylogenetic analysis using regions from gag and pol revealed that this isolate was
more closely related to HIV-1 isolates and other chimpanzee isolates than to the
other four major lineages. However, this isolate grouped outwith this lineage being
no more similar to SIVcpz_gab than to HIV-1 isolates. The isolation of this SIV
isolate is important regarding the origin(s) of HIV-1 and SIVcpz viruses. The
phylogenetic position of SIVcpz_ant suggests that the two major HIV-1 clusters,
groups M and O, must have arisen through two independent transmission events.
Whether this cross-species transmission occurred from chimpanzee to human is
unknown, although the low seroprevalence among chimpanzees argues against it.
Therefore, it is possible that both humans and chimpanzees have acquired their
lentiviruses from a third, as yet unidentified, African primate species.
1.2.8 LIFE CYCLE OF HIV-1.
The life cycle of HIV-1 requires the infection of a human cell (Fig 5). It
can be divided into a number of phases summarised below. (1) Prior to infection an
interaction with a receptor molecule occurs facilitating the attachment of the virus












the CD4 molecule found on the surface of a number of human cells. (2) Following
attachment the virus is internalized and uncoated. The mechanism of entry is
somewhat controversial and a number of mechanisms have been proposed,
including pH dependent and independent processes. (3) Once internalized, the
genomic RNA is transcribed into DNA using the viral enzyme RT. (4) The proviral
DNA is then integrated into the host chromosomal DNA utilizing another virally
encode enzyme IN. (5) A latent phase may follow viral integration restricting the
life cycle until the infected cell is activated allowing the transcription of viral
genomic RNA and mRNA. (6) Protein synthesis and processing then occur
followed by virus assembly and maturation as the virion buds from the cell surface
acquiring its coat.
1.2.8.1 ATTACHMENT.
The first step in the initiation of infection is the binding of the virus to the
surface of a susceptible cell via an interaction with a specific receptor. In the case
of HIV this specific receptor was found to be dependent on the surface presentation
of cluster determinant 4 (CD4; Maddon et al., 1986; McDougal et al., 1986;
Dalgleish et al., 1984; Klatzmann et al, 1984). The CD4 molecule is a
transmembrane glycoprotein of 58Kd and consists of a extracellular region,
transmembrane region and a cytoplasmic region at the C-terminal. The extracellular
region is folded into four domains, D1 to D4 (Maddon et al., 1985). CD4 is a
member of the immunoglobulin superfamily and is present predominantly on T
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helper cells but can also be found on B cells, cells of the monocyte-macrophage
lineage and specialized cells of the CNS (Maddon et al., 1986). The CD4 molecule
interacts with the envelope glycoprotein gpl20 prior to infection. A number of
studies have been carried out which have precisely mapped the regions on both the
CD4 molecule and gpl20 involved in this highly specific interaction (Clayton et
al., 1989; Arthos et al., 1989; Lasky et al, 1987; Kowalski et al., 1987; McDougal
et al., 1986). The carboxy-terminal of gpl20 is thought to interact with a region
located in the first domain of the CD4 molecule homologous to the second
complementary determining region (CDR2) of immunoglobulin variable region.
This interaction is also thought to facilitate the fusion of the virus membrane with
the cell membrane and will be discussed in section 1.2.8.2.
Chemokine receptors have been found to act as secondary receptors for
HIV-1 infection. A member of the a chemokine receptor family was the first to be
identified which acts as a co-receptor for T cell line tropic strains (Feng et al.,
1996). This receptor was previously named LESTR/fusin and has recently been
redesignated CXCR-4 (Bleul et al., 1996). Subsequent studies revealed that a
member of the (3 chemokine receptor family, CCR-5, serves as a co-receptor for
macrophage tropic isolates or dual tropic primary isolates (Alkhatib et al., 1996;
Deng et al., 1996; Dragic et al., 1996). Bruel et al., have shown that infection of
HeLa-CD4+ cells, PBMCs and CXCR-4 transfectants were inhibited by the CXC
chemokine stromal cell derived factor-1 (SDF-1), the natural ligand for CXCR-4,
but did not affect CCR-5 mediated infection of macrophage tropic or dual tropic
primary HIV-1 isolates (Bleul et al., 1996). Similar inhibition studies have revealed
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that RANTES, MlP-la and MIP-1(3 (natural ligands for CCR-5) blocked infection
of lymphocytes but failed to block infection of macrophages (Cheng-Mayer et al.,
1997; Schmidtmayerova et al., 1996). These findings suggest that HIV-1 variants
may utilise different co-receptors for infection of macrophages. A further difficulty
with understanding the tropism of HIV for macrophages has arisen from the
observation that macrophages, common with most human cells in vivo, express the
CXCR-4 receptor but are non-permissive for infection by SI strains that specifically
use this second receptor. A recent study by Rana et al., found that primary CD4+ T
cells recovered from individuals homozygous for a mutation in the CCR-5
chemokine receptor (see below) were resistant to infection with macrophage tropic
strains but permissive to infection with T cell tropic and dual tropic isolates that
use CXCR-4, CCR-5, CCR-3 or CCR-2b (Rana et al., 1997). Clearly expression of
CD4 and CXCR-4 in macrophages is insufficient to confer susceptibility. However,
transfection of these genes into non-human cells such as cat, hamster and mink was
sufficient to permit infection with SI isolates.
There is little information on the distribution of chemokine receptors
amongst different cell types in vivo. However, CXCR-4 is thought to be widely
distributed in human cells and tissues (Feng et al., 1996) and has been detected in
PBMCs and a number of CD4+ cell lines (Loetscher et al., 1994). CCR-5 has been
found to be expressed in primary monocytes/macrophages, primary T cells and
granulocyte precursors (Alkhatib et al., 1996; Deng et al., 1996), while CCR-3 has
so far only been detected in eosinophils (Daugherty, 1996) and microglia (He et
al., 1997).
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Differential chemokine secondary receptor usage of T cell tropic and
macrophage tropic variants suggests that the cellular host range of HIV-1 may be
determined by utilization of co-receptors. Recent studies have shown that the V3
region is a determinant of chemokine receptor usage (Cocchi et al., 1996; Choe et
al., 1996). Choe et al., demonstrated that recombinant viruses containing chimaeric
glycoproteins with a V3 loop from primary macrophage tropic isolates were able to
infect HeLa-CD4 cells more efficiently when either CCR-3 or CCR-5 was exposed
on the target cell (Choe et al., 1996). Wu et al., and Trkola et al., have shown that
binding of MIP-1J3 to CCR-5 was blocked by the gpl20/CD4 complex, suggesting
gpl20 specifically interacts with this co-receptor (Wu et al., 1996; Trkola et al.,
1996). The gpl20-CCR-5 interaction was enhanced by CD4 suggesting an
interaction between gpl20 and CD4 may result in a conformational change within
gpl20 facilitating the binding of CCR-5. These findings are consistent with
previous observations that the V3 region is an important determinant of HIV-1
tropism and phenotype (see sectionl.4.3).
Secondary receptor usage has also been shown to influence infection of
microglia in brain. Recently, He et al., reported that macrophage tropic HIV-1
viruses that use CCR-5 and CCR-3 as co-receptors were able to efficiently infect
microglia but that a T cell tropic virus that uses CXCR-4 was not (He et al., 1997).
These findings suggest that both CCR-3 and CCR-5 serve as co-receptors for
infection of brain microglia. This is supported by the observation that CCR-5 and
CCR-3 ligands can inhibit infection of microglia by several primary neurotropic
HIV-1 isolates (He et al., 1997). This is an interesting finding and may help to
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explain the overlap observed between macrophage tropism and that of microglia
since blood derived monocyte/macrophages express CCR-5 but do not express
CCR-3.
The discovery of co-receptors for HIV-1 infection also has important
implications regarding disease pathogenesis. Two recent studies have identified a
mutant allele of CCR-5 that is homozygous in two exposed, yet uninfected
individuals (Liu et al., 1996; Samson et al., 1996). This allele was found to contain
a 32 base-pair deletion, resulting in a truncated protein which was unable to
mediate chemokine signalling. These findings have far reaching implications
suggesting CCR-5 is a major determinant of HIV-1 infection in vivo and that the
absence of CCR-5 may confer protection against HIV-1 infection. Consistent with
this hypothesis, Samson et al., reported that out of 723 HIV-1 infected individuals
none were found to harbour this mutant allele while 8 out of 704 uninfected
individuals were found to express this allele (Samson et al., 1996). They also found
a reduced frequency of heterozygotes in the HIV-1 infected group compared with
the uninfected group suggesting a single copy of this mutant allele may confer
some degree of protection. Hwang et al., reported evidence for an association
between the heterozygous genotype with a slower rate of CD4+ T cell decline and
a lower viral load (Huang et al., 1996). These studies were fairly small and more
extensive analysis of the populations will be required to determine the true
relevance of these observations in disease pathogenesis.
The observation of some degree of protection awarded by the presence of
CCR-5 mutants is potentially important in viral transmission. Mutant CCR-5 alleles
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may confer resistance to infection following sexual transmission since macrophage
cells are likely to be the first cell type encountered by the virus upon transmission.
This would be consistent with previous reports that macrophage tropic isolates are
predominantly detected following transmission (Zhu et al., 1993). However, further
epidemiological studies will be required to examine the distribution of mutant
alleles in other risk groups to determine if this is an important factor during
transmission and if this mutation alone confers natural resistance to infection with
HIV-1. Indeed, a combination of genotypic variation within virions and co-receptor
usage may determine the transmission of HIV-1 variants.
1.2.8.2 FUSION AND ENTRY.
Enveloped animal viruses, such as HIV, enter host cells following fusion
with the cell membrane. The mode of entry of enveloped viruses can be broadly
divided into two mechanisms. The first is by a pH-dependent process involving
internalization of the virus by receptor mediated endocytosis (RME) into acidic
compartments (endosomes), where a reduction in pH induces a conformational
change in the TM glycoprotein, exposing the hydrophobic fusion domain thereby
facilitating fusion of viral and endosomal membranes. The second possible mode of
entry is via a pH independent process. This mechanism involves the direct fusion
of the virus envelope with the plasma membrane of the cell and is independent of a
decrease in pH. The mechanism by which HIV enters cells is one of the most
poorly understood aspects of the virus life cycle. Thin section EM studies on viral
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fusion and uptake have provided evidence for both RME (via clathrin coated pits)
and direct fusion with the cell membrane (Pauza et al., 1988; Stein et al., 1987;
Grewe et al., 1990). Early studies on the fusion and uptake of HIV concentrated on
determining whether uptake was pH dependent or independent. To enable this
distinction to be made a number of studies have been carried out using various
methods. HIV infection was reported to be inhibited by treating cells with
lysosomotropic agents (weak bases) such as ammonium chloride and amantadine
(Maddon et al., 1986). Subsequently, however, it was reported that lysosomotropic
agents and carboxylic ionophores, such as monensin, did not abrogate HIV fusion
and infectivity (McClure et al., 1988; Stein et al., 1987). Following these studies
Maddon et al constructed cell lines expressing defective CD4 molecules that were
unable to undergo RME, yet found they remained susceptible to HIV infection.
This suggests a mechanism whereby binding of the virus to the CD4 molecule is
followed by the direct introduction of its RNA into the cell by fusion with the cell
membrane (Maddon et al., 1988).
Little more is known about the fusion event itself, how the fusion process is
triggered and the intra- and intermolecular associations involved. It is likely that
this step is mediated by a region of hydrophobic amino acids at the amino terminal
end of the TM protein, gp41 (Kowalski et al., 1987; Freed et al., 1990).
Substitutions within gp41 which insert charged amino acids into this hydrophobic
region have been found to impair syncytium formation (Kowalski et al., 1991).
Regions in the carboxy and amino terminal 30 residues of gpl20 have been found
in association with gp41 (Ivey Hoyle et al., 1991; Helseth et al., 1991), and are
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thought to form a molecular pocket masking the amphipathic regions of gp41.
Interaction of gpl20 with the cell surface receptor CD4 is subsequently thought to
trigger conformational changes resulting in dissociation from gp41 exposing the
fusogenic domain (Freed et al., 1990). This also results in the shedding of gpl20
since both glycoproteins are weakly associated through non-covalent bonds on the
virion surface (Gelderblom et al., 1987). Epitope mapping studies have shown that
upon binding of soluble CD4 to gpl20 conformational changes important for fusion
occur in the V3 loop (Sattentau et al., 1991). Similarly, neutralizing antibodies
against V3 can inhibit HIV infection without preventing CD4 binding, suggesting
the V3 loop is involved in post-binding events (Skinner et al., 1988).
1.2.8.3 REVERSE TRANSCRIPTION.
All retroviruses must reverse what is generally thought to be the normal
flow of genetic information, DNA to RNA to protein, because their genome is
entirely composed of RNA and hence must convert genomic RNA into DNA prior
to protein synthesis. This phenomenon is achieved in the cell cytoplasm by the
action of the virally encoded enzyme RT. The viral RNA genome is synthesised
using a host DNA-dependant RNA polymerase (DNA-dep RNA pol) and as a
consequence contains cellular post-translational modifications, namely the 5' end of
the genome is capped (Gppp) and the 3' end has a poly A tail (AAA; Weiss et al.,
1985). Reverse transcription is initiated at the 5' end of the RNA genome and
requires a host cell molecule, transfer RNA (tRNA), to act as the initial primer of
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DNA synthesis. This tRNA is complementary to a region of the genome known as
the primer binding site (PBS) near the 5' end of the viral genome. An RNA-
dependant DNA polymerase (RNA-dep DNA pol) activity of RT uses this primer
to synthesise a DNA copy of the 5' U5 and R regions of the genome. A second
component of RT, RNaseH, then degrades the RNA copied by the polymerase
allowing the newly synthesised DNA region to act as a second primer binding site
to the complementary R sequence at the 3' end of the genome. This transfer is
known as the first jump. Synthesis of the (-) DNA strand is then completed using
the RNA-dep DNA pol, while the RNaseH degrades the remainder of the RNA
template. A small region is left upstream of the 3' U3 and R regions which acts as
the primer for (+) strand DNA synthesis. Synthesis of the (+) strand begins at the
3' end of the (-) DNA strand and continues through U5 and the tRNA primer. A
second jump occurs, as the tRNA primer is complementary to the 5' PBS,
completing the synthesis of the (+) DNA strand. Synthesis of the (+) DNA strand
can occur as an intermolecular or an intramolecular event.
1.2.8.4 INTEGRATION.
Following reverse transcription double stranded HIV DNA is transported to
the nucleus in association with a nucleoprotein complex. Once in the nucleus HIV
is integrated into the host genome in its linear form. Integration is catalyzed using
the virally encoded enzyme IN. This process can be separated into three stages, the
first being the removal of two bases from the 3' ends of both DNA strands.
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Second, the 3' ends of the viral DNA are joined in a concerted reaction to
previously nicked sites in the host DNA. Finally, the gaps in the mismatched
intermediate are repaired (Engelman et al, 1991). The integrated HIV DNA
genome is known as the HIV provirus. This integration process was thought to
occur at random sites within the host genome however there is some evidence that
integration occurs at 'hot spots' in the host genome (Scherdin et al., 1990).
Following integration some retroviruses persist for the lifetime of the cell, and may
spread further amongst the descendants of the cell as each harbour copies of the
original provirus in their genome.
1.2.8.5 SYNTHESIS OF HIV-1 RNA.
Synthesis of HIV RNA is initiated by cellular proteins called transcription
factors. The 5' LTR of HIV contains similar sequences to regions of the host
genome which bind these proteins initiating transcription. The HIV provirus can
therefore effectively hijack the cellular transcription machinery. As previously
mentioned transcription occurs in two stages, early and late. Cellular transcriptional
factors initiate mRNA synthesis and maintain it at a basal level which is
insufficient to drive replication. Significant levels of fully spliced HIV mRNA are
achieved by the action of the regulatory protein tat. This protein binds a specific
region at the 5' end of the mRNA termed trans-activation response element (TAR).
It is thought that tat acts to stimulate elongation by RNA polymerase II leading to
the synthesis of complete mRNAs. When sufficient mRNA is produced rev acts as
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a balance shifting the synthesis of short, multiply spliced mRNAs to the production
of late, singly spliced and unspliced mRNAs encoding the structural proteins.
1.2.8.6 ASSEMBLY AND RELEASE.
Retroviral assembly and release is controlled by interactions between the
gag proteins, viral genomic RNA and the plasma membrane of the cell. The pol
and gag gene products are incorporated into virions in the form of their polyprotein
precursors, pl60 (gag:pol) and p55 (gag). They undergo proteolytic cleavage
during or after budding from the cellular membrane to form mature virus particles.
The amino-terminus of these precursors are post-translationally modified by the
addition of myristic acid which facilitates the interaction with the membrane
(Vazeux et al., 1992). The gag and gag:pol precursors are cleaved by the viral PR
enabling morphological maturation of virions. Incorporation of envelope
glycoproteins during virus budding is essential for the formation of infectious
virions. HIV envelope glycoproteins are incorporated as a gpl20-gp41 complex
which mediates attachment and membrane fusion. The process by which this
complex is incorporated into virions is not well understood. However, a number of
studies suggest that the MA protein and the cytoplasmic tail of gp41 may interact
during virus assembly and release (Freed et al., 1996; Dorfman et al., 1994).





The quest to abrogate HIV infection has proved to be a very difficult task.
The complex nature of this virus and its life cycle has impeded and mystified
scientists in this field for almost 15 years. A number of strategies have been
employed, not only to try and prevent infection and replication of this elusive
virus, but also to prolong and improve the lives of those infected. A great deal of
effort has been directed towards the identification of viral receptor(s) and
elucidating the life cycle of HIV since its discovery in 1982. An important impetus
for such investigations is the possibility of the development of effective antiviral
agents. A number of potential targets, during the life cycle of HIV-1, have been
identified which may present opportunities for antiviral therapy (Table 4). Reverse
transcription is a phenomenon unique to retroviruses. The first successful inhibitor
of RT activity was a dideoxynucleoside analogue that had initially been synthesized
as a potential therapy for cancer, 3'-azido-3-deoxythymidine or AZT (zidovudine).
It acts as a competitor for nucleotides used by the polymerase and is a potent chain
terminator of viral DNA synthesis. Initial studies on the efficacy of this antiviral
drug demonstrated increased levels of CD4+ T cell counts, and delayed
development of AIDS-defining symptoms in symptomatic and asymptomatic
individuals (Volberding et al., 1995; Fischl et al., 1990; Fischl et al., 1987). There
has been a great deal of debate regarding when, during infection, AZT should be
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TABLE 4: POTENTIAL TARGETS FOR THERAPEUTIC DRUGS.



















Ig, immunoglobulin; AZT, 3'-azido-3-deoxythymidine; ddl, 2',3'-
dideoxyinosine; ddC, 2',3'-dideoxycytidine.
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administered to provide the greatest benefit. A number of early studies
demonstrated that early administration was more effective in slowing progression to
disease (Fauci, 1993a; Cooper et al., 1993a; Graham et al., 1992a; Volberding et
al., 1995a). However, the Concorde trial revealed that patients who received AZT
prior to developing symptoms progressed to AIDS as quickly as those who were
given AZT once symptoms had developed (Concorde coordinating committee.
1994). The benefits of AZT monotherapy have been shown to be of limited
duration with resistant strains emerging, especially after prolonged therapy,
associated with mutations at four positions in HIV RT (Boucher et al., 1992).
Other nucleoside analogues that inhibit RT activity have also been developed,
didanosine (2',3'-dideoxyinosine [ddl]; Lambert et al., 1990), zalcitabine (2',3'-
dideoxycytidine [ddC]; Yarchoan et al., 1994; Yarchoan et al., 1988) and stavudine
(d4T; Broune et al., 1993; Anonymous., 1993). Combinational therapy with one or
more nucleoside analogue drug may reduce the emergence of resistance through
synergistic or additive effects (Fischl et al., 1995; Knox et al., 1996; Larder et al.,
1996).
The limited success of nucleoside analogue RT inhibitors (AZT, zalcitabine,
ddl, ddC) in HIV infected patients led to the development of drugs that use
alternative viral targets. The protease of HIV is essential for replication of the
virus. It cleaves the gag (p55) and gag:pol (pl60) polyproteins into the structural
gag proteins and three virally encoded enzymes, RT, IN and PR itself. HIV
protease is also distinct from human proteases making it a very favourable target
for antiviral therapy. To date four protease inhibitors have shown antiviral activity
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in patients; saquinavir, idinavir, ritonavir and nelfinavir (Nelson, 1996; Vella,
1994). It was initially thought that due to the nature of this enzyme the
development of resistance would be less of a problem than that encountered with
RT inhibitors. However, resistance was seen to accumulate rapidly (Eastman et al.,
1995; Molla et al., 1996; Jacobsen et al., 1996; Markowitz et al., 1995; Condra et
al., 1995; Danner et al., 1995). For example the antiviral effects of idinavir were
lost within 12-24 weeks. Fortunately, increasing the dose given resulted in
inhibition of virus replication and delayed drug resistance without increased
toxicity (Markowitz et al., 1995; Danner et al., 1995).
An accumulation of three or more mutations was found to confer resistance
to these viral variants. Also cross resistance with other protease inhibitors was
evident raising concern that treatment with one protease inhibitor would confer
resistance to all (Condra et al., 1995). These observations reflect the commonality
in the action of these antiviral drugs and suggest that divergent, as opposed to
convergent, strategies may have a more favourable outcome for combination
therapy. A number of studies have been carried out to investigate the therapeutic
potential of combination therapies using two and three combined drug regimes
(Caliendo et al., 1994 and references within). A randomised double blind controlled
trial (Delta) compared combinations of RT nucleoside inhibitors with therapeutic
potential of AZT alone (Delta co-ordinating committee., 1996). Treatment with
AZT combined with ddl or ddC resulted in prolonged survival when compared
with AZT alone. A similar double blind trial comparing the combination of three
drugs (AZT, saquinavir and zalcitabine) was found to result in a considerably more
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favourable outcome than with combinations of AZT and saquinavir or AZT and
zalcitabine (Collier et al., 1996). This triple combination resulted in a reduction in
HIV-1 replication, increased CD4+ T cell counts and decreased the level of serum
(3-2-M and neopterin. Another trial investigating the combination of AZT,
lamivudine and idinavir in symptomatic patients and found this triple combination
resulted in the clearance of HIV viraemia to below the limit of detection by PCR
(500 copies per ml; Delfraissy, 1993). More recently, the potential use of
combination therapy in infants with maternally acquired HIV-1 infection was
investigated (Luzuriaga et al., 1997). Previous therapeutic strategies for infants has
primarily consisted of a single RT inhibitor showing moderate efficacy with limited
duration. The three drug regime investigated (AZT, ddl and nevirapine) was found
to reduce plasma RNA levels within four weeks of administration. Also, of the 8
infants examined 7 were found to have reduced levels of HIV-1 RNA in plasma
(0.5 log) for the duration of the trial (6 months).
1.3 DIVERSITY OF HIV-1.
Following the discovery of HIV-1 it was reported that the viral genome
displayed a high degree of variability (Hahn et al., 1984). In early studies
restriction mapping of molecularly cloned provirus was used to describe this
heterogeneity. Saag et al., described variation within three HIV-1 isolates (RJS4,
WMF1 and WMF3) by restriction mapping of 17 to 27 clones (Saag et al., 1988).
This study revealed 17 of 27 RJS4 clones, 9 of 17 WNF1 clones and 13 of 18
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WMF3 clones had distinct cleavage patterns, although intrapatient variation was
decidedly less than interpatient variation. However, two sequential isolates
recovered 16 months apart (WMF1 and WMF3) contained no identical clones
(estimated nucleotide divergence of 2 to 7%) indicating a rapid rate of change of
HIV-1, a finding consistent with results obtained by Fisher et al (Fisher et al.,
1988). Shaw et al., compared the restriction patterns of HIV-1 from a number of
AIDS patients in a number of different T cell lines and found varying restriction
patterns (Shaw et al., 1984). HIV-1 has been cloned and sequenced by a number of
independent research groups and a large number of nucleotide differences were
detected (Muesing et al., 1985; Sanchez-Pescador et al., 1985; Ratner et al., 1985).
Both restriction mapping and complete sequencing of clones proved to be very
labour intensive and the resolution obtained by restriction mapping was low. The
introduction of the polymerase chain reaction (PCR) heralded a new era in
molecular biology making it possible to amplify small quantities of DNA, such as
those found in PBMC's (Ou et al., 1988). In a study by Goodenow et al., two
regions of the HIV-1 genome were amplified by PCR (gag and env segments) and
multiple clones sequenced (Goodenow et al., 1989). They detected sequence
heterogeneity in both regions with varying degrees of complexity. A number of
other studies have been carried out which report findings of genomic heterogeneity
in HIV-1 (Hahn et al., 1986; Wong-Staal et al., 1985; Alizon et al., 1986; Ratner
et al., 1985; Benn et al., 1985), both within and between patients, reminiscent of
other RNA viruses such as influenza A (Young et al., 1979; Webster et al., 1982),
poliovirus (Nottay et al., 1981), foot and mouth disease virus (FMDV; Domingo et
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al., 1980), enterovirus 70 (Takeda et al., 1984)} and other retroviruses such as
visna virus (Lutley et al., 1983) and equine infectious anemia virus (Montelaro et
al., 1984). Genomic heterogeneity of this nature has given rise to the concept of a
quasispecies commonly used to describe a population of closely related yet
genetically distinct viral variants.
There is a great deal of discussion regarding the generation of diversity in
HIV-1. The complex nature of the HIV-1 life cycle provides many opportunities
for mutation. Retroviruses require three enzyme systems during replication, reverse
transcriptase, cellular DNA polymerase and RNA polymerase, of which the most
attention has centred on the reverse transcriptase. Secondly, HIV-1 has the ability
to transfer from one template to another during DNA synthesis, known as strand
transfers or 'jumps', which are required to generate the LTR's at either end of the
viral genome. However, other factors may enhance genetic diversity such as the
high turnover rate of HIV-1 and various selective forces imposed by the host
immune response and requirements for cell tropism.
Genetic variability is determined by three separate variables: the mutation
rate per replication cycle, the number of replication cycles in a given time and the
selective advantage or disadvantage of a particular variant. A number of studies
have attempted to calculate the in vivo mutation rate of a number of retroviruses.
However, experiments of this nature are problematic in that the accumulation of
mutations in a single round of replication must be measured to eliminate the effects
of selection. In order to circumvent this difficulty Dougherty and Temin used a
retroviral DNA vector system to measure the mutation rate of spleen necrosis virus
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(SNV; Dougherty et al., 1988), using selectable marker or reporter genes, in which
the replication cycle was limited to one round. They determined that the mutation
rate for a single base pair substitution was 2 x 10"5 per base pair per replication
cycle and an insertion rate of 10"7 per base pair per replication cycle. Using a
different SNV based vector, the base substitution mutation rate over a longer
sequence was found to be 0.7 x 10"5 per base per replication cycle, corroborating
the findings of Dougherty and Temin (Pathak et al., 1990). Monk et al., determined
the point mutation rate of a murine retrovirus by direct examination of RNAs from
viruses isolated after a single replication cycle, reporting a mutation rate of 2 x 10"5
bases per replication cycle (Monk et al., 1992). Studies on Rous sarcoma virus
have estimated the mutation rate to be in the order of 10"3 to 10 4 (Leider et al.,
1988; Coffin et al., 1980). From these studies the mutation rate for HIV-1 was
previously estimated to be of the order of 10"4 per base per replication cycle
(Nowak et al., 1991b; Wain-Hobson, 1993b), comparable to the error rate of
purified HIV-1 RT (Gregson et al., 1994). However, a recent study by Mansky et
al., determined the mutation rate of HIV-1 to be 3.4 x 10"5 mutations per base pair
per replication cycle, 20 fold less than previous error rates (Mansky et al., 1995).
The point mutation rates for retroviruses are in the range of estimates for RNA
viruses in general, for example, influenza virus (1.5 x 10"5; Parvin et al., 1986) and
poliovirus (2 x 10"6; Sedivy et al., 1987; Parvin et al., 1986). This suggests that the
extraordinary diversity of HIV-1 is not only due to a relatively high mutation rate
but may also reflect the number of replication cycles and the fixation rate of
mutations.
84
The high level of RNA virus diversity has been attributed to error prone
replicating enzymes. For example, nucleotide misincorporation in retroviruses is
uncorrected as RT does not encode an exonuclease activity (Battula et al., 1976;
Roberts et al., 1988), and hence any errors arising during transcription are not
subject to proofreading. A number of studies have been carried out to measure the
fidelity of HIV-1 RT (Bebenek et al., 1989; Roberts et al., 1988; Preston et al.,
1988). Using nonsense codon reversion assays, the error rate of HIV RT was
1/1700 (Roberts et al., 1988) to 1/4000 (Preston et al., 1988), translating to
approximately 5 to 10 errors per HIV-1 genome per round of replication in vivo.
Error rates for HIV RT are approximately 10 fold higher when compared with
avian myeloblastosis virus or murine leukaemia virus, both lacking an RT
proofreading mechanism, with error rates of 1/9000 (Preston et al., 1988) to
1/17000 (Roberts et al., 1988) and 1/30000 (Roberts et al., 1988) respectively.
These findings suggest that the lack of a proofreading activity alone may not
completely explain the infidelity of HIV-1 RT. Indeed a number of studies have
described a variety of other types of errors or rearrangements in addition to base
pair substitutions which may greatly increase the infidelity of this enzyme. These
include frameshifts, deletions, insertions and recombination events (Katz et al.,
1990; Coffin, 1992; Bebenek et al., 1989; Temin, 1993). Furthermore, these studies
have revealed that certain regions of the genome have a significantly higher error
rate suggesting there may be 'hotspots' for mutation in the HIV-1 genome. For
example Bebenek et al., suggested the mutation rate for env was in the region of
103 nucleotide substitutions per site per year while that for gag was in the region
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of 10"4 nucleotide substitutions per site per year (Bebenek et al., 1989). Indeed, the
env region itself is composed of conserved and hypervariable regions (Willey et al.,
1986; Starcich et al., 1986; Modrow et al., 1987). Regions of hypermutation have
also been documented, characterised by a large number of G to A changes
particularly within GpA dinucleotides (Bebenek et al., 1989; Pathak et al., 1990;
Vartanian et al., 1991). It was proposed that hypermutation may be due to slippage
and realignment during reverse transcription, termed dislocation mutagenesis (Wain
Hobson, 1992; Bebenek et al., 1989; Vartanian et al., 1991).
Although the above experiments reveal a high rate of mutation they do not
distinguish between the enzyme systems utilized during HIV-1 replication. The
fidelity of RNA polymerase II is not known but it is likely to be of the same order
as other viral RNA polymerases i.e. approximately 10"4. Therefore, errors
incorporated in genomic RNA during synthesis may be equally important as those
produced by RT during transcription in the generation of sequence variation. An
alternative mechanism has been proposed, by Temin, who suggested variation may
be a direct consequence of strand transfers during DNA synthesis, required to
generate LTR sequences at either end of the proviral DNA (Temin, 1993). Hence,
(-) strand synthesis may transfer back and forth between the two RNA templates
present, using a similar mechanism to the production of the LTR's, increasing
genetic diversity.
Genetic recombination is frequently observed during the life cycle of
retroviruses. Both avian and murine type C viruses display a high frequency of
genetic recombination (Wyke et al., 1979; Vogt, 1971; Linial et al., 1979; Hunter,
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1978; Coffin, 1979; Blair, 1977). Recombination within lentiviruses has not been
well documented although recombination between HIV-1 genomes has been shown
to occur (Hu et al., 1990; Vartanian et al., 1991; Srinivasan et al., 1989; Clavel et
al., 1989). The above studies may have produced somewhat erroneous results since
recombination events described occurred in tissue culture systems and may not be
observed during in vivo infection. Recently a study by Robertson et al., analysed a
number of published HIV-1 sequences and reported a large number of apparent
recombinant viruses (Robertson et al., 1995), implying co-infection with divergent
HIV-1 stains may not be as rare as previously predicted (Sabino et al., 1994).
Interestingly all the possible recombinant viruses originated from geographic
regions where multiple subtypes are known to co-circulate, for example, Central
Africa, South America and South East Asia (Clavel et al., 1989). Therefore,
recombination is increasingly being recognised as a biological phenomenon among
HIV-1 isolates/subtypes and may play an important role in viral evolution.
Evolution of the virus is greatly enhanced by the very high rates of
replication. It has been known for some time that HIV-1 actively replicates
throughout the course of infection (Embretson et al., 1993; Pantaleo et al., 1993).
However, recent findings have revealed that HIV-1 infection is a highly dynamic
process in which very high levels of virus replication and CD4+ cell turnover are
apparent. By treating patients with a number of antiviral drugs Wei et al., and Ho
et al., were able to show that both virus and CD4 cells in the peripheral blood
exhibit fast rates of turnover (Ho et al., 1995; Wei et al., 1995). Extrapolating from
changes seen in the blood they estimated that between 108 and 109 virions were
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cleared daily. Since a steady state is observed during infection the number of
virions cleared daily must be equal to the number produced daily. Therefore with
approximately 109 virions produced each day the scope for creating diversity must
be extremely high.
Regardless of how the extensive variation in HIV-1 is generated the
ultimate result will be determined by the selective forces acting on HIV-1 variants.
For example, a number of studies have described the isolation of minor variants
upon in vitro cultivation in PBMC's, suggesting the preferential selection of those
viruses best adapted to tissue culture conditions (Vartanian et al., 1991; Meyerhans
et al., 1989). The degree of diversity among different strains of HIV-1 may be
partly due to selection by the host immune system. This is supported by in vivo
studies which have demonstrated the generation of viruses that have escaped
neutralization by serum antibodies (Robert-guroff et al., 1986; Reitz et al., 1988;
McKeating et al., 1989). Similarly, resistant mutants can also be selected for in the
presence of antiviral drugs, such as AZT (Larder et al., 1989). Differences have
also been reported regarding the cellular host range among HIV-1 strains. Various
studies have shown that some viruses grow in certain T, B and monocyte cell lines
while others do not (Schwartz et al., 1989; Sakai et al., 1997; Levy et al., 1985;
Fenyo et al., 1988; Cloyd et al., 1990). Different strains have also been found
during early and late stages of infection showing substantial variability in
replicative abilities in T cell lines and macrophages (Schwartz et al., 1989; Fenyo
et al., 1989). Similarly, selective forces can act on coding regions which may result
in the accumulation of mutations that generate new functions. For example, various
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groups have shown that the sequence of the V3 envelope region can influence
tropism for T cell lines or macrophages (Westervelt et al., 1992; Westervelt et al.,
1991; Shioda et al., 1991; O'Brien et al., 1990; Hwang et al., 1991; Rhim et al.,
1991; Chesebro et al., 1992). Therefore, diversity of HIV-1 may facilitate infection
of different cell types in vivo.
1.4 TROPISM OF HIV-1.
1.4.1 HIV-1 INFECTION OF DIFFERENT CELL TYPES.
HIV infects a wide variety of tissues in vivo, and has been detected in a
number of human cell lines in culture. Using various techniques, such as cell
culture, in situ hybridization, immunohistochemistry, electron microscopy and PCR,
HIV has been detected in vivo in cells of the haematopoietic lineage (Freedman et
al., 1991; Livingstone et al., 1996; Tsubota et al., 1989; Patterson et al., 1994;
Knight et al., 1993; Ali et al., 1993; Uittenbogaart et al., 1996; Shattock et al.,
1996; Nicholson et al., 1986; Levy et al., 1985; Scottalgara et al., 1993; Kunzi et
al., 1993; Gartner et al., 1986; Cullen, 1991), brain (Wiley et al., 1996; Wiley et
al., 1986; Pang et al., 1990; Koenig et al., 1986; Price et al., 1988; Li et al., 1991;
Moses et al., 1993; Wiley et al., 1990; Gartner et al., 1986), gastrointestinal tissue
(Kotler, 1993; Pumarola Sune et al., 1987; Gill et al., 1992), heart (Luginbuhl et
al., 1993; Grody et al., 1990), lungs (Plata et al., 1990; Dolei et al., 1992; Chayt et
al., 1986), kidneys (Cohen et al., 1989), adrenals (Barboza et al., 1992), eye
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(Cantril et al., 1988), salivary glands (Qureshi et al., 1995), cervix (Nuovo et al.,
1993), prostate (da Silva et al., 1989), testes (Bagasra et al., 1994; da Silva et al.,
1989) and skin (Tschachler et al., 1987). Similarly, cell culture studies have shown
a wide variety of human cells to be susceptible to infection with HIV-1. Initial
studies carried out to delineate the host cell range of HIV-1 suggested that CD4+
lymphocytes were preferentially infected (Klatzmann et al., 1984a; Coffin et al.,
1986a; Dalgleish et al., 1984a).
The concept of differential tropism arises from several studies which have
shown HIV-1 strains differ in their ability to productively infect various human
cells in in vitro culture (Folks et al., 1986; Evans et al., 1987; Levy, 1988;
Kikukawa et al., 1986; Levy et al., 1985). Established T cell lines expressing
similar amounts of CD4 antigen on their surface displayed widely varying degrees
of virus production and induction of cytopathic effect (Evans et al., 1987;
Kikukawa et al., 1986). A similar variation in virus production was observed
following infection of human peripheral blood lymphocytes, from a number of
seronegative individuals, with HIV-1 (Folks et al., 1986; Evans et al., 1987).
The host range or tropism of a virus may be controlled at the entry level or
post entry level. In some retroviral systems tropism of the virus is determined at
the entry level by a receptor-ligand interaction at the cell surface. For example, in
feline leukaemia virus (FeLV) the 3'/>o/-5'env region of the FeLV genome
determines the host range of the virus (Reidel et al., 1988). The envelope protein
of Avian leukosis virus, gp85, specifically interacts with distinct cellular receptors
(Dorner et al., 1986). However, in other retroviral systems the expression of other
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viral genes contributes to the host range of the virus. It has been suggested that
sequences within murine leukaemia virus (MuLV) LTR region and gag gene
interact with cellular factors influencing host range and tissue tropism (Evans et al.,
1987; Celander et al., 1984). In a murine retrovirus, involvement of multiple genes
has been suggested to enhance tropism and oncogenesis (located mainly in the 3'
half of the genome, although sequences in the 5' half have also been identified;
Holland et al., 1985). When the effect of each gene was examined alone a
markedly reduced effect was apparent and only moderately increased when using a
combination of two.
Several studies have identified the CD4+ molecule as the major receptor for
HIV-1 infection (Fisher et al., 1988; McDougal et al., 1986; McDougal et al.,
1986; Maddon et al., 1986). Maddon et al., expressed the CD4+ molecule in a
number of human CD4- cell lines and found that expression of the CD4+ molecule
was sufficient to render human cells susceptible to HIV-1 infection (Maddon et al.,
1986). McDougal et al., carried out binding and blocking experiments to show the
direct binding of HIV-1 to CD4+ molecules and reciprocally, the inhibition of this
action with anti-CD4+ antibodies (McDougal et al., 1986b). A number of groups
have constructed truncated soluble forms of the CD4+ molecule (Berger et al.,
1988; Deen et al., 1988; Smith et al., 1987). All were shown to block HIV-1
infection of CD4+ cells measured by the inhibition of infectivity, syncytium
production and binding. Further studies have delineated the region on the CD4
molecule involved in the highly specific interaction with the virion surface
proteins, namely the D1 domain (see section 1.2.8.1).
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Although CD4 is recognised as the major receptor for HIV, it has been
known for some time that CD4 expression alone was not sufficient for HIV
infection. This was first demonstrated by Maddon et al who showed that when
human CD4 is expressed in mouse cells, HIV is unable to gain entry (Maddon et
al., 1986). Subsequently, a number of cells that do not express the CD4 antigen on
their surface have been productively infected with HIV-1 (Li et al., 1990; Chesebro
et al., 1990; Cao et al., 1990; Tateno et al., 1989; Harouse et al., 1989; Folks et
al., 1988; Chiodi et al., 1987; Cheng Mayer et al., 1987; Clapham et al., 1989;
Dewhurst et al., 1987). HIV molecular clones have been transfected into a wide
variety of cells including human T lymphocytes and monocyte cell lines
(permissive for HIV-1 infection) and human, mouse, mink and monkey fibroblast
cell lines (resistant to direct HIV-1 infection; Nowak et al., 1991b; Cichutek et al.,
1992b). Both these studies demonstrate the production of infectious virus particles
in all cell lines examined, suggesting the block to HIV-1 infection primarily occurs
at the cell surface. Intracellular mechanisms may also participate in controlling
virus replication since virus production by human and animal fibroblast cell lines
was greatly reduced when compared with that of human lymphocytes (Nowak et
al., 1991b). Similar findings were observed using phenotypically mixed particles or
pseudotypes produced through co-infection with HIV-1 and an animal retrovirus.
For example, murine amphotropic retrovirus (Spector et al., 1990), or the
xenotropic or dual tropic mouse type C virus (MuLV; Canivet et al., 1990). Both
human and animal cell lines became productively infected, however replication was
best in human cells and very limited in murine and avian cells. These findings lead
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to the speculation that a co-factor or possible second receptor may be required for
infection. A number of candidates have been proposed as accessory molecules,
including MHC class I and II (Grassi et al., 1991), LFA-I (Hildreth et al., 1989),
tryptase II (Hattori et al., 1989), CD26 (Alizon et al., 1994; Callebaut et al., 1993)
and a number of undefined molecules (Henderson et al., 1993). Recently a number
of proteins from the superfamily G-protein-coupled-receptors with a characteristic
seven transmembrane domain have been implicated as co-factors required for HIV-
1 entry. The first to be characterised was CXCR-4 which facilitates the infection of
T cell lines but not infection of macrophage tropic stains of HIV-1 (Feng et al.,
1996). A second co-receptor for HIV which facilitates infection of macrophage
tropic strains was identified simultaneously by three research groups and is called
CCR-5 (Alkhatib et al., 1996; Dragic et al., 1996; Deng et al., 1996).
1.4.2 DIFFERENTIAL PROPERTIES IN THE HOST RANGE OF HIV-1.
A large number of studies have been carried out to investigate the
biological properties of variants of HIV-1 infecting different tissues. Several studies
have demonstrated that different HIV-1 isolates infect monocytes more readily than
T cells (Koyanagi et al., 1987; Gartner et al., 1986; Cheng Mayer et al., 1990;
Gendelman et al., 1990; Schuitemaker et al., 1991; Briesen et al., 1990; Valentin et
al., 1990). Gartner et al., compared viral isolates obtained from lung and brain
derived macrophages, and found they displayed a significantly higher ability to
infect macrophages than T cells (Gartner et al., 1986b). These findings are in
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contrast with the properties of the laboratory adapted isolate, HIV-IIIB, which
showed a 10,000 fold lower ability to infect macrophages than T cells. A second
study compared isolates from cerebrospinal fluid (CSF) and brain tissue from
patients presenting with AIDS encephalopathy (Koyanagi et al., 1987). Both
isolates were found to replicate efficiently in PBL's, although efficient and
productive infection of macrophages was only accomplished using isolates obtained
from brain tissue.
Kinetic studies have described differences in cytopathogenicity and
replicating abilities among HIV-1 isolates. Initially pathogenic strains of HIV were
identified using the MT-4 plaque assay which identified HIV variants with
enhanced replication kinetics and cytopathogenicity isolated from patients with
clinical disease compared to healthy seropositive individuals (Tateno et al, 1988).
Subsequently, an increasing number of studies have reported a relationship between
the clinical severity of HIV-1 infection and the in vitro replication potential of
HIV-1 (Tersmette et al., 1988; Fenyo et al., 1989; Sakai et al., 1988; Fenyo et al.,
1988; Schwartz et al., 1989; Asjo et al., 1986). It has been suggested that HIV-1
exists in two different states early and late in infection. Viruses isolated from
asymptomatic individuals are thought to be less virulent, displaying low replication
rates, do not produce syncytia and replicate efficiently in macrophages but not
transformed T cell lines. These have been designated as slow/low, non syncytium
inducing viral isolates (NSI). During disease progression more virulent strains can
be isolated displaying higher replication rates and decreased ability to replicate in
macrophages (SI). In approximately 50% of all infected individuals SI isolates
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emerge which have the capacity to cause syncytia and replicate in transformed T
cell lines. These have been designated rapid/high viral isolates.
In order to understand the differences involved during replication of these
isolates Schwartz et al., were able to distinguish between slow/low and rapid/high
isolates using the CAT bioassay (Schwartz et al., 1989). Rapid/high isolates can
activate CAT expression in T lymphoid and monocytoid cell lines, whereas
slow/low viruses only activate CAT expression in monocytoid cell lines. This assay
is based on the ability of HIV-1 isolates to activate an LTR derived from the
HXB2c molecular clone ( isolated from the laboratory adapted strain HIVIIIB). A
block in productive infection of T cell lines by the slow/low isolates must therefore
take place early in the infection cycle and is probably associated with a lack of
entry.
1.4.3 ROLE OF THE V3 REGION OF gpl20 IN CELLULAR TROPISM
Regions located in the env gene of gpl20 outwith the CD4 binding domain
(carboxy terminal) have been associated with viral tropism. These include the VI,
V2 and V3 hypervariable regions. While most HIV-1 stains are capable of
replication in primary lymphocytes, replication in other cell types is more restricted
(Schuitemaker et al., 1991). HIV-1 isolates capable of infecting macrophages are
generally unable to infect T cell lines and vice versa (Cheng-Mayer et al., 1988).
The restriction of HIV-1 isolates for replication in macrophages is thought to be at
the level of virus entry, the critical determinant being within the V3 region of
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gpl20. V3 also serves as a major target for neutralizing antibodies (Rusche et al.,
1988; Matsushita et al., 1988; Javaherian et al., 1989). Additional studies have
shown that V3 contains epitopes that elicit CTL responses (Takahashi et al., 1989;
Clerici et al., 1991). Extensive sequence analysis has been carried out on the V3
region to identify the regions of the virus responsible for macrophage tropism.
Hwang et al., demonstrated that the V3 loop was a major determinant of cell
tropism. They substituted a 20 amino acid sequence from the V3 loop of a
macrophage tropic isolate (HIVBAL) into a T cell tropic virus (HTLVjIIB). This
provirus (IIIB/V3-BaL) replicated in macrophages equally as well as the HIVBAL
proviral clone but was no longer able to infect T cell lines (Hwang et al., 1991).
Shioda et al., constructed recombinant viruses between molecular clones of HIV-1
isolates showing differential abilities to infect T cell lines and macrophages (HIV-
1SF2: T cell line tropic and HIV-1SF162: macrophage tropic; Shioda et al., 1991a).
They found that infection of primary macrophages was associated with a 159
amino acid region encompassing the V3 hypervariable region. A similar finding
was reported by O'Brien et al., following examination of the molecular clone HIV-
1 JR.FL (O'Brien et al., 1990).
A number of studies have reported an accumulation of amino acid
substitutions within the V3 region during the course of infection, some of which
alter the cellular host range of HIV-1 variants (Morris et al., 1994; Shioda et al.,
1994; Wolfs et al., 1991; Chesebro et al., 1992). Macrophage-tropic isolates
showed remarkable similarity in V3 while T cell tropic isolates were found to be
highly heterogenous (Chesebro et al., 1992; Yamashita et al., 1994). Morris et al.,
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found that a single amino acid substitution at position 312 (threonine to alanine) in
the V3 loop resulted in the generation of a revertant virus, infectious for Sup-Tl
cells (T cell-line) but not for AA5 cells (Epstein barr virus transformed B cell line
highly permissive for HIV-1 infection). A subsequent mutation at position 306
(arginine to serine) restored the ability of the virus to infect AA5 cells (Morris et
al., 1994). Substitution of an acidic amino acid (aspartic acid) for a basic amino
acid (lysine) at position 30 (from the first cysteine) in the V3 loop altered the
capabilities of a recombinant virus to grow in a human T cell line (Oka et al.,
1994; Shioda et al., 1994). A study by Wolfs et al., observed a reduction in the
binding affinity of a patients antibodies following an amino acid substitution at
position 308 in the V3 loop. Subsequently, a specific humoral immune response
was mounted against this new variant indicating antigenic variation within the viral
population (Wolfs et al., 1991). This amino acid has previously been reported to be
a critical determinant of antibody binding specificity (McKeating et al., 1989).
Analysis of V3 loop sequences obtained from cloned and primary HIV-1
isolates has revealed a distinct pattern of amino acid substitutions within this region
that correlated with virus phenotype (Millich et al., 1993). It was found that a
combination of non-conservative basic amino acid substitutions in positions 11, 24,
and 32 plus a basic or uncharged amino acid residue at position 25 were predictive
of an SI phenotype. The presence of an acidic amino acid at position 25 was found
to correlate with an NSI phenotype. These findings are consistent with previous
analyses of this hypervariable loop (de Jong et al., 1992; Koup et al., 1994;
Fouchier et al., 1992; Shioda et al., 1992; Shioda et al., 1994; Morris et al., 1994).
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Several studies have shown that amino acid substitutions flanking the GPGR
sequence (found predominantly in V3 sequences) were sufficient to alter virus
tropism to T cell-line tropic (de Jong et al., 1992; Chesebro et al., 1992). De Jong
et al., found a correlation between a high charge in the V3 region, due to basic
amino acid substitutions, and an SI phenotype (de Jong et al., 1992). A more
recent study has examined the V3 loop in a number of HIV-1 group O isolates of
known phenotype, as determined by the MT-2 assay (de Jong et al., 1996). SI
isolates were found to have a high net positive charge with a positive amino acid at
positions 11 or 25, while NSI isolates had a low positive net charge accompanied
by a positive charge at position 37.
A recent study carried out by Donaldson et al., investigated the in vivo
distribution and cytopathology of HIV-1 (Donaldson et al., 1994a). The aim of this
study was to investigate whether there were consistent differences between HIV-1
variants obtained from lymphoid tissue (lymph node, spleen and PBMCs) with
those from non-lymphoid tissues (brain, spinal cord, lung and colon). Comparisons
of variants from lymphoid and non-lymphoid tissues between asymptomatic and
symptomatic individuals were not possible as it has previously been shown that
HIV-1 is not detected in non-lymphoid tissue until the onset of AIDS (Donaldson
et al., 1994b). In the group of patients dying in AIDS, distinct HIV-1 populations
were detected in different organs, although a general observation was of a common
set of sequences present at varying frequencies within the tissues sampled. For
example, the major V3 sequence present in brain and spinal cord (12 of 17 and 6
of 7 respectively) was also detected in this individuals colon, lung and lymph node
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as minor variants (5 of 16, 7 of 15 and 1 of 16 respectively). In some instances,
however variants appeared to be more restricted in distribution. For example,
variants detected in the colon of patient 4, the brain of patient 5 and the colon of
patient 6 were not detected elsewhere in each respective patient (10 of 16, 17 of 17
and 12 of 15 respectively). In addition, in patient 9 two distinct populations were
detected in left and right brain tissue suggesting a random component in the in vivo
distribution of env sequences. Previously, Millich et al., proposed a method
whereby the phenotype of a virus could be inferred from the overall charge of the
V3 sequence combined with the number of observed differences from a subtype B
consensus sequence. This type of analysis provided an almost complete spatial
separation of published HIV-1 variants of known phenotype (Millich et al., 1993).
This method was employed to infer the phenotype of post mortem sequences in
this study. Almost all sequences were found to have a predicted NSI/macrophage
tropic phenotype with low charge and few changes from the subtype B consensus
irrespective of disease status.
1.4.4 NEUROTROPISM OF HIV-1.
Virological analysis, of HIV-1 infection in the CNS, has shown infection of
the brain occurs preferentially in microglia (Koyanagi et al., 1987; Vazeux et al.,
1987; Bagasra et al., 1996; Koenig et al., 1986; Khabbaz et al., 1994). In addition,
only macrophage tropic HIV-1 isolates establish productive infection in primary
human brain explant cultures (Watkins et al., 1990). T cell tropic strains were
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generally found unable to replicate in brain explant cultures (Watkins et al., 1990).
These findings lead to the suggestion that specific neurotropic strains of HIV-1
may exist. Previously, Power et al., reported that a histidine at position 305 in the
V3 loop was predominant in patients with dementia, suggesting that this residue
may determine neurotropism (Power et al., 1994). However, later studies have been
unable to reproduce these findings. Di Stephano et al., (1996) analyzed the V3
region from brain and CSF of individuals at different stages of disease and found a
histidine at position 305 in both demented and nondemented individuals A similar
study reported no evidence for conserved differences in this region between brain
and spleen isolates (Reddy et al., 1996). A comparison of isolates derived from
blood and brain tissue in the V3 region described a monophyletic population of
brain derived compared to blood derived isolates (Korber et al., 1994). In contrast,
two further studies comparing isolates from the CSF and blood observed no
consistent differences between nucleic acid sequences from the distinct
compartments (Kuiken et al., 1995; Keys et al., 1993). A more recent study
examined the tissue distribution of HIV-1 variants from HIV-1 infected individuals
dying in AIDS and those dying from unrelated causes while asymptomatic.
Although organ-specific differences in V3 were observed, the majority of
individuals were found to harbour NSI macrophage tropic isolates regardless of
tissue origin or disease status (Donaldson et al., 1994a). Infection of the CNS may
be determined solely by the ability to infect cells of the macrophage lineage, as
conclusive evidence for a specific neurotropic HIV-1 variant has not been obtained.
The limited amino acid substitutions observed in the V3 region, between different
100
tissues, would be unlikely to alter biological properties to such an extent as to
confer different tropic properties.
1.5 PATHOGENESIS OF HIV-1 INFECTION.
Since the identification of HIV-1 as the aetiological agent for AIDS
enormous progress has been made in our understanding of this virus. As discussed
is sections 1.2.2 to 1.2.8 the biological and molecular characterization of HIV has
revealed a complex genomic structure that encodes proteins with structural and
regulatory functions. It is also clear that an important event in the pathogenesis of
HIV is the binding of the HIV surface glycoprotein, gpl20, to the CD4 receptor
present on the surface of CD4+ lymphocytes and a number of other cells (see
section 1.2.8.1). However, the precise mechanisms whereby HIV causes the
dramatic decline in CD4+ T cells, resulting in severe immunosuppression and the
development of opportunistic infections and neoplasms, are presently unknown or
speculative at best. A number of mechanisms have been proposed involving both
direct and indirect methods by which HIV could destroy CD4+ T cells. Similarly,
the way in which this increase in immunosuppression relates to disease progression
is currently a topic of great discussion. Why does the immune system fail to
control HIV-1 infection, ultimately resulting in the plethora of clinical
manifestations associated with AIDS? Again a number of mechanisms have been
proposed involving the direct action of HIV and indirect mechanisms related to the
host immune response.
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1.5.1 MECHANISMS OF HIV-1 INDUCED CYTOPATHICITY.
1.5.1.1 DIRECT MECHANISMS.
The direct relationship between the high levels of viraemia and a
precipitous drop in CD4+ T cells during the acute phase of HIV-1 infection
suggests that HIV-1 is directly responsible for the death of CD4+ cells. The
mechanisms involved, however are not fully understood. A number of studies have
suggested disturbances in membrane permeability may lead to cell death.
Formation of holes in the cell membrane may occur as a result of virion budding.
In a cell that is producing very high levels of HIV-1 virions, consistent budding
from the cell surface may weaken the integrity of the cell membrane resulting in
cell lysis. Cloyd and collaborators reported findings which demonstrated a
perturbation of the host cell membrane and lipid synthesis leading to an inability of
the cell to control the influx of Ca2+ which accumulated in the cell (Lynn et al.,
1988; Cloyd et al., 1991). The loss in control of the intracellular ionic strength
may lead to the impairment of cellular functions and the eventual lysis of the cell.
Previously, it has been shown that HIV infected individuals, regardless of
clinical stage, exhibit persistent plasma viraemia in the range of 102 to 107 virions
per ml (Piatak et al., 1993). More recently a number of novel experiments have
been carried out to measure the dynamics of HIV-1 replication in vivo. Wei et al.
(1995) and Ho et al. (1995), recently provided estimates of viral replication and
CD4+ T cell destruction in the peripheral blood following the administration of
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potent anti-retroviral drugs. Both studies showed very high rates of turnover, with
approximately 30% of the total virus population and 5% of the total CD4+ T cell
population being replaced each day. By measuring the reduction in plasma viraemia
following antiretroviral treatment both groups estimated the half life of the virion
population to be approximately two days. The rate of virus production was
calculated by factoring in the patients blood volume and initial virus density and
was found to be approximately 109 virions per day consistent with later studies
(Perelson et al., 1996). Therefore, the vast turnover of CD4+ cells throughout the
course of infection may have a significant effect on the pathogenesis and clinical
course of HIV-1 infection.
HIV-1 has been found to persist in substantial amounts in cells as
unintegrated linear DNA (Shaw et al., 1984). Pauza et al.(1990), reported that the
accumulation of unintegrated DNA was directly associated with death of the
culture. A similar phenomenon has been reported for a number of animal
retroviruses where accumulation of unintegrated DNA in the cytoplasm of infected
cells has been associated with subsequent cell death (Keshet et al., 1979; Weller et
al., 1980). These studies support the conclusion that high levels of unintegrated
viral DNA may be toxic to the cell and could contribute to the observed depletion
of CD4+ cells. However, in a more recent study, single cell lysis was reported to
occur in the absence of the accumulation of unintegrated DNA (Bergeron et al.,
1992), suggesting other mechanisms are involved in cell death.
High levels of viral RNA have been detected in the cytoplasm of HIV-1
infected cells in vitro (Koga et al., 1988; Somasundaran et al., 1988).
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Somasundaran et a/.(1988), reported HIV-expressing cells contained from 300,000
to 2,500,000 copies of viral RNA per cell. However, more recent work has
indicated substantially lower copy numbers of viral RNA, in the region of 40,000
copies per cell (Robinson et al., 1990). Koga et al., have shown that HIV infection
of a T cell line (HUT-78) results in the accumulation of high levels of large
molecular weight heterodisperse RNAs (containing repetitive sequences; Koga et
al., 1988). More specifically, significantly increased levels of viral RNA in
mitochondria compared with that in the cytoplasm or nucleus have been detected
(Somasundaran et al., 1994). Therefore, the presence of high levels of viral RNA
may result in the interruption of normal cellular RNA synthesis and processing,
which in turn may contribute to cell dysfunction and death.
1.5.1.2 INDIRECT MECHANISMS.
A major biologic feature of HIV-1 infection is the formation of
multinucleated cells in culture, formed from the fusion of uninfected CD4+ T cells
with infected cells. HIV-1 envelope glycoproteins are inserted into the host cell
membrane during virion assembly prior to the acquisition of the envelope as the
virion buds from the cell. As a result a number of infected cells have envelope
glycoproteins on their surface which are able to bind CD4 molecules on the surface
of uninfected cells. In vitro studies have shown the formation of multinucleated
giant cells in infected cultures which have formed through cell fusion (Yoffe et al.,
1987; Lifson et al., 1986a; Lifson et al., 1986b). These giant cells died shortly after
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they were formed suggesting cell fusion leading to cell death may be one
mechanism to account for the progressive depletion of CD4+ cells observed in
individuals infected with HIV-1 (Yoffe et al., 1987; Lifson et al., 1986a; Lifson et
al., 1986b). However, a number of other studies have revealed a discordance
between syncytium formation and cytopathicity reporting that HIV induced cell
killing does not always involve cell fusion (Somasundaran et al., 1987; Stevenson
et al., 1990). Indeed, Dedera et al., suggested that both single-cell lysis and
syncytium formation occur simultaneously during acute infection (Dedera et al.,
1991).
It has also been proposed that disease progression is driven by factors of the
hosts immune system. When a virus enters the body a multifaceted response is
mounted involving a number of cells, such as macrophages, T helper cells and
natural killer cells, culminating in the production of specific antibodies and
cytotoxic T lymphocytes. It has been suggested that HIV-1 may be non-cytopathic
and that disease manifestations observed during infection may reflect
immunopathological consequences of an anti-HIV CD8+ T cell response
(Zinkernagel et al., 1991; Plata et al., 1987; Zinkernagel et al., 1994; Zinkernagel,
1995), shown to be produced throughout infection (Pinto et al., 1995; Walker et
al., 1987). A parallel between HIV-1 infection and persistent infections with other
viruses have been suggested (Zinkernagel et al., 1994; Mosier et al., 1993; Leist et
al., 1988; Odermatt et al., 1991) where the balance between spread of the virus and
the immune response is critical to the disease outcome. For example, infection of
mice with a low dose of the non-cytopathic lymphocytic choriomeningitis virus
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(LCMV) results in clearance of the virus and little, if any, tissue damage due to an
effective CTL response. On the other hand, if LCMV spreads rapidly before an
active immune response is elicited, widespread tissue damage may occur as a result
of the ensuing CTL response directed against infected cells (Odermatt et al., 1991;
Leist et al., 1988; Zinkernagel et al., 1994). Evidence suggests that destruction of
macrophages and follicular dendritic cells may be caused by an antiviral CD8+
response (Odermatt et al., 1991; Leist et al., 1988). Similarities between LCMV
infection and HIV infection have been suggested since both show tropism for
different cell types, cause severe immunosuppression, and to some extent, establish
persistent infections (Odermatt et al., 1991; Leist et al., 1988). Walker et al.
proposed that a similar mechanism of destruction may operate during HIV infection
(Walker et al., 1986). However, a number of studies have proposed a protective
role for CTL's in HIV-1 infection (Sharpless et al., 1992; Mackewicz et al., 1991;
Wolinsky et al., 1996). A recent study demonstrated that there was an inverse
relationship between progression to disease with the humoral immune response or
with the CTL response (Wolinsky et al., 1996). They found an increased CTL
activity in those individuals showing a slower rate of disease progression,
suggesting CTL activity may protect the host.
Various autoimmune mechanisms may inadvertently kill uninfected cells as
'innocent bystanders'. Uninfected CD4+ T cells may bind free gpl20 molecules to
their surface CD4 receptor giving them the appearance of an infected cell and
therefore become a target for lysis by antibody-dependent cellular cytotoxicity
(ADCC) responses (Weinhold et al., 1989; Lyerly et al., 1987). HIV-specific CTL
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may also mistakenly kill uninfected CD4+ cells that have captured and processed
soluble gpl20 produced by infected cells, presenting it on their surface (MHC class
II restricted antigen presenting cells; Lanzavecchia et al., 1988; Siliciano et al.,
1988). In this regard, CTL that can lyse uninfected CD4+ T cells have been
reported in HIV infected individuals but not HIV infected chimpanzees, suggesting
the lack of CTL response in chimpanzees may account for the lack of progression
to AIDS (Zarling et al., 1990). It has also been shown that natural killer cells can
mediate ADCC against uninfected cells that have HIV antigens on their surface
(Katz et al., 1988).
More recently, superantigens have been implicated in HIV-mediated
immunosuppression. Superantigens differ from typical antigens in their interactions
with T cells. Typical antigens must bind in the groove of the MHC class II
molecule interacting with both a and (3 subunits of the T cell receptor (TCR).
Superantigens, on the other hand, are presented on the outside of the MHC class II
molecule and only require to bind to the V(3 subunit of the TCR. As a result
superantigens can stimulate a much higher proportion of T cells than conventional
antigens, followed by depletion and anergy (Kappler et al., 1980). However, it is
likely that superantigens are not directly responsible for the deletion of CD4+ T
cells since several studies have observed distinct V(3 perturbations in HIV infected
individuals (Dalgleish et al., 1992; Imberti et al., 1991). It is therefore more likely
that superantigens activate large numbers of T cells, resulting in enhanced HIV-1
infection, replication and subsequent cytopathicity. Indeed, in mice, it has been
shown that murine retrovirally encoded superantigen can stimulate the proliferation
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and expansion of V(3-bearing subsets of T cells (Hugin et al., 1991).
Inappropriate induction of apoptosis has been proposed as a mechanism to
explain CD4+ T cell loss during HIV-1 infection. During normal thymic
development, autoreactive T cells are eliminated by the induction of apoptosis, a
physiological process that is a form of programmed cell death (Jenkinson et al.,
1989; McConkey et al., 1989; Smith et al., 1989; Duvall et al., 1986). Apoptosis is
characterized by an increase in cystolic calcium levels and the function of a Ca2+-
dependent endogenous endonuclease that produces fragmentation of nuclear DNA
(Sasaki et al., 1996; Wylie et al., 1991). Apoptosis in HIV-mediated pathogenesis
is supported by several studies. It has been shown to occur in vitro after HIV-1
infection of MT-2 lymphoblasts or activated PBMC (Laurent-crawford et al., 1991;
Terai et al., 1991). Stimulation of CD4+ T cells with MHC class II dependent
superantigens or pokeweed mitogen resulted in the cell death of CD4+ cells from
asymptomatic individuals. However, activation-induced cells death did not occur in
CD4+ T cells from seronegative donors (Groux et al., 1992). Also, large amounts
of histones and fragmented DNA have been detected in the nucleoplasm of infected
cells by SDS PAGE, immunoblot assays and Coomassie blue staining (Laurent-
crawford et al., 1991). Similarly, autoantibodies to histones and DNA have been
found to circulate in the serum of infected patients consistent with the release of
nuclear antigens by apoptosis (Muller et al., 1992). The mechanism by which
induction of apoptosis occurs during HIV-1 infection remains unclear. A number of
studies have suggested an initial interaction involving the cross-linking of CD4 and
gpl20 followed by T cell activation, inducing apoptosis (Ameisen et al., 1991;
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Corbeil et al, 1995; Maldarelli et al, 1995; Laurent-crawford et al., 1993). These
studies demonstrate a central role for env-CD4 interactions in initiating apoptosis
however the subsequent mechanisms involved have not been elucidated. Various
mechanisms have been proposed which include the direct action of HIV, HIV viral
proteins, CD4 antibodies, gpl20-antibody complexes, cytokines and superantigens.
A number in vitro studies have reported the regulation of HIV expression
by cytokines. Various cytokines, such as tumor necrosis factor (TNF) -a,
interleukin (IL) -6, granulocyte-macrophage colony stimulating factor (GM-CSF),
interferon (INF) -y, transforming growth factor (TGF)-p, IL-6 and IL-3, have been
shown to induce HIV expression in vitro (Poli et al., 1992; Hober et al., 1993; Poli
et al., 1990a; Butera et al., 1993; Poli et al., 1990b; Matsuyama et al., 1989).
Several studies have suggested that HIV-1 itself can upregulate cytokine
expression. For example, increased production of TNF-a and IL-6 have been
detected in HIV-infected cells in vitro (Molina et al., 1990). Similarly, increased
expression of TNF-a and IL-6 are secreted from PBMC from AIDS patients (Brix
et al., 1990; Wright et al., 1988). Therefore, abnormal expression of cytokines may
act to upregulate HIV-1 expression and hence may contribute to the observed
pathogenesis. Indeed, TNF-a preferentially induces lysis of HIV-infected cells
suggesting that it may also function in the destruction of CD4+ T cells (Hober et
al, 1992).
1.5.2 NEUROPATHOGENESIS OF HIV-1 INFECTION.
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Infection with HIV-1 is frequently complicated in the later stages by the
AIDS dementia complex (ADC), a neurological syndrome characterized by
abnormalities in cognition, motor performance and behaviour. Exactly how HIV-1
enters the brain is uncertain. Infected brain macrophages may originate from
expansion of peripherally infected monocytes that carry HIV-1 into the brain
('Trojan horse' hypothesis), in a similar manner to that proposed for visna virus
(Peluso et al., 1985). Alternatively, virus may cross the blood-brain barrier as cell
free virus or via trafficking by infected T cells (Michaels et al., 1988). Recent
studies have suggested that infection of brain microvascular endothelial cells
(BMVECs) may be one of the primary routes whereby HIV-1 gains entry into the
CNS (Nottet et al., 1995; Bagasra et al., 1996). Indeed, infection of BMVECs has
been demonstrated in cell culture (Moses et al., 1993), and in vivo for SIV
(Mankowski et al., 1994). Another possible route of infection may be the
productive infection of the choroid plexus via the penetration of cell-free virions
from the CSF. Bagasra et al., recently reported productive infection (by detection
of mRNA) of the choroid plexus of AIDS patients by dual in situ PCR (Bagasra et
al., 1996). Studies to date suggest HIV-1 is predominantly localized within blood-
derived brain macrophages, microglia and multinucleated giant cells (MGC;
Vazeux et al., 1987; Koenig et al., 1986; Wiley et al., 1986; Bagasra et al., 1996).
There are few reports of HIV-1 infection of neurons, oligodendrocytes and
astrocytes and it is thought these cells are rarely infected in vivo, if at all (Gyorkey
et al., 1987; Wiley et al., 1986). As with infection of the CNS, the mechanisms
underlying the pathogenesis of HIV-1 infection in the brain are far from clear.
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Several studies have detected large amounts of proviral and unintegrated HIV-1
DNA in brain tissue (Shaw et al., 1985; Vazeux et al., 1992; Pang et al., 1990).
Pang et al., demonstrated a correlation between HIV encephalitis and the presence
of unintegrated DNA in brain tissue similar to that observed from infection with
avian leukaemia viruses (ALV) and some strains of feline leukaemia viruses
(FeLV; Weller et al., 1981; Mullins et al., 1986). However, infection in brain
tissue is restricted to macrophage and microglia cells and destruction of these cells
would not be expected to cause the neuropathology observed in brain tissue of
HIV-1 infected individuals. Similarly, the number and distribution of these infected
cells does not correlate with the degree of tissue pathology observed.
Several studies have suggested that HIV-1 may effect CNS function without
direct infection of neuroectodermal cells themselves. One such mechanism concerns
the toxic effects of gpl20 on nerve cells in vitro related to increases in intracellular
calcium. Dryer et al., reported that HIV-1 env gpl20 was toxic to primary rodent
neurons and that cell death occurred subsequent to excessive calcium influx into
the neurons (Dreyer et al., 1990). This effect was abrogated by adding calcium
channel blockers. Subsequent studies suggested that the intracellular increase in
Ca2+ and consequential neuronal injury was mediated by the combined action of
gpl20 with glutamate via the N-methyl-D-aspartate (NMDA) receptor (Pittaluga et
al., 1996; Lipton, 1992). Noradrenaline has been implicated in learning and
memory and activation of NMDA receptors is a primary event in cognitive
processes in the hippocampus and cerebral cortex (Collingridge et al., 1987;
McGaugh, 1989). Hence, activation of NMDA receptors may facilitate persistent
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and abnormal levels of noradrenaline leading to imbalances in the processes
underlying learning and memory which may result in the cognitive defects
characteristic of AIDS dementia. The HIV-1 trans-activating regulatory protein, tat,
has also been shown to be neurotoxic to glioma, neuroblastoma and cultured
human fetal brain cells in vitro and to rats and mice in vivo (Nath et al., 1996;
Sabatier et al., 1991). The active site is thought to be located between amino acids
31 and 61, the action of which alters cell permeability resulting in increased levels
of intracellular Ca2+ and neuronal damage.
Other investigators have suggested indirect effects related to toxic
substances secreted from HIV-1 infected macrophages. Cellular factors released
from HIV-1 infected monocytes were found to be neurotoxic to chick and rat
neurons (Giulian et al., 1990), and human brain aggregates cultured in vitro
(Pulliam et al., 1991). These studies suggest HIV-1 infected macrophages, and
possibly microglia, may release toxins that disrupt neurological function. A more
recent study failed to confirm these findings (Benton et al., 1992), although further
studies reported the requirement for cell-cell contact between HIV-infected
monocytes and astroglia prior to the generation of neurotoxins (Gerus et al., 1992;
Tardieu et al., 1992). The presence of activated macrophages and T cells in the
CNS of HIV-1 infected individuals suggests that a number of cytokines may
participate in neuropathogenesis (Tayor et al., 1992). Production of IL-1 and TNF-
a have been reported both in in vivo and in vitro studies. IL-1 has many activities
including inducing T cell stimulation, activation of macrophages and endothelial
cells, induction of fever and inflammation and stimulation of astrocytosis in vivo
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which is frequently observed in HIV encephalitis (Dinarello et al., 1987; Movat,
1987). TNF-a has also been reported to be produced by macrophages and
microglia in culture (Rosenberg et al., 1990; Movat, 1987), is toxic to
oligodendrocytes in culture (Selmaj et al., 1990), and has been shown to be
increased in the CSF of HIV-infected individuals presenting with neurological
disorders. Similarly, higher levels of TNF-a have been detected in symptomatic
individuals compared with asymptomatic individuals (Wright et al., 1988). Other
cytokines such as IFN-y and IL-6 have also been implicated in CNS damage.
Hence, T cells, macrophages, microglia, endothelial cells and astrocytes appear to
be involved in the response to and generation of cytokines. These cytokines may
modulate the immune response and may also have toxic effects in the CNS.
1.5.3 HIV-1 PATHOGENICITY AND DISEASE PROGRESSION.
An important advance in our understanding of the pathogenesis of HIV-1
infection was the observation that HIV-1 actively replicates in lymphoid tissue
throughout the course of disease. Studies on the viral burden and levels of virus
replication in the peripheral blood and lymphoid organs have found infection of
lymph nodes to be approximately 10 times that of the peripheral blood and that
active replication occurred in lymphoid tissues during the asymptomatic phase.
(Embretson et al., 1993; Pantaleo et al., 1993). Using in situ hybridization a
number of investigations have shown restriction of viral particles to the germinal
centres (Biberfeld et al., 1986; Schuurman et al., 1988; Pantaleo et al., 1993),
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confirming previous reports of extracellular association of HIV with follicular
dendritic cells (Armstrong et al., 1948; Baroni et al., 1986). This association may
be important in infection of lymphocytes as they migrate through the lymph nodes.
It has also been suggested that as disease progresses the integrity of the lymph
node breaks down reducing the trapping of virus in germinal centres, allowing
proliferation into peripheral sites of the body.
Recent findings have shown a rapid turnover of virus and CD4+
lymphocytes in the peripheral circulation throughout infection with HIV-1 (Ho et
al., 1995; Wei et al., 1995). Both groups were also able to show the rapid
replacement of wild type virus by drug-resistant virus after 14 to 28 days of drug
therapy indicating the enormous capacity of HIV-1 to evolve in response to
selection pressure such as that exerted by the immune system. These new findings
have a number of implications for the pathogenesis of HIV-1 infection. First, the
observed rates of viral and CD4+ T cell turnover were much higher than expected,
indicating a dynamic process involving continuous viral infection and replication
and rapid cell turnover. Second, Wei et al. (1995), also estimated the half life of
PBMC by measuring the time required for the resistant virus to spread into this
population and obtained a half life of 50-100 days.. This substantially longer
lifespan of latently infected cells suggests that virus production itself is paramount
in the observed depletion of CD4+ T cells. Finally, the rapid replacement of wild
type virus by mutants demonstrated the ability of the virus to evolve in response to
selection pressure supporting the antigenic variation model for the subsequent
progression to AIDS (see below).
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Nowak and colleagues proposed the 'antigenic diversity threshold' theory to
explain the breakdown of the immune system during HIV-1 infection (Nowak et
al., 1991a). The central theme of this theory is that antigenic diversity is the cause
and not the consequence of the observed immune deficiency in HIV-1 infection. It
was proposed that HIV is capable of infecting all CD4+ cells but that the
immunological response directed against the virus involves a specific response to
individual strains in conjunction with a cross-reactive response to all strains
(Nowak et al., 1991a). Hence, as new antigenic variants appear (escape mutants),
they are able to evade elimination by the immune system. Eventually, antigenic
diversity is thought to increase beyond a threshold value and exceeds the capacity
of the immune response to regulate viral population growth. This model has since
been adapted to include the CTL response against multiple epitopes (Nowak et al.,
1995). This new improved model suggests that an antigenically homogenous
population will elicit a response against a single epitope (immunodominance),
while a heterogenous population may stimulate a response against multiple epitopes
which may result in a steady state number of CD4+ T cells and viral load.
However, antigenic variation in the immunodominant epitope may direct immune
responses to weaker epitopes reducing the immunological control of the viral
population (Nowak et al., 1995).
Wolinsky et al. (1996), have studied the evolution of HIV-1 in 6 infected
patients with variable rates of disease progression and refute the 'antigenic
diversity threshold' theory of Nowak and colleagues.. In this study two patients
with high levels of plasma RNA and rapid CD4+ T cell loss maintained a
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relatively homogenous population throughout the entire course of infection. In
contrast, two further patients with moderate or relatively stable CD4+ T cell counts
showed the highest levels of virus diversity. Therefore, no evidence was found to
suggest an increase in antigenic diversity as the driving force behind the rate of
CD4+ T cell loss. Interestingly, in this patient group the accumulation rate of
nonsynonymous substitutions (dN) was found to be higher in those patients with
moderate or relatively stable CD4+ T cell counts compared with the two patients
with rapid CD4+ T cell loss. The rate of synonymous substitutions (ds) was similar
in both groups. However, proviral sequences were obtained from PBMCs which
does not distinguish between active infection and residual provirus in the memory
cell population (Simmonds et al., 1991). dN/ds ratios for those patients with
moderate or stable CD4+ T cell counts were far higher (2.5 to 3.75) compared to
the two patients with rapid CD4+ T cell loss (1.25 and 0.75) where a value greater
than 1 is indicative of positive selection for change. Therefore, in the slower
progressing patients positive selection for change was associated with prolonged
rather than shortened survival. In this respect, Lukashov et al., recently reported a
correlation between the accumulation of nonsynonymous substitutions and the
length of the immunocompetent period from the analysis of RNA obtained from
the sera of a number of progressors and nonprogressors (Lukashov et al., 1995).
Wolinsky et al., also found increased CTL activity in patients with a slower rate of
disease progression and very poor CTL responses in rapid progressors suggesting a
protective role for the CTL response (Wolinsky et al., 1996), contrary to
predictions that immunopathogenic effects of CTL are responsible for the depletion
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of CD4+ T cells. A similar relationship has been reported by Harrer et al., (Harrer
et al., 1994).
1.6 MOLECULAR EVOLUTION.
Molecular evolution encompasses the study of the rates and patterns of
change occurring in genetic material (for example DNA sequences) and the product
of such coding regions (proteins) through evolutionary time and the mechanisms
responsible for these changes. This field of study also involves the reconstruction
of the evolutionary history of genes and organisms, also known as molecular
phylogeny, inferred from molecular data.
1.6.1 DISTANCE ESTIMATION.
Increasingly the data becoming available for the analysis of evolutionary
relationships consists of nucleotide sequences. A basic process in the evolution of
nucleotide sequences is the change in nucleotides with time. However, as the
process of nucleotide substitution and fixation within a population is a
comparatively slow process evolutionary changes within a DNA sequence can be
detected through comparative methods such as distance estimation. This requires
that a given sequence be compared with another sequence with shared common
ancestry. The evolutionary distance between a pair of sequences is usually
measured by the number of nucleotide or amino acid substitutions between them
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(pairwise distance). There are many methods for measuring evolutionary distances,
although I have only discussed two such methods that are relatively simple and
frequently used (the first of which, Jukes-Cantor, was used in this study: Gojobori
et al, 1990; Nei et al, 1987; Saccone et al, 1990).
This method of Jukes and Cantor was developed under the assumption that
the rate of nucleotide substitution was the same for all pairs of the four nucleotides
A, T, G and C (i.e. a random process), and gives the maximum likelihood estimate
of the number of nucleotide substitutions between two sequences (Jukes et al,
1969). Jukes-Cantor is a one parameter distance method and does not take into
account differences in the frequency of transitions (purine to purine and pyrimidine
to pyrimidine substitutions) and transversions (purine to pyrimidine substitutions)
when calculating evolutionary distances. However, in this study, the pairwise
distances between sequences were relatively small and it is unlikely that saturation
will have occurred at sites of transition to an extent that major underestimates of
the rate of sequence change would have been made. This one parameter distance
method can be used to calculate distances for synonymous (do not result in amino
acid changes) and non-synonymous (change amino acids) substitutions as there is
no transition/transversion bias in this analysis.
The assumption that all nucleotide substitutions occur randomly, as in the
Jukes-Cantor model, is unrealistic in some cases as transitions generally occur
more frequently than transversions. Kimura proposed a two parameter model in
which the rate of transitional and transversional substitutions per site are taken into
account (Kimura, 1980).
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1.6.2 RATES OF NUCLEOTIDE SUBSTITUTION.
The rate of nucleotide substitution is defined as the number of substitutions
per site per year and can be calculated by dividing the pairwise distance calculated
for any two sequences with twice the time of divergence between the two
sequences. The divergence time is assumed to be the same for the two sequences
considered. The rate of nonsynonymous substitution may be extremely variable
among genes as the majority of nonsynonymous substitutions are subject to
purifying selection from external factors such as the host immune response.
Consequently, nonsynonymous substitutions which improve protein function may
be selected resulting in a greater rate of nonsynonymous to synonymous
substitution. Reciprocally, nonsynonymous substitutions resulting in a deleterious
effect on protein function will be eliminated by selection, reducing the rate of
nonsynonymous substitution. However, synonymous substitutions do not cause
changes in amino acids and will not be subject to purifying selection. These
substitutions are thought to reflect the underlying mutational rate allowing the
estimation of the rate of nucleotide substitution.
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1.6.3 ESTIMATION OF DIVERGENCE TIMES.
Sequence data can be used to estimate times of divergence between species,
individuals and indeed sequences within an individual. Assuming the rate of
nucleotide substitution (evolution) is known from a previous study (see section
1.6.2) the time of divergence between two sequences can be estimated by dividing
the synonymous pairwise distance by twice the rate of change. Again this
calculation assumes rate constancy, an assumption which often does not always
hold. Using synonymous pairwise distances reduces any errors incurred while
estimating divergence times as these nucleotide sites are not subject to selection
pressures to the extent that nonsynonymous substitutions are. Li et al. have
proposed a method that can reduce the effects of unequal rates of substitution when
estimating times of divergence (Li et al, 1987).
1.6.4 MOLECULAR PHYLOGENY.
In phylogenetic studies, the evolutionary relationship among a group of
organisms (population tree) or genes (gene tree) can be illustrated by means of a
phylogenetic tree. Phylogenetic trees can be either rooted or unrooted. A rooted
tree indicates the direction of evolution, and the root is the common ancestor of all
the OTUs (operational taxonomic units) studied. An unrooted tree specifies the
relationship among the OTUs but does not define the evolutionary path. In practice
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the majority of tree-making methods produce unrooted trees. However, in order to
root an unrooted tree an outgroup can be added which is evolutionarily related to
the OTUs under study, having diverged from the other OTUs prior to their
divergence from one another.
There are a number of methods available for the construction of
phylogenetic trees (Nei, 1987; Felsenstein, 1988), which can be classified as
distance matrix methods and character based (maximum parsimony) methods.
Distance matrix methods involve the calculation of evolutionary distances (pairwise
distances) for all pairs of taxa (e.g. nucleotide sequences), and a phylogenetic tree
is constructed by certain principles and alogarithms. In maximum pasimony
methods discrete character states (e.g. nucleotides or amino acids at a site) are
used, and a phylogenetic tree is constructed by considering the shortest pathway
leading to these character states.
The simplest method for reconstruction of phylogenetic trees is the
unweighted pair group method with arithmetic mean (UPGMA). This method
employs a sequential clustering alogarithm. Initially the two OTUs that are most
similar from among all the OTUs are identified and subsequently are treated as a
new single OTU. This new OTU is referred to as a composite OTU. Subsequently,
the next pair with the highest similarity are identified, and so on, until only two
OTUs are left. This method assumes a constant rate of evolution and hence a
rooted tree is produced.
Computer simulations have shown that one of the most efficient distance
methods for producing phylogenetic trees with the correct topology (branching
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pattern of a tree) is the neighbor-joining method (Nei et al, 1991) proposed by
Saitou and Nei (1987). This method is a simplified version of the minimum
evolution method in which distance measures that correct for multiple hits at the
same sites are used. In this method the smallest value of the sum of all branches is
chosen as the correct tree. In the neighbor-joining method the smallest value of the
sum of all branches is not calculated for all the topologies. Instead, the examination
of different topologies is embedded in the alogarithm, so that only one final tree is
produced. This method produces an unrooted tree, and usually requires an outgroup
to find the root.
The principle of maximum parsimony or minimum evolution involves the
identification of a tree that requires the smallest number of evolutionary changes to
explain the differences observed among the OTUs being studied. However, quite
often more than one tree with the same minimum number of changes can be found,
so that no unique tree may be inferred in some instances. These topologies are
called equally parsimonious trees. When constructing a maximum parsimony tree
informative sites must first be identified. These are sites at which at least two
different kinds of nucleotides, each represented twice, are used. Other variable sites
are not used for constructing maximum parsimony trees, although they are
informative for distance methods. Following this the minimum number of
substitutions at each informative site is calculated for each possible tree. Finally,
the sum of the number of changes over all the informative sites is calculated for
each tree and the tree associated with the smallest number of substitutions is
chosen. The maximum parsimony method produces unrooted trees, primarily
122
determining the topology of a tree.
1.6.5 STATISTICAL SIGNIFICANCE OF TREE TOPOLOGIES.
There are two different types of methods available for testing the reliability
of a tree obtained. These are the maximum likelihood method (Felsenstein, 1981)
and the bootstrap test (Felsenstein, 1985). The maximum likelihood method
examines the reliability of every interior branch of the tree. This method can be
very time consuming and is generally limited to small data sets. The bootstrap test
involves randomly resampling the data from which the tree was constructed,
producing a new tree with the resampled data. This process is repeated several
hundred times and the frequency at which particular branches are observed in the
newly constructed trees is calculated giving a probability to each branch in the





The aims of this study were to characterize genetically HIV-1 variants
obtained from various lymphoid and non-lymphoid tissues, investigate whether
separate populations existed and determine whether such differences reflected
variation in biological properties, such as their inferred in vitro tropism and
cytopathology. I also planned to investigate the diversity of variants (LPA) in pre-
symptomatic and symptomatic patients to identify whether more or less divergent
populations emerge during disease progression. Finally, I have investigated
whether, through evolutionary analysis of the pl7gag region, the time of spread of
HIV-1 from lymphoid to non-lymphoid tissues can be estimated to determine if this
occurs as an early or late event in disease progression.
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CHAPTER TWO: MATERIALS AND METHODS.
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2.1 CLINICAL DETAILS OF STUDY PATIENTS.
Tissues from various organs were obtained at autopsy, carried out within
three days of death, from 43 HIV-infected individuals. Eight individuals died from
other reasons and were classified as pre-symptomatic on the basis of an absence of
HIV-related symptoms before death and an absence of HIV-related changes in
pathological examination. In contrast, 35 individuals died from complications
associated with HIV-infection, such as opportunistic infections and neoplasia
(symptomatic group). Details of the clinical symptoms each patient presented with
are summarised in Table 5. Samples of brain (left frontal lobe), lymph node
(mesenteric) from each individual were dissected into 1 to 2 cm pieces and stored
at -70°C. Samples of lung, colon and spleen were also analysed from patient 4.
CD4 lymphocyte counts were obtained on three occasions in the year before death
from each individual (Table 5).
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TABLE 5.
""Abbreviations: IVDU: injecting drug abuser; HO: male homosexual; HE:
heterosexual contact; B: infection through blood transfusion
bCD4 lymphocyte (cell/^l) count over one year prior to death (mean of 2-3 values).
N/D=not done.
"Diagnosis of giant cell encephalitis, based upon pathology, p24 antigen detection
and quantitative PCR (Bell, 1996).
dAbbreviations: 1 ^Pneumocystis carinii pneumonia; 2=oral thrush; 3=oesophageal
thrush; 4=oral candidiasis; 5=oesophageal candidiasis; 6=dementia; 7=shingles;
8=neurological degeneration; 9=atypical mycobacterial infection; 10=herpes zoster;
ll=oral ulceration; 12=lymphoma; 13=cerebral atrophy; 14=widespread
cytomegalovirus infection; 15=lymphadenopathy; 16= splenomegaly; 17=cutaneous
Kaposi's sarcoma; 18=systemic Kaposi's sarcoma; 19=dysphasia; 20=cerebral
toxoplasmosis; 21=autonomic neuropathy; 22=persistent diarrhoea; 23=weight loss;
24=muscle wasting; 25=HIV retinopathy; 26=HIV myelitis; 27=focal
cytomegalovirus infection in brain.
eThis patient is the heterosexual contact of a known IVDU.
fThese patients are included in the study described in chapter 3.











































Age Risk3 CD4 countb GCEC Symptoms'1
41 IVDU 802 -
31 IVDU 370 -
32 IVDU 240 -
31 IVDU 180 -
28 IVDU 170 - 20
28 HE 155 -
23 HE 140 - 1,2
46 IVDU 140 -
27 HE 115 -
28 HO 105 + 1,21
34 IVDU 95 + 2,6
28 IVDU 90 + 4,13,23,25,26
38 IVDU 85 - 12,19
33 IVDU 50 +
42 IVDU 40 - 15
35 IVDU 33 -
25 IVDU 28 + 6,11
28 IVDU 26 + 11,12,13,14
36 HO 19 - 1,9,13,16,17
32 HO 19 - 12,13
50 HO 15 - 1,14,21
25 IVDU 13 + 27
24 IVDU 12 - 1
30 IVDU 11 + 15,24
44 HO 10 - 1,2,3,9,17
35 HO 10 + 12,15
34 IVDU 8 + 1
34 IVDU 8 + 1,5,13
33 IVDU 6 - 13,15,16
30 B 6 + 12,13,20
34 IVDU 5 + 1,4,5,9
31 HO 5 - 13,14
45 HO 5 - 1,9,20
30 HO 4 - 2,12,14,17,18
34 HO 3 - 1,13,14
46 IVDU 2 + 13,14
30 HO 2 - 9,22
36 IVDU 2 - 1,4,9,23
36 HO 2 - 4,9,10,23
26 IVDU 0 + 1,10
33 IVDU 0 - 1,14
28 HE N/D + 7,12
43 HO N/D - 9,14,24
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2.2 BUFFERS AND REAGENTS.
2.2.1 EXTRACTION OF DNA FROM TISSUE SAMPLES.




100/zg of proteinase K per ml




Centrifuge (Hereus Biofuge 15R)
2.2.2 AMPLIFICATION OF PROVIRAL DNA.





Nucleoside triphosphate mixture (lOOmM stock; dilute to 3mM; Boehringer
Mannheim)
Taq polymerase (Promega: lfA is equal to 5 units)
Water cooled thermal cycler (Techne PHC-1A and GeneE)
2% agarose gel: 6 g agarose (Sigma)
300 ml 10 x TBE
20 [A Ethidium Bromide
10 x TBE (1 litre): 108 g Tris base (AnalaR)
55 g Boric acid (Molecular Biology Certified; Kodak)
40 ml 0.5M EDTA (Molecular Biology Certified; Kodak)
Make up to 1L with dH20
1 x TBE buffer used as electrophoresis buffer in gel tank.
2.2.3 SOLID PHASE PURIFICATION OF PCR PRODUCTS.
BSA: 0.1% bovine serum albumin in PBS (pH 7.2).





Binding and washing buffer (BW): 10 mM Tris-HCL (pH 7.5)
1 mM EDTA
2.0 M NaCl (final concentration 1.0 M)
TE buffer: 10 mM Tris-HCL (pH 7.5)
1 mM EDTA
0.15 M NaOH
Dynabeads M-280 streptavidin (Dynal).
Dynal magnetic particle concentrator 6 (MPC 6; Dynal).
2.2.4 SEQUENCE ANALYSIS.
5 x Sequenase reaction buffer: 200
100
250
5 x labelling mix: 7.5 yuM dGTP
7.5 fM dTTP
7.5 fiM dCTP
[a35S] dATP or [a-32P] dATP (Amersham).
Termination solutions: 80 fjM of all four dNTPs supplemented with 8 yuM ddATP,




ddTTP, ddGTP or ddCTP.




5% Denaturing PAGE gel: 21 g Urea (AnalaR)
5 ml Long Ranger gel solution (50%; Flowgen)
5ml 10 X TBE (Sanger)
0.05 g Ammonium persulfate (APS; Sigma)
Make up to 50 ml with dH20
Add 25 [A TEMED prior to pouring gel mix.
10 x TBE (Sanger; 2 litre): 324 g Tris base
85 g Boric acid
19 g EDTA
Make up to 2L with dHzO.
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2.3 EXTRACTION OF DNA FROM TISSUE SAMPLES.
Extraction of DNA from tissues was carried out by re-suspending 1-2 cm
pieces of tissue in 500 fA of lysis buffer and incubated at 65°C for two hours.
Following this 450 [A of phenol was added to the extraction tubes and mixed
thoroughly. Extraction tubes were then centrifuged at 13000 rpm for 10 mins. This
process was repeated until the interface was clear. The aqueous layer was then
transferred to a fresh 1.5 ml eppendorf containing 450 fA of chloroform. This
mixture was then mixed thoroughly and centrifuged at 13000 rpm for 10 mins. The
aqueous layer was again transferred to a fresh 1.5 ml eppendorf containing 900 fA
of 100% ethanol, mixed and left overnight at -20°C to allow precipitation of the
nucleic acid. The nucleic acid extract was collected by centrifugation at 13000 rpm
at 0°C for 20 min. The supernatant was then discarded and the precipitate dried at
65°C for 10 min. Following this the nucleic acid pellet was re-suspended in 100-
200 fA of distilled water. To ensure adequate solubilization of the pellet the sample
was incubated at 50°C for 15-30 min. During each extraction process 1-2 cm pieces
of known positive and negative tissue samples were included providing a
comprehensive check for contamination.
2.4 QUANTITATION OF TOTAL EXTRACTED DNA.
The concentration of DNA in each sample was accurately quantified using
spectrophotometric UV absorbance readings at wavelengths of 260 and 280 nm.
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Samples were diluted 1 in 20 in pyrogen free water and the absorbance measured
in a spectrophotometer. The ratio of the optical density (OD) at 260 nm to that at
280 nm gave an indication of purity of each preparation. Pure DNA preparations
have an A260/A280 ratio of approximately 1.8. The concentration of DNA was
calculated from the following equation: A260x D x 50 = DNA concentration
(jig/mX), where A260 = absorbance at 260nm, D is the dilution factor (=20) and 50
is equivalent to the concentration (yUg/ml) of ds DNA at A260 of 1.0.
2.5 AMPLIFICATION OF PROVIRAL DNA.
Proviral DNA was amplified using the polymerase chain reaction (PCR).
Nested PCR was employed, further amplifying the first PCR product with a second
set of specific primers that lie within those employed in the first PCR. This
increases the overall sensitivity and specificity of the PCR, increasing the
amplification by 10 000 fold compared to that attained by using only one set of
primers. The first and second PCR were subjected to a thermal cycle of 36 seconds
at 94°C to allow denaturation of ds DNA, 42 seconds at 46°C (V1/V2) and 50°C
(gag), to allow primer annealing to the ss DNA and 90 seconds at 72°C to allow
strand extension. Each template strand was subjected to 25 cycles of amplification.
At the end of the last cycle samples were heated to 72°C for 5 min to allow
termination of uncompleted stands. The first PCR was carried out in a 50 /A
volume, for each sample, containing 5 [A of DNA, 5 /A of 10 x PCR buffer , 0.5 /A
of nucleoside triphosphate mixture (3 mM each of dGTP, dATP, dTTP and dCTP),
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0.25 fA of sense primer (approximately 20 /iM), 0.25 (A of antisense primer
(approximately 20 /iM), 38 (A of pyrogen free water and 1 unit of Taq polymerase.
The second, nested, PCR was carried out in a 20 /A volume, for each sample,
containing 1 (A of primary PCR product, 2 fA of 10 x PCR buffer, 0.2 /A of
dNTP's, 0.1 fA of sense primer (approximately x 8 /iM), 0.1 fA of antisense primer
(approximately x 8 /iM), 16.5 fA of pyrogen free water and 0.4 units of Taq
polymerase. Prior to transfer to the thermal cycler each sample was covered with a
drop of mineral oil to prevent loss of sample due to evaporation. Amplification of
DNA was carried out using primers flanking hypervariable regions 1 and 2 from
env and pl7 from gag. The nucleotide sequences of the primers were as follows:
V1/V2:
a: GAG GAT ATA ATC AGT TTA TGG; + (sense), 6539
b: GA TCA AAG CCT AAA GCC ATG; +, 6560
c: TTG AAA GAG CAG TTT TTT ATC TCT CC; - (antisense), 6677
d: TG(A)A AAA ACT GCT CTT TCA A; +, 6684
e: CAA TAA TGT ATG GGA ATT GG; -, 6857
f: AAT GTA CTG TGC TGA CAT T; -, 6944
GAG:
a: GCG AGA GCG TCA GTA TTA AGC GG; +, 795
b: GGG AAA AAA TTC GGT TAA GGC C; +, 835
c: CTT CTA CTA TTT TTA CCC ATG C; -, 1248
d: TCT GAT AAT GCT GAA AAC ATG GG; 1296
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All positions numbered according to the HXB2 genome: (Myers et al., 1991)
During each PCR amplification 1 fj.g of known positive and negative DNA samples
were included providing a comprehensive check for contamination. An additional
negative control was included whereby no DNA was added to the reaction mix
ensuring contamination of the PCR buffer had not occurred.
2.6 LIMITING DILUTION ASSAY.
In order to obtain single molecules of HIV proviral DNA to allow analysis
of heterogenous viral sequences a limiting dilution assay was carried out. To
isolate single proviral sequences multiple replicates of DNA were amplified at a
dilution resulting in the detection of only a small proportion of positive PCR
products. Using the poisson formula, which assumes a random distribution of DNA
molecules, the probability of positive PCR products having originated from a single
proviral sequence can be calculated. If 20% of the PCR replicates are positive then
approximately 95% of reactions can be said to have originated from a single
proviral sequence. Initially triplicates of 4 ten-fold dilutions were set up (0.1 /ig-
0.0001 /ug) and amplified using nested PCR, as previously described. A further 20
replicates were set up at the dilution resulting in the least number of positive
reactions and amplified using nested PCR. If 20% of these replicates proved to be
positive they were considered to have originated from a single proviral sequence
and were retained for sequence analysis.
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2.7 VISUALIZATION OF AMPLIFIED PCR PRODUCTS.
Amplified PCR products were visualized on 2% agarose gels containing
ethidium bromide. Ethidium bromide is an intercalating agent which exhibits a
fluorescence under UV light, allowing any positive PCR products to be detected as
fluorescent bands. The gel was run for 10 mins at 150 V and analyzed under UV
light.
2.8 SOLID PHASE PURIFICATION OF PCR PRODUCTS.
For direct sequencing of PCR products a higher purity than that provided by
previous ethanol precipitation is required. The sequencing reaction (Sanger method)
is highly sensitive to various components present in the PCR product, such as
dNTP's, primers and buffer solutions. Single strand purification was therefore
carried out using a solid phase method (Dynal) allowing highly specific isolation
and purification of target PCR products. This purification method involves a highly
specific interaction between streptavidin (covalently attached to the bead surface)
and biotin (incorporated into the primer oligonucleotide). Therefore, prior to
purification, a secondary PCR reaction was performed using one biotinylated
primer and one unlabelled primer generating a PCR product with one strand having
a biotin moiety at either the 5' or 3' end. This reaction is carried out in a 100 /A
volume, for each sample, containing 1 fA of PCR product, 10 (A of reaction buffer,
1 /A of dNTPs (approximately 33 mM ), 0.25 /A of normal primer (approximately
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20 mM), 0.25 fA of biotinylated primer (approximately 20mM), 87.1 [A of pyrogen
free water and 0.4 /A of Taq (2 units per reaction). For each sample to be
sequenced 20 fA of re-suspended Dynabeads were transferred to a 1.5 ml eppendorf
and washed with 40 /A of 0.1% bovine serum albumin. This was then placed in a
magnet (Dynal MPC-6) and the supernatant removed. The beads were then re-
suspended in 40 /A of BW , mixed with 40 fA of the amplified PCR product and
incubated at room temperature for 20 mins, re-suspending the beads occasionally,
allowing the immobilization of the PCR product to the Dynabeads. The beads were
then washed in 40 fA of BW and re-suspended in 8 fA of 0.15 M NaOH and
incubated at room temperature for 10 mins, denaturing the ds DNA bound to the
beads leaving only ss DNA bound. The supernatant, containing the unbound
complementary sense DNA, was then removed and the beads were washed once
with 50 fA of NaOH, once with 50 fA of BW and once with 50 fA of TE, ensuring
the complete separation of the DNA strands. Finally, the beads were re-suspended
in 20 fA of TE and stored at 4°C. During washes beads must only be pipetted up
and down gently and should not be centrifuged or vortexed.
2.9 DIRECT SEQUENCING OF AMPLIFIED PCR PRODUCTS.
Single molecules of HIV provirus were isolated by limiting dilution and
amplified in a nested PCR to produce sufficient DNA to allow direct sequencing of
the PCR products. Direct sequencing of amplified DNA was achieved by using a
solid phase sequencing method described above. In this study Sequenase Version
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2.0 DNA sequencing kits were used (United States Biochemical) with Sequenase™
Version 2.0 T7 DNA polymerase. This enzyme is a genetic variant of
bacteriophage T7 DNA polymerase created by in vitro genetic manipulation,
completely lacking a 3' to 5' exonuclease activity and including properties such as
high processitivity, high speed and the ability to use nucleotide analogues for
sequencing making it the ideal enzyme to use for chain termination sequencing. For
each template strand of ssDNA a single annealing reaction was used to allow the
primer strand to bind to the ssDNA. The primer is needed because template
dependent DNA polymerases are unable to initiate DNA synthesis on an entirely
single stranded molecule. A short double stranded region is required to provide a 3'
end onto which the polymerase can add new nucleotides, annealing of the primer
provides this 3' end without which strand synthesis would not take place. For each
template, 2 fj.1 of the appropriate primer, 2 //I of 5 x Sequenase reaction buffer, 1 fA
dimethylsulphoxide (DMSO) and 5 fA of DNA (bound to magnetic beads) were
mixed together. This mixture was then warmed at 65°C for approximately 5 mins
and allowed to cool slowly to room temperature over a period of approximately 30
mins. To each annealed template-primer the following labelling (extension) mix
was added: 1 [A dithiothreitol (DTT, 0.1 M), 2 /A of diluted labelling nucleotide
mix (1:20), 0.5 fA of [a-35S] or [a-32P] dATP (5 fxCi) and 2 fA diluted Sequenase
polymerase (1:8, approximately 3.25 units). The annealing reaction and labelling
mix were mixed thoroughly and incubated at room temperature for approximately 5
mins, during which time the termination reaction was prepared. For each template
four tubes were labelled 'G', 'A', 'T', and 'C'. Each tube was filled with 2.5 fA of
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the appropriate dideoxy termination mixture and pre-warmed at 37°C (the optimal
temperature for Sequenase polymerase enzyme). When the labelling reaction was
complete, 3.5 [A were transferred to each of the four termination tubes (G, A, T
and C) and incubated at 37°C for approximately 5 mins and then 4 /A of stop
solution was added to each termination reaction stopping the termination reaction.
Following this sequencing reaction the product was heated to 95°C to destroy the
interaction between the streptavidin and biotin and release the DNA templates
together with the dideoxy fragments. This product was then electrophoresed on a
5% denaturing polyacrylamide gel (PAGE). Gels were run for 2 hours allowing
approximately 250 to 300 bases to be read. Gels were dried and exposed overnight
on BioMAX film.
2.10 LENGTH PROFILING ANALYSIS OF AMPLIFIED PCR PRODUCTS.
To obtain length profiles across the VI and V2 hypervariable regions
proviral DNA was amplified using nested PCR, as previously described. However,
the second PCR was modified as detailed below. The concentration of the dNTP's
were reduced from 33 jjM to 8 /uM with the addition of 2 //Ci[a35-S]
dATP/reaction. In addition 0.1 fA instead of 1 /A of primary PCR product was
transferred reducing extra bands resulting from the carry over of excess primary
PCR product and primers. Subsequently, I (A of the secondary PCR product was
mixed with 5 fA of stop solution and heated to 90°C to denature DNA. 5-6 /A were
then electrophoresed on a 5% denaturing polyacrylamide gel. Gels were run for
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approximately 30 mins. Gels were then dried and exposed overnight on BioMAX
film.
At the start of this study [a35-S]dATP was used. However, it has recently
been shown that this radionucleotide releases H2S when heated during thermal
cycling which can permeate polypropylene tubes and cause radioactive
contamination. In more recent experiments this radionucleotide has been substituted
with [a32-P]dATP in all experiments, using 0.5 fj,Ci per reaction.
2.11 NUCLEOTIDE SEQUENCE ACCESSION NUMBERS.
The sequences obtained in this study have been submitted to GenBank and
assigned accession numbers U79785 to U79869 (gag; P4, 5 and 6) and U79870 to
U80057 (V1/V2; P4, 5 and 6). Nucleotide sequences for P79 in the pl7 gag region
are listed in appendix IV.
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CHAPTER 3: INVESTIGATION OF THE DYNAMICS OF THE SPREAD
OF HUMAN IMMUNODEFICIENCY VIRUS TO BRAIN AND OTHER
TISSUES BY EVOLUTIONARY ANALYSIS OF SEQUENCES FROM THE
p!7gag AND env GENES.
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3.1 INTRODUCTION.
Infection with HIV is associated with a slow, progressive and irreversible
impairment of the immune system eventually leading to AIDS. Inherent in the
nature of infection with HIV-1 is the prolonged asymptomatic period that proceeds
the development of disease (Fauci, 1993b; Miedema et al., 1990b; Bednarik et al,
1992b; Pantaleo et al., 1993b), where infection may be subclinical for as long as
10-15 years. This phenomenon was originally hypothesised to result from viral
latency, whereby viral or proviral DNA became integrated into the host genome
with the simultaneous cessation of viral expression and independent replication
(Bednarik et al., 1992). The ensuing progression to AIDS would then result from
subsequent re-activation of virus replication by various factors acting upon the
infected cell such as antigens, mitogens and transcriptional factors produced by
other viruses. However, it has been recently shown that from the time of
seroconversion there is active replication of the virus in lymphoid tissues (Fauci,
1993b; Miedema et al., 1990b; Pantaleo et al., 1993b). There are few convincing
demonstrations of active infection of non-lymphoid tissues until later in infection,
and this change in distribution may be associated with increased
immunosuppression in AIDS (Donaldson et al., 1994b). Alternatively, it is possible
that variants detected in non-lymphoid tissue such as brain in AIDS patients may
have been continuously present from initial infection, but that infection only
becomes clinically significant during severe immunosuppression. In this model,
HIV encephalitis could be regarded as re-activation rather than de novo infection.
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This study was undertaken to estimate the time of spread of HIV-1 to non-
lymphoid tissues to determine whether re-activation or actual virus spread was
responsible for the pathology observed in non-lymphoid tissues in AIDS. The
individuals observed in this study were from a cohort of infected IDU identified in
Edinburgh. These individuals were chosen for this study because infection of this
cohort occurred at approximately the same time (Robertson et al., 1986a), and
clinical follow up studies have been possible due to the isolation of this group of
individuals and their social stability (Goodwin et al., 1996; Davies et al., 1995;
Brettle et al., 1996). Serologic analysis of stored serum samples indicated that
HIV-1 was introduced into Edinburgh and spread rapidly in late 1982 and early
1983 (Peutherer et al., 1985). This rapid spread of the virus in Edinburgh may be
explained by high risk behavioural habits of IDU in Edinburgh. At the time of this
rapid spread there was a high frequency of needle sharing and use of contaminated
needles (Robertson et al., 1986b; Robertson et ah, 1986b), the likely result of
difficulties in obtaining sterile needles and syringes. A recent study by Holmes et
al., analysed the phylogenetic relationships between HIV-1 infected individuals in
different risk groups in Edinburgh (Holmes et al., 1995). Phylogenetic analysis
using the pl7 region from the gag gene revealed three distinct groups within this
population, two of which comprised sequences from haemophiliac patients and a
third distinct group containing sequences from IDU and those infected from them
through heterosexual contact. This finding was somewhat surprising, suggesting
that the epidemic in this group may have arisen from a single HIV variant that first
infected the IDU population in 1982/83. Therefore, this IDU cohort provides a
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unique opportunity to examine the divergence of viral variants over time within a
population infected from a common source.
In this study sequences were obtained from the pi7^ region and V1/V2
flanking regions of HIV-1 from four individuals from the Edinburgh IDU cohort.
The pl7 region was chosen because most nucleotide differences in this region
are synonymous and therefore are not subject to positive selection pressures, unlike
many other regions in the HIV-1 genome. Nonsynonymous substitutions alter the
amino acid composition and may arise through a process of natural selection. For
example, the appearance of escape mutants through selection pressures exerted by
the host immune system. However, synonymous substitutions do not cause amino
acid changes of proteins and are therefore less subject to selection. Hence,
synonymous substitutions are more likely to be caused by a random fixation of
mutations (neutral theory) and are therefore more likely to reflect the underlying
mutational rate allowing reliable estimates of divergence times to be calculated.
It has previously been suggested that the extent of HIV-1 replication
throughout infection is not constant. Extensive replication was previously thought
to occur during the acute phase of infection and again later on in infection prior to
the progression to AIDS. These observations have led to the suggestion that the
rate of sequence change may be greatly increased early and late in infection and
greatly reduced during the asymptomatic phase. However, more recent studies have
shown continuous productive viral replication, regardless of clinical stage, with 108
to 109 virions produced daily (Connor et al., 1994; Ho et al., 1995; Wei et al.,
1995). Secondly, more extensive replication does not necessarily imply that the rate
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of sequence change will occur more rapidly, being principally dependent on the
replicative cycle of the virus, rather than immune control of the host. If rates of
sequence change are measured at genuinely neutral sites, then the observed rate
should simply be proportional to the number of replicative cycles.
The rate of sequence change of the pl7gag region has previously been
determined from haemophiliacs, in the first two years of HIV-1 infection, who
were infected from a common batch of clotting factor concentrate (Kasper et al.,
1995). Greater rates of synonymous (6.0 to 7.2 x 10"3) to nonsynonymous
substitution (3.6 to 4.8 x 103) were observed, suggesting that this region is not
subject to positive selection pressures. In this study, of individuals infected for 10
years or more, similar rates of synonymous and nonsynonymous substitutions were
observed, suggesting that the rate of sequence change for the pl7 region of gag is
constant from early on in infection (2 years) until AIDS (10 years). This region is
therefore of use in reconstructing epidemiological relationships between HIV-1
infected individuals (Holmes et al., 1993) and can be used as a type of molecular
clock allowing estimates of the divergence time between any two sequences to be
carried out. This molecular clock can be extended to the comparison of variants
within different cell types within a single infected individual.
Tissues from various lymphoid and non-lymphoid organs were obtained at
autopsy from a number of HIV-1 positive patients known to have a high viral load
in the brain and evidence of giant cell encephalitis (GCE) by pathology.
Phylogenetic analysis of both pl7gag and V1/V2 flanking regions was carried out in
order to explore the relationship between the various lineages present and the
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spread of infection to non-lymphoid tissues. It was possible to estimate the time of
divergence between lymphoid and non-lymphoid tissues allowing an estimation of
the length of time, prior to death, that non-lymphoid tissue has been infected.
3.2 CLINICAL DETAILS OF PATIENT SAMPLES.
Tissue from various organs were obtained at autopsy, carried out within
three days of death, from four individuals who died with an AIDS-defining illness.
All individuals showed evidence of HIV infection of the brain upon post-mortem
examination, as determined by the histological appearance of giant cells, the
detection of p24 by immunocytochemistry, and the finding of high proviral loads in
brain by quantitative PCR (Donaldson et al., 1994b). Pathological examination of
the fixed brains revealed evidence of atrophy on external examination and this was
confirmed on section by the presence of ventricular dilatation and opening up of
the sulci in all four patients. In p6 a focal 1cm diameter lesion was identified on
macroscopic inspection in the right basal ganglia. Histological examination of this
lesion showed that it was a primary CNS lymphoma. In p79 focal 2cm diameter
lesions were identified upon macroscopic inspection in the left thalamus, internal
capsule and left occipital lobe both in cortical ribbon and paraventricular regions.
Microscopic examination showed that these lesions were composed of
periventricular foci of lymphoma, much of which was necrotising. Neither of the
other two patients showed macroscopic focal lesions of the brain. Histological
examination in all four patients displayed evidence of quite florid HIV encephalitis
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and leukoencephalopathy, characterised by giant cells and focal collections of
macrophages and microglia cells, associated with myelin damage. There was no
evidence of perivascular or leptomeningeal inflammatory infiltrates and in
particular, lymphocytes were not identified within the CNS parenchyma. Additional
clinical information for the five years prior to death for each patient is summarised
in Fig 6.
3.3 PHYLOGENETIC ANALYSIS.
Sequence comparisons between viruses from the four study patients were
made in the pl7gag gene and in three of the study patients (p4, 5 and 6), in the
hypervariable flanking regions of VI and V2 of the env gene of HIV-1. The pl7gag
region amplified began at nucleotide 795 of HXB2 and extended to position 1319.
The V1/V2 region amplified began at position 6539 of HXB2 and extended to
position 6976. The length of the gag region used for sequence comparisons was
413 nucleotides and that of the V1/V2 region was 297 nucleotides. All nucleotide
sequences were aligned manually. An unrooted phylogenetic tree for 85 pl7gag (p4,
5 and 6) nucleotide sequences obtained from lymph node, brain and lung samples
was constructed using the neighbour-joining method using the program
NEIGHBOR in the PHYLIP package (version 3.5; Felsenstein, 1989). Distances
between each pair of sequences were estimated using the program DNADIST in
the PHYLIP package (version 3.5; Felsenstein, 1989). Rooted trees were
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Fig. 6. Clinical and laboratory markers of disease progression in the three study
patients in the 5 years before death. CD4 counts are shown as the mean counts
over each year. Abbreviations: AZT: Zidovudine; PCP: Pneumocystis carinii
pneumonia.
as an outgroup (Kumar et al., 1993). Phylogenetic analysis of the env region was
confined to regions flanking the VI and V2 hypervariable regions, because of the
indeterminate and often arbitrary alignment of the hypervariable sequences and the
possibility of positive selection. The number of synonymous substitutions at
synonymous sites (ds) and nonsynonymous substitutions at nonsynonymous sites
(dN) between sequences were estimated using the method of Nei and Gojobori (Nei
et al., 1986). Finally, the bootstrap resampling method was used (500 replicates) to
assess the confidence of each node in all trees constructed using the MEGA
package.
3.4 STATISTICAL ANALYSIS.
The distribution of distances between and within patients were subjected to
nonparametric statistical treatment using the Wilcoxon signed rank test included in
the SYSTAT version 5.0 package.
3.5 RESULTS.
3.5.1 RATE OF SEQUENCE CHANGE IN pl7gag REGIONS.
An unrooted neighbour-joining tree was constructed using 85 sequences
from the pl7gag region (positions 835-1270 in the HXB2 clone; Myers et al., 1991)
from a range of lymphoid and non-lymphoid tissues of three HIV-infected
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individuals dying in AIDS (p4, 5 and 6). Sequences from each of the three study
patients were distinct, grouping separately into three clades. Bootstrap resampling
supported the distinction of three separate groups (Fig 7).
All three study subjects were infected with HIV through drug abuse in
1982/83. Previous phylogenetic studies have implicated a common source of
infection for the majority of drug users in Edinburgh, including the three described
here (Holmes et al., 1995). The current sequence differences between the study
subjects therefore must have originated from a process of divergent sequence
change over a period of between 9 and 10 years. Using a mean figure of 9.5 years
(or 19 years of divergent sequence change), the mean synonymous pairwise
distances in the pl7gag region between individuals (0.149) indicated a rate of
sequence change of 0.0077 substitutions per site per year. The rate of sequence
change between pairs of individuals was similar, ranging from 0.006 to 0.009
(Table 6; Fig 8A-8C). This estimate was similar to those obtained in previous
studies. For example, sequence comparisons in the pl7gag region of plasma RNA
sequences from haemophiliacs infected from a common source indicated a mean
rate of synonymous substitution in pl7gagof 0.006 to 0.0072 substitutions per site
per year (Kasper et al., 1995).
The mean rate of nonsynonymous substitution between the study subjects
was 0.058, lower than the silent rate. The mean dN/ds ratio of 0.39 indicated a bias
towards silent substitutions in this region of the gag gene, consistent with previous
estimates (Gojobori et al., 1990b; Myers et al., 1992b; Li et al., 1988b; Kasper et
al., 1995b).
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Fig. 7. Neighbor-joining tree of sequences in the pl7gag region of the three study




SEQUENCE COMPARISONS BETWEEN STUDY SUBJECTS IN THE pl7gfl?
REGION
MEANS Silent
Pair Divergence No. pairwise Silent Non-silent Ratio rate2
(years)1 comparisons sites sites (dN/ds)
P4-P5 19 960 0.152 0.053 0.35 0.008
P4-P6 18 736 0.112 0.052 0.47 0.006
P5-P6 19 689 0.184 0.070 0.38 0.009
All 18.7 795 0.149 0.058 0.39 0.0077
'Based upon infection from a common source in 1982 (see Results)
2Silent substitution rate of sequence change between study subjects (per site per
year)
Fig. 8. Frequency histograms of silent pairwise distances in the pl7gflS region
between study subjects: (A) p4/p5; (B) p4/p6; (C) p5/p6, and within study subjects
between sequences obtained from different tissues: (D) p4; (E) p5; (F) p6. Median
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In this study I also determined the sequences of the VI and V2
hypervariable regions and flanking regions in the env region from the three study
patients (positions 6560-6876). Between individuals, the mean pairwise
synonymous distance between sequences from the flanking regions (but omitting
the hypervariable regions between 6623-6679 [VI] and 6701-6796 [V2]) was
0.104, lower than for the pl7gag region. In contrast the rate of nonsynonymous
substitution in the V1/V2 flanking region was higher (0.083), producing an overall
dN/ds ratio of 0.80, similar to previous estimates for the env region (Wolfs et al.,
1990; Li et al, 1988).
In this study I used the measured rate of sequence change in the pl7gas
region at silent sites to estimate the time of divergence between variants infecting
different tissues within an infected individual. These data should indicate when the
spread of HIV into non-lymphoid tissue occurred (Donaldson et al., 1994b).
3.5.2 PHYLOGENETIC ANALYSIS OF VARIANTS FROM DIFFERENT
TISSUES.
Phylogenetic analysis was carried out using sequences from the pl7^
region and V1 and V2 flanking regions from a range of lymphoid and non-
lymphoid tissues to determine the relatedness of variants between each tissue (e.g.
lymph node, brain and lung; Fig 9). Bootstrap resampling using 500 replicate trees
was carried out to estimate the robustness of the observed groupings.
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Fig. 9. Phylogenetic analysis of sequences obtained from different tissues from the
three study subjects (A, D: p4, B, E: p5; C, F: p6) in different subgenomic regions
(A, B, C: pl7gag region; D, E, F: V1/V2 flanking regions). Trees shown in rooted
form using the unrelated subtype B sequence of HIV-MN as an outgroup.
Bootstrap values of >75% indicated for branches highlighted in bold. Symbols: +
Brain, ♦ Spinal cord, • Lung ,■ Colon, □ Lymph node, O Spleen.
V1-V2
There was little evidence for consistent phylogenetic grouping by tissue
origin. For example, pl7gag sequences from lymph node of patient 4 were found in
two distinct lineages, one of which contained a variety of sequences from other
tissues (lung and spleen; Fig 9A). Similarly sequences from brain were interspersed
with those from colon, lung and spinal cord. In the V1/V2 flanking regions, a
number of lineages were present supported by high bootstrap values (Fig 9D). For
example, sequences from the brain were found in lineages a, b, c and f, all of
which included sequences from various tissues such as brain, lymph node and lung.
However, lineage a contains a large group of mainly brain isolates which may be
an artifact of sampling error, whereby a very limited area of brain tissue has been
sampled resulting in detection of a restricted population (see below).
Similar mixing of sequences from lymphoid and non-lymphoid tissues was
observed amongst sequences from the other two study subjects (Fig 9B, 9C, 9E,
9F). For example, pl7gag sequences from both brain and lymphoid tissue of patient
5 were each found on lineages a and b, separated from each other by high
bootstrap values (Fig 9B). In patient 6, sequences were obtained only from brain
and lymph node but each of the lineages contained sequences from both sources
(Fig 9C, 9F).
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3.5.3 TIME OF DIVERGENCE OF HIV VARIANTS IN DIFFERENT
TISSUES.
Pairwise synonymous distances between sequences from the pi7^ region
from each patient were calculated to estimate the time of divergence of variants
within each tissue. The previously established rate of sequence change in the pl7gag
region of 0.0066 substitutions per site per year was used (Kasper et al., 1995),
although similar results would have been obtained if I had used the synonymous
substitution rate observed in this study (mean of three study individuals: 0.0077).
Mean synonymous pairwise sequence distances within study subjects were
calculated by comparing sequences from all tissues with each other, as well as
comparisons restricted to variants found in particular tissues, such as brain, lymph
node and lung (Table 7; Fig 8D-8F). Comparison of variants found in all tissues
produced a range of pairwise distances from 0.035 to 0.086, approximately a third
of the mean inter-patient silent distance. These implied times of divergence of 2.6
to 6.5 years (Table 7).
In all three patients the mean distance between sequences from brain tissue
was greater than the mean distance between variants in lymphoid tissue (Table 7;
Fig 10), reflecting their wide distribution in multiple lineages by phylogenetic
analysis (Fig 9). For example, the mean synonymous pairwise distances calculated
for brain tissues ranged from 0.054 to 0.086 while that for lymphoid tissue ranged
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Fig. 10. Distribution of pairwise distances in different tissues from the three study
patients (p4, 5 and 6) at (A) silent sites and (B) non-silent sites in the pi7gag
region.
times of 4.1 to 6.5 years and 2.65 to 5.6 years for the brain and lymphoid variants
respectively. Overall, sequences between variants found in brain were no more
similar to each other (0.080 for three study patients; Table 7) than they were to
those present in lymphoid tissue (mean silent pairwise distance between brain and
lymph node sequences: 0.070). In two of the patients mean synonymous pairwise
distances were also calculated for variants isolated from lung tissue. In p4 the
mean distance for lung variants (0.070) was greater than that for brain (0.054) and
lymphoid variants (0.035), while in p5 the mean distance for lung variants (0.043)
was approximately half that of brain (0.082) and very similar to lymphoid variants
(0.048). In p5 focal inflammatory cell infiltrates were detected within lung tissue.
Hence, sampling an area with such a focal infiltrate may provide an under-
representation of the diversity of variants within this tissue. Indeed, the majority
V3 sequence detected in lung tissue, lymphoid tissue and PBNCs was identical. In
p4 patchy collections of macrophages and MGCs were present in the lung sections
examined and the majority V3 sequence detected in lung tissue was identical to
that detected in brain tissue, contrasting that found in p5.
Mean nonsynonymous pairwise distances were also calculated and were
found to be lower than the distances at silent sites only. Nonsynonymous distances
calculated for brain tissue only ranged from 0.010 to 0.042 and were higher than
those observed between variants in lymphoid tissue of the three study individuals
(0.012 to 0.020; p<0.001). Subsequently these values produced dN/ds ratios of
between 0.158 and 0.49 for brain tissue only and 0.16 and 0.46 for lymphoid tissue
only, similar to that observed previously using inter-patient comparisons. These
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ratios indicate that most substitutions occurring within an individual in pl7gag
region were silent.
3.5.4 PHYLOGENETIC ANALYSIS OF SEQUENCE VARIANTS FROM
PATIENT 79 ISOLATED FROM DIFFERENT TISSUES.
Following this study I examined the diversity of HIV-1 within a fourth
individual (p79), from the Edinburgh IDU cohort, who had been infected for
approximately 12 years to discern whether a similar distribution of viral variants
from various tissues could be observed in an individual infected for a considerably
longer period of time than p4, 5 and 6 (infected for 9 to 10 years). In this study
subject I determined the sequences from the pl7gag region only. Phylogenetic
analysis was carried out to determine the relatedness of variants between each
tissue (brain, lymph node and lung; Fig 11). Bootstrap resampling using 500
replicate trees was carried out to estimate the robustness of observed groupings.
Consistent with the previous phylogenetic analyses, sequences from lymph node
and lung tissues were interspersed throughout the tree, although fairly low
bootstrap values were observed. Only two lineages had values higher than 75%;
lineage a contained sequences from brain tissue only and lineage b contained
sequences from lung tissue only. In contrast to the previous phylogenetic analysis,
sequences obtained from brain tissue from this individual grouped closely together
with only one variant falling outside the main group, being more closely related to



















Fig. 11. Phylogenetic analysis of sequences obtained from different tissues of p79
in the pi7^ region.Trees shown in rooted form using the unrelated subtype B
sequence of HIV-MN as an outgroup. Bootstrap values of >75% indicated for
branches highlighted in bold. Symbols: + Brain, • Lung, □ Lymph node.
Pairwise synonymous distances between sequences from the pl7gag region of
p79 were calculated to estimate the time of divergence of variants within each
tissue (Table 8; Fig 12). The previously established rate of sequence change for
synonymous sites (0.0066 substitutions per site per year) was used (Kasper et al.,
1995). In contrast with estimates from the previous study, the mean distance
between sequences from brain tissue from p79 were considerably smaller than the
mean distance between variants from lymphoid or lung tissue. For example, at
synonymous sites the mean distance for brain tissue was 0.015, compared with 0.06
and 0.07 in lymph node and lung respectively. These distances translate into
approximate mean divergence times of 1.14, 4.54 and 5.3 years for brain, lymph
node and lung variants respectively. Mean synonymous pairwise distances between
brain and lymph node and brain and lung sequences were calculated to be 0.042
and 0.044 respectively. Therefore, variants found in brain were far more similar to
each other than they were to those found in lymphoid or lung tissue. Phylogenetic
analysis reflects this limited diversification of brain variants with all brain
sequences grouping tightly together.
Mean nonsynonymous pairwise distances were also calculated for P79 and
were found to be lower than distances at silent sites only, consistent with the
previous analysis (Table 8; Fig 12). These values were used to calculate dN/ds
ratios for each tissue and produced ratios of 0.47, 0.4 and 0.44 for brain, lymphoid
and lung tissues respectively. These ratios were similar to those observed





















































































































































































Fig. 12. Distribution of pairwise distances in different tissues from p79 at (A)
silent sites and (B) non-silent sites in the pl7sas region.
substitutions which occurred within the pl7gag region were silent.
3.6 DISCUSSION.
3.6.1 DIVERSITY OF HIV-1 in vivo.
In this study a comparison of the diversity of HIV-1 in different tissues,
including brain, lymph node and lung, obtained from four individuals infected from
a common source in 1982/83 was carried out. Three of the individuals were found
to have very diverse populations in all tissues although, in one individual (p79),
relatively restricted diversity within brain tissue was observed. Similar results were
obtained by Wong et al., who analysed the distribution of pol sequences within
different tissue compartments from a number of patients who died in AIDS and
who had received AZT treatment for variable periods of time (6 months to 2
years), prior to death. In three of the study subjects Wong et al., observed
restricted diversity within brain tissue , while in a fourth subject a more diverse
population was formed from two distinct evolutionary lineages, with one containing
substitutions in pol at codons 41 and 215 that confer resistance to AZT treatment.
Within the three individuals showing restricted diversity, differences in AZT
resistance were noted. In subject A restricted diversity was seen in brain tissue and
the entire population was found to be resistant to AZT with mutations at codons 41
and 215. Subject B and D also showed restricted diversity in brain however, in
these two patients, no variants contained mutations associated with antiviral
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resistance.
In this study two individuals (p4 and p79) underwent extensive AZT
treatment for up to five years prior to death. Diverse populations were observed in
the brain from p4 which contrasted to the very restricted diversity seen in the brain
from p79. P6 was treated with AZT for two years prior to death and diverse
populations were observed in brain. Finally p5, who remained untreated throughout
infection, also showed diverse populations within brain tissue. Therefore, in this
study and the study by Wong et al., both diverse and restricted populations have
been detected in brain tissue from a number of individuals. This discrepancy cannot
be attributed to AZT resistance since similar degrees of diversity have been
observed in individuals with and without AZT resistant variants. For example, in
subject A all variants detected were resistant to AZT yet this individual showed
restricted diversity within the brain. Similarly, p5 had never been treated with any
retroviral agents and yet displayed considerable diversity within brain tissue.
How can these differences in diversity within brain tissue be explained?
One explanation could be that AZT resistant mutant variants may infect brain
tissue and replace the initial infecting populations, thereby producing a
homogenous brain population. This hypothesis would explain the restricted
diversity in the pol region of subject A. However, complete replacement would be
hampered by the lack of mobility of infected cells within a solid tissue. In the
peripheral circulation, however constant viral replication and rapid cell turnover
can lead to rapid population replacements within PBMCs (Coffin, 1996; Ho et al.,
1995; Wei et al., 1995). Although we do not know the lifespan of HIV-infected
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cells in the CNS it is less likely that such a process would occur so rapidly within
brain tissue.
Another, more likely explanation for the observation of different populations
within brain tissue could be due to inappropriate sampling. The brain itself is a
large mass of solid tissue where cellular movement would be very restricted, unlike
the peripheral circulation. It is therefore, highly likely that separate populations
could emerge within the brain following initial infection. Brain tissue may be
seeded early on in infection by infected cells from the peripheral circulation and
form distinct foci of infection. Indeed, in this study I have shown that multiple
lineages exist within brain tissue of three of the study subjects (p4, 5 and 6) and it
is possible that each represents an independent focus of infection. Similarly in a
previous study analysing the distribution of V3 sequences within different tissues,
variants found in the left brain of one individual were not detected in the right
brain of the same individual, again providing strong evidence to suggest multiple
infection of brain tissue (Donaldson et al., 1994a). Following replication each focus
of infection will have diverged from a single infected cell and therefore may
display restricted diversity. The number of foci present will depend on how diffuse
the initial seeding of the brain was.
When sampling brain tissue for analysis it is very possible that an
unrepresentative population may be selected. For example, the tissue from which
DNA was extracted may contain only one focus of infection, ultimately derived
from a single infecting virus particle. Consequently, restricted diversity would be
observed in any variants sampled from this tissue section and appear monophyletic
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by evolutionary analysis. Conversely, the tissue section analysed may contain a
number of independent infected centres leading to a much more diverse,
polyphyletic population. These differences could explain the variation observed
between populations of HIV sequences in the brain tissue of p4, 5, 6 and 79.
Similarly, in the study by Wong et al., the observation of two brain populations in
subject C may have resulted from the presence of two foci of infection in the same
tissue sample, one lineage being resistant to AZT while the other was sensitive.
The monophyletic populations observed in the other three individuals may have
resulted from sampling very small amounts of tissue which contained only one
infection site. Unless the effect of sampling is taken into account, it is wrong to
infer that the restricted diversity in one sample reflects that of the whole tissue.
Conclusions regarding the biological relevance of such observations may be
premature.
In the future studies should include multiple sampling sites to ensure that
representative populations of HIV variants from the brain tissue are analysed. This
theory could be investigated experimentally by dissection of foci of infection. For
example, discrete foci of infection could be identified using in situ PCR,
subsequently dissected from brain tissue and analysed in a similar manner to that
described here. This type of analysis would discern whether each discrete focus of
infection was indeed derived from a single infecting virus. From my own study ,
the observation that populations in the brain can be polyphyletic remains valid,
however it is likely that the monophyletic populations observed in p79 and in the
study by Wong et al., under-represent the true diversity of HIV-1 in the CNS.
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3.6.2 RATE OF SEQUENCE CHANGE OF HIV in vivo.
In this study I have used published rates as well as estimates based upon
the sequences recovered from three of the study patients (p4, 5 and 6), to estimate
the times of divergence of variants infecting different tissues in vivo. Measurement
of the rate of sequence change was possible for the study patients because it was
known that all 3 patients were originally infected with HIV from a common source
in an outbreak around 1982/1983, so that each was infected for approximately 9 to
10 years prior to death. Therefore between any 2 individuals, there was
approximately 19 years of divergent sequence change. Synonymous rates of
substitution were calculated for each patient in pl7gag (Table 6) and ranged from
0.006 to 0.009 substitutions per site per year (mean 0.0077), while the rate for the
V1/V2 flanking regions was slightly lower (mean 0.0056 substitutions per site per
year).
One assumption that must be made when calculating times of divergence
from sequence distances is that the rate of sequence change remains constant
throughout the course of infection, and there is little direct evidence that this is
justified. Although higher levels of virus replication clearly occur later in the
course of disease, this does not necessarily imply that the rate of sequence change
should be higher. The rate of sequence change is proportional to the number of
replication cycles, whose length is determined by the replicative processes within
the cell, unless a substantial proportion of the sampled population originates from
virus that has reactivated from latently infected cells where viral replication may
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not have occurred for several years.
Empirically, however, the rate of sequence change at silent sites in pi7gag
over the first 2 years of infection in haemophiliacs (0.0066 per site per year;
Kasper et al., 1995) was similar to that observed in the three study patients
(0.0077), in which the period of infection was 9-10 years, covering primary
infection to death from AIDS. These figures are in turn within the range of those
from several other studies using different observation periods and study subjects at
different stages of disease (Gojobori et al., 1990b; Li et al., 1988b; Wolfs et al.,
1990b).
Although the rate of non-silent sequence change in the gag region was
lower than the synonymous rate, times of divergence based on non-silent sites
provided similar times of divergence of variants in different tissues (mean time of
divergence of variants within each subject: 3.1 years compared with 3.7 years using
the published rate of silent sequence change in pl7gag; Kasper et al., 1995). This is
despite the theoretical possibility that the rate would be affected by phenotypic
selection of variants with changes in the pl7gag region.
Using the mean synonymous rate of substitution for pi7^ of 0.0066
substitutions per site per year (Kasper et al., 1995), the average time of divergence
between brain and lymph node variants within an individual patient were calculated
(Table 7) and a range of values from 3.5 to 6.5 years was obtained. In lymphoid
tissue, the mean diversity of gag sequences implied an approximate population age
of 2.65 to 5.6 years, while those infecting brain were significantly more variable,
suggesting an even earlier time of diversification (4.1 to 6.5 years). Despite the
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large potential inaccuracies in calculating times of divergence based upon sequence
distances, it is clear that compared with the total duration of infection within the
patients (9 or 10 years), the observed diversity within brain tissue suggests
infection occurred relatively early in the course of HIV infection, clearly preceding
the onset of AIDS in two of the four study individuals (Fig 6).
In p79 the average time of divergence between brain and lymph node
variants was calculated and found to be 3.2 years, within the range calculated for
the other study patients. In lymphoid tissue an approximate population age of 4.5
years was calculated using the mean synonymous pairwise distance values, similar
to the values calculated for the other three study subjects. However, variants
infecting brain were considerably less variable with a diversification time of
approximately 1.14 years. As previously suggested, this figure may underestimate
the diversity of variants in the brain, through variants sampled from a restricted
number of foci of infection. The similarity in the calculated divergence times of
variants in lymphoid tissue and lung and those in the study by Wong et al., are
consistent with the much greater degree of mixing of populations from trafficking
of lymphocytes and macrophages through lymph nodes and other tissues.
3.6.3 ORGAN SPECIFIC DIFFERENCES OF HIV IN THE V3 REGION.
Populations of HIV variants infecting different tissues in vivo are generally
distinct in the V3 hypervariable region of env (Ball et al., 1994; Korber et al.,
1994; Power et al., 1994) including three of the patients in this study (Fig 13A-
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13C; Donaldson et al., 1994a). For example, for p5, none of the V3 sequences of
either the major population (15/17) or minor population (2/17) found in the brain
were found amongst those from lung, PBMCs and lymph node; these latter tissues
were dominated by a variant with a substitution at position 28 (35/42; Fig 13A).
Similarly, for p6, variants in the brain were uniform, and differed from lymph node
variants in all but one case by 1-3 amino acids (Fig 13B). The diversity of
sequences in the V3 region of p4 made comparison more difficult, but again the
main variants in brain (14/17) were not found in PBMCs or spleen (n=16) or, with
a single exception, in lymph node (15 sequences; Fig 13C).
On the basis of this apparently tissue-specific distribution of variants in V3,
it has been suggested that these population differences have adaptive significance
and reflect different tropism for the different infected cell types in different tissues.
The involvement of V3 would be consistent with the previous observation of its
role in determining the ability of HIV to replicate in different cell types in vitro
(Millich et al., 1993). Within macrophage-tropic isolates an acidic amino acid or
alanine was predominantly seen at position 25 while a basic or uncharged amino
acid at this position was associated with non-conservative basic amino acid
substitutions at positions 11, 24 and 32 correlating with T-cell tropism, consistent
with other studies (Hwang et al., 1991; Shioda et al., 1994; Morris et al., 1994;
Kasper et al., 1994; Shioda et al., 1992; Westervelt et al., 1991; Chesebro et al.,
1992). Extending this work, Power et al., compared cloned sequences from brain
and spleen in demented and non-demented patients, and found evidence for specific
amino acid substitutions at 2 positions in the V3 loop (histidine at position 305 and
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FIG.13. Proviral V3 loop amino acid sequences from infected organs from terminal
AIDS patients (A) p4; (B) p5; (C) p6; (D) p9. All sequences compared to subtype
B consensus sequence for V3 (LaRosa, 1990); identity with subtype B
consensus; gap introduced to preserve alignment with consensus sequence; "n":















































































































































































































proline at position 329) that correlated with neurotropism and the clinical
expression of HIV dementia (Power et al., 1994). However, while other studies
have also found separate populations infecting brain compared with those infecting
lymphoid tissue, there appears to be no conserved features of the V3 loop that
correlate with neurotropism (Di Stefano et al., 1995; Korber et al., 1994; Reddy et
al., 1996; Liu et al., 1990; Epstein et al., 1991; Keys et al., 1993).
Furthermore, there is no evidence for a correlation between tissue
distribution with the predicted phenotype of such V3 sequences in vitro. For
example, in a previous study of the three patients analysed in this study and others
(Donaldson et al., 1994a), each tissue was found to be predominantly infected with
variants with a predicted NSI /macrophage tropic phenotype, irrespective of tissue
origin. In these cases, the observed amino acid differences between brain and
lymphoid tissue were relatively few and probably unlikely on their own to alter the
phenotype of the virus (Donaldson et al., 1994a; see below).
Other studies support the conclusion that the V3 region is to some extent
involved in tissue tropism but that interaction with other regions in the HIV-1
genome is required for infectivity (Koito et al., 1994; Carrillo et al., 1996;
Stamatatos et al., 1993; Carrillo et al., 1996). It has been suggested that mutations
altering the structure of the V3 loop can affect the conformation of gpl20 and that
in turn the structure of the V3 loop is influenced by the conformation of other
regions in gpl20 (Stamatatos et al., 1993). An interaction of the V3 loop with a
small region of the C4 domain has been suggested to be required for infectivity of
Jurkat T cells lines (Carrillo et al., 1996a; Moore et al., 1993b; Wyatt et al.,
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1992b; Morrison et al., 1993b). Therefore, although it is universally accepted that
restricted variability exists in the V3 loop of HIV-1 gpl20 there is no agreed
interpretation of this observation.
3.6.4 MULTIPLE EVOLUTIONARY LINEAGES IN pl7gag AND V1/V2
REGIONS.
Given the previously observed organ-specific populations in the V3 region,
it was surprising to find a different relationship between variants when sequences
elsewhere in the genome were compared. In both pl7gag and V1/V2 flanking
regions of p4, 5 and 6, I observed numerous independent lineages containing
sequences from non-lymphoid tissues such as brain and lung mixed with those
from lymphoid tissues. In p79, although a similar mixing of lymph node and lung
variants to that seen in the other three study subjects was observed, brain variants
all grouped within the same lineage distinct from the other tissues. Some of these
groupings were confirmed by bootstrap resampling analysis (Fig 9 and 11).
Comparison of the actual VI and V2 sequences showed a pattern of sequence
variability between tissues similar to that of the flanking regions, and without
evidence of tissue specific groupings; this data is discussed in chapter 4.
There are at least three possible explanations for differences in grouping in
different regions of the genomes; these include (a) different rates of sequence
change in different tissues, (b) convergence and (c) recombination, and are
reviewed below.
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The first hypothesis, originally proposed by Korber et al. (Korber et al.,
1994), is based upon the principle that infection of non-lymphoid tissue such as
brain occurs early in the course of infection at a time when the viral population is
relatively homogeneous in the V3 region. Therefore, variants infecting the brain
would be initially similar to variants infecting non-lymphoid tissues. Subsequently,
as disease progresses, variants found in lymphoid tissues may undergo more rapid
sequence change in V3 and elsewhere in the genome associated with population
replacements arising from immune escape or antiviral treatment. For example,
variants resistant to neutralization or to antivirals such as AZT would outgrow
other variants present within the lymphoid tissue. Rapid turnover and population
replacements may be facilitated by the continuous movement of lymphocytes and
other susceptible cells through lymphoid tissue. The previously estimated high rate
of turnover of HIV-infected lymphocytes (Ho et al., 1995; Wei et al., 1995)
following antiviral treatment is consistent with the existence of a relatively
dynamic lymphoid-cell population, whereas at least for antiviral resistance, the
brain population is not (Strappe et al., personal communication). Recently,
evidence for extremely slow turnover of variants in brain tissue was obtained by
sequence comparisons of the pol gene of variants infecting brain and lymphoid
tissues from study subjects dying in AIDS (Wong et al., 1997). Despite frequently
prolonged antiviral treatment prior to death, many individuals showed
predominantly wild-type (i.e. AZT sensitive) variants in brain, while variants
recovered from spleen and/or lymph node were predominantly or exclusively
resistant.
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Alternatively, variants infecting lymphoid cells may be subject to more
rapid changes over time associated with changes in the V3 region that determine
the shift in the phenotype of HIV upon disease progression. Variants in the brain
however, may be unable to undergo such radical changes in the V3 region due to
the continued strict requirements for replication in cells of the brain that are largely
monocyte derived cells, i.e., infiltrating macrophages and microglia cells (Vazeux
et al., 1987; Price et al., 1988). The survival of the original infecting population in
the brain and its replacement in lymphoid cells would explain the former's greater
diversity in all parts of the genome other than those that determined tropism and
the observed organ-specific differences in V3 populations. This hypothesis implies
early entry of HIV into the brain, and although the V3 region is involved in
tropism, it is not in the simple way it has been previously imagined.
It is possible to account for the organ-specific populations in V3 by other
processes that do not necessarily imply early entry into the brain. For example, the
organ-specific similarities in V3 sequences amongst variants that are not closely
related in evolutionary terms could have originated from a process of strong
convergent evolution, whereby the V3 sequence determines the ability of variants
to grow in different cell types. Independent evidence for the existence of positive
selection leading to convergence in V3 has been obtained from a study of
haemophiliacs infected from a common source, who showed similarities in the
pattern of sequence change in the V3 region in different individuals (Kasper et al.,
1995). Similarly, a longitudinal study of a single infected individual showed several
independent occurrences of certain amino acid changes in the V3 loop in variants
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forming two evolutionarily distinct lineages (Holmes et al., 1992).
It is unlikely that the V3 loop could be the sole determinant of tropism, as
the differences between populations infecting brain and lymphoid tissue are often
trivial, and would be unlikely on their own to affect the phenotype of the virus. For
example, all variants in the brain of p5 differed from those of lymphoid tissue at
only one position (position 28), where a glutamate replaced an aspartate, a
conservative amino acid change. Evidence for the functional equivalence of these
two residues at this position can be inferred from their approximately equal
distribution in isolates of the NSI phenotype, and amongst variants infecting a
range of tissues collected at autopsy from these and other individuals (Di Stefano
et al., 1995; Korber et al., 1994; Power et al., 1994; Reddy et al., 1996; Liu et al.,
1990; Epstein et al., 1991; Keys et al., 1993). Furthermore, if convergence were
the explanation for the organ-specific grouping of V3 sequences, we might expect
to observe general similarities between variants infecting specific tissues from
unrelated HIV-infected individuals. However, apart from the one study (Power et
al., 1994), it has generally proved impossible to demonstrate any specific conserved
sequence or motif in V3 or elsewhere in env that correlates with the cell type
infected in vivo (see above). On the other hand, as noted above, it is possible the
actual V3 sequence required for replication in different cell types may depend upon
interactions between V3 and other regions of env, so that different V3 sequences
may evolve to carry out equivalent functions in different HIV strains.
The other mechanism for different relationships in different parts of the
genome is recombination, where a requirement for specific V3 sequences that
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confers an ability to infect different tissues may favour recombination with an
already divergent pre-existing population either within or out-with the tissue where
the variants were found. Recombination occurs frequently in retroviruses including
HIV-1, and is a mechanism by which genetic variation can be increased (Coffin,
1979). Recombination requires that multiple infection of cells occurs, and although
there is evidence that this may occur in vitro (Rey et al., 1986; Koyanagi et al.,
1987), the scarcity of HIV-infected cells in brain and other tissues seems to suggest
that it may be an unlikely event in vivo. However, it is possible that recombinants
may be generated elsewhere where high levels of replication occur (eg. in
lymphoid tissue) producing variants that are uniquely able to enter and replicate
within the CNS.
Whether the similarities in V3 originated from convergence or
recombination, these hypotheses suggest that the observed diversity of variants
within brain tissue could have originated by a process of multiple entry from
sources outside the CNS. Therefore, the actual duration of infection in the brain
may be substantially lower than can be calculated by estimating its population
diversity. Indeed, the grouping of variants from brain and lymphoid tissue by
phylogenetic analysis of the pl7ga? and V1/V2 flanking regions could be regarded
as evidence for a process of multiple entry. On the other hand this hypothesis does
not easily explain how populations in brain should be consistently more diverse
than those in lymphoid tissue or other presumed sources of infection in brain. The
observed diversity of pl7gag sequences in brain tissue, from patients 4, 5 and 6, is
more consistent with the first hypothesis of a lower rate of population replacement
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in brain compared with lymphoid tissue. In the case of p79 however, a less
divergent population was detected in brain tissue (as previously discussed).
Therefore, this finding may simply highlight the limitations encountered when
sampling from solid tissues. In the future more rigorous sampling techniques
should be applied to determine whether the difference in divergence observed in
the four study patients here was due to insufficient sampling or not.
In summary, the main findings of this study were the observation of an
unusually diverse population of HIV variants in brain of three of the study subjects,
without evidence for any closer evolutionary relationship between them than to
variants infecting other tissues in the body. Although late entry of recombinant
viruses is a possibility, it is more likely that viral entry into the brain occurs
relatively early in the course of disease, based upon observations of its higher
diversity in brain than in other tissues and the existence of multiple evolutionary
lineages containing sequences from brain. These findings suggest that loss of
immune competence is not solely required for entry into non-lymphoid tissue, and
the strong association between HIV-induced neuropathology and disease
progression may be consequent to reactivation rather than de novo infection of the
CNS. The finding of variants in the brain on several different evolutionary lineages
challenges the hypothesis of the evolution of a uniquely neurotropic strain. It is
possible that the only requirement for infection of the brain may be macrophage-
tropism and hence the possession of a V3 loop sequence that is of low charge and
shows few differences from the subtype B consensus sequence (Donaldson et al.,
1994a).
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This study represents the first attempt to use evolutionary analysis of
variants infecting different tissues. The finding of different inter-relationships
between variants in different parts of the genome, combined with uncertainty about
the frequency and site of recombination in vivo and the selection pressures that
could produce convergent evolution in V3, highlights the complexity in trying to
understand the dynamics of HIV replication and dissemination to different tissues.
However, this research at least provides a starting point for a more rigorous
examination on the existence of HIV tropism in vivo.
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CHAPTER 4: INVESTIGATION OF POPULATION DIVERSITY OF HIV-1
IN VIVO BY NUCLEOTIDE SEQUENCING AND LENGTH




HIV-1 may exist in a state of permanent transition to survive external
factors such as immune surveillance. This continual fluctuation has given rise to
the term quasispecies to describe a population of closely related variants of HIV-1.
Different viral variants, which exist within such a quasispecies, could potentially
differ in their biological properties such as cellular tropism, cytopathicity,
syncytium induction, replication rates and neutralization properties. A number of
these differences in phenotype have been attributed to the envelope glycoprotein
gpl20. Previous studies have implicated the V3 domain, located within the third
major cysteine loop, as the major determinant for these biological properties with
specific amino acid changes in the V3 domain associated with differences in cell
tropism and the ability to produce syncytia (Shioda et al., 1992; Shioda et al.,
1991; Shioda et al., 1994; Chesebro et al., 1992; Millich et al., 1993; Morris et al.,
1994; Power et al., 1994; Westervelt et al., 1991). This region has also been shown
to be the principal target of neutralising antibodies produced by infection or
immunization (Gorny et al., 1994a; LaRosa et al., 1990a; Freed et al., 1991a;
Zwart et al., 1991a; Hwang et al., 1991a).
Functional determinants, however, are not solely restricted to the V3
domain of gpl20. More recently, biological characteristics of HIV-1 have been
attributed to the VI and V2 hypervariable regions located in the second major
cysteine loop (Boyd et al., 1993; Wu et al., 1995; Toohey et al., 1995; Sullivan et
al., 1993; Koito et al., 1994; Westervelt et al., 1992; Koito et al., 1995). Sullivan
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et al., have shown that the V1/V2 hypervariable regions may be involved in post-
receptor binding events in the membrane fusion process (Sullivan et al., 1993).
They carried out a mutational analysis showing that the replacement of certain
highly conserved amino acid residues resulted in envelope glycoproteins deficient
in syncytium formation and/or virus infectivity. Similarly, Wang et al., using site
directed mutagenesis, identified a conserved aspartic acid residue required in the
early stages of HIV-1 replication (Wang et al., 1995). Replacement of this residue
with either an alanine, leucine or glutamic acid residue resulted in a marked
reduction in growth kinetics when compared with the wild-type phenotype. It is
therefore conceivable that this aspartic acid residue is critical for postreceptor
binding events and may interact with other regions in the gpl20 molecule to confer
the correct conformation required for virus entry.
Several structural features within the V2 region have been suggested to
determine the phenotype of the virus (Groenink et al., 1993; Fouchier et al., 1995;
Andeweg et al., 1995). Andeweg et al., constructed chimaeric envelope genes to
delineate the regions of the envelope glycoprotein important in membrane fusion.
They reported that in SI variants, the N-terminal part of the V2 region was likely
to form a stable a-helix not predicted for NSI variants (Andeweg et al., 1995).
Groenink et al., observed a greater length and overall positive charge of the V2
domain amongst SI, non-macrophage tropic isolates (Groenink et al., 1993).
However, in a follow up study, only 2 out of 11 study patients were found to have
elongated V2 domains 11 to 60 months prior to SI conversion (Fouchier et al.,
1995). In an extension of this analysis, variants infecting 11 out of 12 individuals
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(3 months after SI conversion) and 14 out of 26 individuals (6 months after SI
conversion) were shown to have elongated V2 domains. These findings suggest that
elongated V2 domains may be required transiently for SI conversion but are not
necessarily required for maintenance of this phenotype (Schuitemaker et al., 1995;
Fouchier et al., 1995). Subsequent investigations have effectively discounted a
causal association between phenotype and primary amino acid sequence of V2
(Cornelissen et al., 1995; Palmer et al., 1996; Wang et al., 1995), even though
determinants of cytopathology and cellular tropism are clearly in part dependent on
this and neighbouring regions of gpl20.
The V2 domain has also been shown to determine efficient infection of
macrophages (O'Brien et al., 1990; Westervelt et al., 1992; Toohey et al., 1995;
Koito et al., 1994; Boyd et al., 1993; Koito et al., 1995). Kioto et al., generated T
cell tropic/macrophage tropic recombinant viruses to investigate whether the V1/V2
domains were required for macrophage tropism (Koito et al., 1994). The results
obtained strongly indicated a role for the V1/V2 regions in macrophage tropism
and suggested these regions may interact with the V3 region modulating the overall
conformation of gpl20. Toohey et al., suggested that without the appropriate
V1/V2 sequence macrophage tropic clones failed to spread following initial
infection again suggesting a role for the V1/V2 regions in membrane fusion
(Toohey et al., 1995).
The lack of correlation between viral phenotype and primary amino acid
sequence of VI and V2 can be clearly seen in Fig 14. Published VI and V2
sequences of known phenotype from 3 independent studies (Groenink et al., 1993;
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FIG 14. Comparison of the relationship between charge, length and glycosylation
of VI and V2 domains with the experimentally determined in vitro phenotype of
previously described HIV isolates. (A), (B): charge and length for VI and V2
domain respectively; symbols: "O": NSI isolates; SI isolates. (C), (D): number
of potential N-linked glycosylation sites for VI and V2 regions respectively, (see
Appendix V).
Wong et al, 1995; Cornelissen et al., 1995), were analysed collectively and the
overall charge and length were compared (see Appendix V). There was
considerable variability in the overall charge of both VI (-5 to +2) and V2 (-3 to
+4) and in the length (VI: 16 to 49 amino acids; V2: 38 to 61 amino acids). They
also differed in the position and number of several of the potential N-linked
glycosylation sites, although some were highly conserved, as were the cysteine
residues that maintain the structure of the VI and V2 loops (Leonard et al., 1990).
However, there was no systematic difference in these properties between NS1,
macrophage tropic isolates and SI variants in either of these regions.
It has also been shown that VI and V2 regions of gpl20 can act as targets
for neutralizing antibodies (Warrier et al., 1994; van Tijn et al., 1989; Ho et al.,
1991; Yoshiyama et al., 1994; Moore et al., 1993; Gorny et al., 1994; Fung et al.,
1992; Sullivan et al., 1993). Monoclonal antibodies with virus neutralizing activity
have been mapped to the V2 region by binding to peptides corresponding to V2
sequences (Fung et al., 1992; McKeating et al., 1993), mutational analysis
(Sullivan et al., 1993) and by competition with previously mapped anti-V2
monoclonal antibodies (Jeang et al., 1993). Consequently, linear, conformational
and glycan dependent epitopes have been detected.
Finally, it has been suggested that the existence of functional interactions
between V1/V2 hypervariable regions and other regions of gpl20 are essential for
viral infectivity and syncytium induction (Cho et al., 1996; Willey et al., 1989;
Andeweg et al., 1993; Freed et al., 1994). Willey et al., have previously shown
that substitution of an asparagine with a glutamine in the C2 region of gpl20
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generated a non-infectious virus (Willey et al., 1988), however revertant virions
were found to emerge during long term coculture. Sequence analysis of these
revertants revealed the substitution of an asparagine for a serine in the V2 region
of gpl20 compensating for the substitution in the C2 region and restoring virion
infectivity (Willey et al., 1989). In another study, substitution of a tyrosine by a
histidine at position 435 in the C4 region of gpl20 prevented the binding of two
conformational dependent anti-Vl/V2 monoclonal antibodies. However, both
monoclonal antibodies were able to bind the V1/V2 region in the absence of C4
suggesting that this region may affect the structure of the V1/V2 region
(McKeating et al., 1993). Wang et al., have shown that substitution of a valine
with an isoleucine at position 84 in CI can compensate for amino acid substitutions
in the V1/V2 regions which impair virus infectivity, demonstrating that the V1/V2
regions can functionally interact with CI also (Wang et al., 1996).
Compared with the extensive analysis of V3 genetic variability in vivo and
in vitro, there are few corresponding studies of the VI and V2 regions. Analysis of
the V1/V2 regions is more arduous since both these regions display extensive
length variation as a result of insertions, deletions and duplications. This extensive
length variation can occur within epidemiologically related groups and indeed
within infected individuals making alignment of sequences far more difficult. In
this study, I have used nucleotide sequencing and length polymorphism analysis
(LPA) to investigate correlations between variability of VI and V2 regions with
disease stage and tissue origin. Tissues from various lymphoid and non-lymphoid
organs were obtained at autopsy from a number of HIV-1 positive individuals.
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Phylogenetic analysis of VI and V2 hypervariable regions was carried out in order
to explore the in vivo distribution of the various lineages of HIV-1 present in each
tissue. I also investigated whether any specific sequence characteristics existed
which could differentiate between individuals at different stages of disease, or
between different infected tissues.
4.2 STATISTICAL ANALYSIS.
Sequence comparisons between viruses from three of the study subjects (P4,
5 and 6) were made in the VI and V2 hypervariable regions. The VI and V2
region amplified began at nucleotide 6539 of HXB2 and extended to position 6976.
The length of the VI and V2 regions used for sequence comparisons were 142 and
193 nucleotides respectively. Unrooted phylogenetic trees based upon uncorrected
pairwise distances between nucleotide sequences obtained from lymph node, lung
and brain samples from study subjects 4, 5 and 6 were constructed by a
combination of the MEGA package (Kumar et al., 1993) and the PHYLIP package,
using the programs SEQBOOT, NEIGHBOR and DRAWTREE (version 3.5;
Felsenstein, 1989). Statistical analysis was performed with the Mann-Whitney U




4.3.1 INTRA-SAMPLE VARIATION IN VI AND V2 HYPERVARLABLE
REGIONS.
I compared the 87 VI and V2 amino acid sequences from the three HIV
infected individuals who died in AIDS (Fig 15a-15c), and found a high degree of
variability in both of these regions, although it was less pronounced in the V2
region. Four cysteine residues defined a double loop structure in VI and V2
(Leonard et al., 1990) and were uniformly conserved in all sequences (residues 10,
15, 56 and 108). Considerable diversity was observed in the VI hypervariable
region both within and between individuals. The V2 hypervariable region, although
showing a great deal of interpatient variation, was less variable than the VI region
within individuals. Few identical amino acid sequences were isolated from the
same individual. For example, in p4 a total of 37 sequences (brain-12, lymph node-
10 and lung-15) were isolated and 25 of these sequences were distinct (brain-5/12,
lymph node-10/10 and lung-10/15). The majority of sequence variability was
located between residues 82 and 103. In the more conserved regions of the V2
hypervariable loop (residues 56 to 81 and 104 to 108) there appeared to be a bias
towards the conservation of charged amino acids. For example residues 65, 66, 67,
70, 71, 77 and 79 were all well conserved both between and within individuals.
However, the VI hypervariable region showed a number of substitutions of charged
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FIG 15A. Proviral VI and V2 domain amino acid sequences from p4. All
sequences are compared with HIVMN sequence for VI and V2. Symbols:
























































































































































































































































































































































































































































































































































































































































































































































FIG 15B. Proviral VI and V2 domain amino acid sequences from p5. All
sequences are compared with HIVMN sequence for VI and V2. Symbols:




































































































































































































































-AK--A. --A. --A. --WN--WN--WN--WN--WN--WN-















































































FIG 15C. Proviral VI and V2 domain amino acid sequences from p6. All
sequences are compared with HIVMN sequence for VI and V2. Symbols:
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amino acids. There were however three charged amino acid residues that were
well conserved in the VI region (residues 17, 52 and 54) which were located in
close proximity to the two cysteine residues.
Both hypervariable regions had several potential N-linked glycosylation
sites (N-X-S/T; N= asparagine, X= any amino acid except proline, S= serine, T=
threonine) which were well conserved throughout all the sequences analysed
(residues 14, 55, 59 and 109). These were located in close proximity to the
cysteine residues which define both loops and therefore may be involved in
maintaining the conformation of these two hypervariable regions. The VI
hypervariable region also contained a number of more variable N-linked
glycosylation sites brought about by amino acid substitutions and insertions.
Additional N-linked glycosylation sites were observed in some V2 sequences from
insertions in the more variable region (residues 82 to 103). In addition, the VI
region contained a number of serine/threonine rich insertions which may lead to the
addition of O-linked carbohydrates (see discussion).
4.3.2 VI AND V2 SEQUENCE VARIABILITY AND TISSUE TROPISM.
I compared the overall charge (Fig 16A-16F), length of variants (Fig 17A-
17F) and number of potential glycosylation sites (Fig 18A-18F) of VI and V2
sequences obtained from the three study subjects (see Appendix VI). For p4 and
p5, there was some evidence for differences in charge between variants from brain
compared with lymph node or lung (Fig 16A-16F). In p4 and p5, the calculated
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FIG 16. Comparison of overall charge of VI and V2 sequence variants from p4
(A, D), p5 (B, E) and p6 (C, F) in VI (A, B, C) and V2 (D, E, F) regions.
Significantly different distributions (p<0.05 using Mann-Whitney U test for non-
normally distributed data) indicated by horizontal bar. BR, brain; LG, lung; LN,
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FIG 17. Comparison of overall length of VI and V2 sequence variants from p4 (A,
D), p5 (B, E) and p6 (C, F) in VI (A, B, C) and V2 (D, E, F) regions.
Significantly different distributions (p<0.05 using Mann-Whitney U test for non-
normally distributed data) indicated by horizontal bar. BR, brain; LG, lung; LN,



















FIG 18. Comparison of the number of potential N-linked glycosylation sites in VI
and V2 sequence variants from p4 (A, D), p5 (B, E) and p6 (C, F) in VI (A, B, C)
and V2 (D, E, F) regions. Significantly different distributions (p<0.05 using Mann-
Whitney U test for non-normally distributed data) indicated by horizontal bar.BR,















overall charge of V2 of variants from the brain were significantly higher than
those from the lung (p=0.055 and 0.014). In contrast, the VI sequences from brain
of p4 showed a significantly lower charge compared to variants from lymph node
and lung (both /?=0.001). However, this difference was not found in the other two
study subjects.
No significant difference between the length of the VI and V2 regions with
tissue origin was observed for patient 4 and 6. However, in patient 5, a significant
difference between brain and lung variants was observed in both VI and V2
regions (p=0.006 and <0.001 respectively). Also, in the V2 region, lymph node
variants from patient 5 were significantly longer than those from brain tissue
(p=0.008; Fig 17A-17F).
The number of potential N-linked glycosylation sites were also compared in
both VI and V2 regions between tissues from each patient (Fig 18A-18F). In
patients 4 and 5 a significant difference in the number of glycosylation sites in
brain and lung tissues was apparent in both VI and V2 regions. In the VI region
from patient 4 brain variants were found to have significantly fewer glycosylation
sites when compared with lung variants (p=<0.001), while in the V2 region lung
variants were found to have significantly fewer glycosylation sites (p=0.03).
Similarly, in patient 5, brain variants in the VI and V2 regions were found to have
significantly fewer glycosylation sites than lung variants (p=0.017 and <0.001). In
only one patient was there a significant difference in the number of glycosylation
sites between brain and lymphoid variants. In the V2 region of patient 5 brain
variants were found to have significantly fewer glycosylation sites when compared
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with that of lymphoid tissues (p=0.001).
The significance of these differences is difficult to interpret as the
distribution of values compared were derived from populations that were in some
cases closely related genetically, therefore do not constitute independent
observations. However, from this analysis, there were no obvious features from the
primary sequences of VI or V2 that correlated with tissue origin.
In the absence of any reproducible specific amino acid sequence differences
between tissues, I calculated the overall degree of divergence between sequences
from each individual, and used these uncorrected pairwise distances to construct
unrooted neighbour-joining trees. The degree to which sequences group together in
the tree was proportional to their overall similarity, while bootstrap resampling
indicated the robustness of the observed groupings (Fig 19A-19C). Although there
were differences between tissues in the frequencies of certain amino acids at
particular sites, none were clearly associated with specific tissues. For example, in
patient 4 at position 24 of the VI domain, the majority of brain-derived sequences
(8 of 11) had an aspartic acid (D) at this position, while this amino acid was absent
in the majority of sequences obtained from lymph node (1 of 10) and lung (0 of
15). Similarly, at positions 65 and 83 of the V2 domain, the majority of brain-
derived sequences had an asparagine (N) and valine (V) at these positions
respectively. However, again these amino acids were absent in the majority of
sequences derived from lymph node (position 65: 0 of 10; position 83: 0 of 10)
and lung (position 65: 2 of 15; position 83: 7 of 15). In brain-derived sequences,
from patient 5, the majority had a lysine (K) at position 20 (7 of 11), glutamine
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FIG 19A. Neighbour-joining trees of sequences in VI and V2 domains from
patient 4. Symbols: Brain A; Lymph node □; Lung •. Bootstrap values indicate the
percentage of trees showing the observed phylogenetic groupings.
FIG 19B. Neighbour-joining trees of sequences in VI and V2 domains from
patient 5. Symbols: Brain ▲; Lymph node □; Lung •. Bootstrap values indicate the
percentage of trees showing the observed phylogenetic groupings.
FIG 19C. Neighbour-joining trees of sequences in VI and V2 domains from
patient 6. Symbols: Brain ▲; Lymph node □. Bootstrap values indicate the
percentage of trees showing the observed phylogenetic groupings.
(Q) at position 82 (10 of 11), glycine (G) at position 84 (9 of 11), arginine (R) at
position 102 (7 of 11) and asparagine (N) at position 107 (9 of 11). However, the
corresponding amino acids at these positions were absent in all of the lymph node-
derived sequences and present as minor populations in lung-derived sequences at
positions 20 (1 of 10), 82 (3 of 10) and 102 (1 of 10) only. In patient 6 there were
no discernable amino acids present in the majority of brain-derived sequences when
compared with those from lymph node tissue.
These differences were reflected in the phylogenetic trees constructed for
each patient. For example, sequences from brain of p4 were found in all four
lineages separated by high bootstrap values (Fig 19A), while, lineages a, b and d
also contained a number of sequences from lymph node and lung tissue. In the
other two study subjects a similar mixing of variants from lymphoid and non-
lymphoid tissue was observed. For example, in p5 five distinct lineages were
observed separated by high bootstrap values, three of which contained sequences
from lymph node and lung tissue (Fig 19B). Two lineages contained brain-derived
sequences only (lineages a and e), reflecting the differences observed in the amino
acid sequences (Fig 15A). In p6, each of the three lineages contained sequences
obtained from brain and lymph node tissue (Fig 19C).
4.3.3 ANALYSIS OF NUMBER OF V1/V2 LENGTH VARIANTS AND
DISEASE STATUS.
To investigate the accuracy of length polymorphism analysis (LPA) and its
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suitability for population analysis, I compared length profiles of VI and V2 with
the range of predicted lengths derived from individual sequences obtained from the
three study subjects (p4-p6). 1 yUg of DNA was amplified, using nested PCR, from
lymph node and brain tissue from each individual. This amplification was carried
out in triplicate to demonstrate that representative populations were compared (Fig
20A-20B). A good concordance was observed between the number and length of
variants obtained using LPA with the actual lengths of variants obtained from
sequencing (Table 9a-9b), although LPA also detected minor variants not
represented among the nucleotide sequences. From this initial investigation I found
no consistent differences between lymph node and brain tissue. For example, in p4
the same length variant was observed in both tissues in VI and V2. However, in
patients 5 and 6 a number of different length variants were observed in both
tissues.
Subsequently this technique was applied to examine the diversity and
overall length of VI and V2 variants infecting brain and lymphoid tissues of a
larger study group (see Appendix VII and VIII). This comprised samples from 8
pre-symptomatic and 34 symptomatic individuals at time of death. Length analysis
of variants from brain tissue was confined to patients with evidence of giant cell
encephalitis (GCE) since low levels or undetectable frequencies of proviral
sequences were observed in individuals without GCE (Bell et al., 1996; Donaldson
et al., 1994). The number and length of variants from non-lymphoid and lymphoid
tissue differed considerably between study subjects (Fig 21). I compared the
number of different length variants obtained from tissues from pre-symptomatic
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FIG 20A. LPA of HIV variants obtained from lymph node and brain tissue of p4,






















FIG 20B. LPA of HIV variants obtained from lymph node and brain tissue of p4,
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FIG 21. Plot of CD4 lymphocyte count -v- population diversity as determined by
LPA in VI (A) and V2 (B) regions; Symbols: "+" Brain from study subjects with
GCE; lymph node from study subjects with AIDS; "O": lymph node from pre-
symptomatic individuals at times of death. (C, D): Comparison of the distribution
of length variants observed in brain from study subjects with GCE (BR), lymph
nodes from study subjects with AIDS (LN) and from pre-symptomatic individuals
at time of death (P) for VI (C) and V2 (D). (see Appendix VII).
and symptomatic individuals with CD4 count and found no significant difference
between each group in either the VI or V2 region (Fig 21A-21B). Similarly there
was no correlation between the length of variants with disease status (Fig 21C-
21D). However, the V2 region was on average longer amongst variants from brain
compared to those from lymph node from symptomatic and pre-symptomatic study
subjects, although their ranges overlapped considerably (p=0.028 and 0.043
respectively). Furthermore, variants from brain showed a significantly lower
number of length variants (diversity) than those from lymph node of symptomatic
patients in the V2 region (mean number of length variants in brain: 1.3 and lymph
node: 2.5; p= 0.00), and pre-symptomatic patients in both VI and V2 (mean
number of length variants, VI: 4.1; V2: 3; /»=0.039 and 0.00 respectively; Fig 21A-
21B).
4.4 DISCUSSION.
4.4.1 LACK OF TISSUE SPECIFIC GROUPING BY SEQUENCE
VARIATIONS IN VI AND V2 HYPERVARIABLE DOMAINS.
This study was carried out to analyse tissue distribution and interpatient
variability of VI and V2 hypervariable domains of HIV-1. A number of VI and
V2 sequence variants from lymphoid and non-lymphoid tissues were analyzed from
three HIV infected individuals dying in AIDS. Examination of primary sequences
revealed no specific amino acid motifs in either the VI or V2 regions that
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correlated with tissue origin. A great deal of length diversity was observed within
the VI and V2 regions associated with either the addition or removal of potential
N-linked glycosylation sites.
The VI and V2 regions may be determinants of HIV-1 tropism and a
number of studies have suggested that these two regions may be involved in
determining the phenotype of the virus. However, there is little evidence to support
the antigenicity of the VI region. Van Tijn et al., (1989) reported the detection of
antibodies to a VI peptide, corresponding to residues 19 to 34 in our numbering
system, in 8 acutely infected individuals. From the three patients analysed here a
number of amino acid changes can be seen within this region, although the vast
majority of sequences contain 2 or 3 glycosylation sites which may effect envelope
conformation. Indeed, Gram et al., recently reported that the lack of an N-linked
glycosylation site in the VI loop rendered the mutant virus less sensitive to
neutralization by V3 monoclonal antibodies and soluble CD4, suggesting the degree
of glycosylation in the VI region may modulate the tertiary structure of gpl20
(Gram et al., 1994). Moore et al., have described a strong linear epitope, between
residues 40 and 51 in our numbering system, recognized by antibodies from the
serum of an infected lab worker (Moore et al., 1993a). However, this region is
highly variable in the three patients examined here and may therefore be highly
type specific.
A number of neutralization epitopes (linear, conformation dependent and
glycan dependent) have been identified in the V2 region (Jeang et al., 1993;
Sullivan et al., 1993; Fung et al., 1992; McKeating et al., 1993). Warrier et al.,
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described a novel glycan-dependent epitope in the V2 region encompassing
residues 60 to 67 in our numbering system (Warrier et al., 1994). Similarly,
McKeating et al., described a linear epitope within this region of V2 (residues 60
to 70 in our numbering system; McKeating et al., 1993). This region is relatively
well conserved within each of the patients described in this study. In patient 4,
however an asparagine (N) at position 65 is prominent in brain isolates (10 of 12)
but rare in lung (2 of 15) and absent in lymph node isolates (0 of 10). This amino
acid was reported to have functional relevance in the C108G epitope described by
Warrier et al, (Warrier et al., 1994), suggesting this region may be of importance
during infection. McKeating et al., have also described a number of conformational
epitopes located in the carboxy-terminal of the V2 loop (McKeating et al., 1993).
The carboxy-terminal from the 3 patients studied here show some degree of
variability, although there was a preponderance towards the presence of a charged
residue at position 87. Patients 4 and 6 contained an N-linked glycosylation site
within this region which is conserved throughout all the sequences in these two
patients. Similarly, patient 5 was highly glycosylated within this region (1 to 4
CHO sites). These features may therefore contribute to the maintenance of
antigenic epitopes. Indeed if these epitopes are well exposed on the virion surface,
as proposed, extensive glycosylation may help to mask these regions facilitating
escape from the immune response.
Carbohydrate residues have previously been implicated in the adhesion of
the gpl20 molecule to CD4 (Matthews et al., 1987). Using enzymatic
deglycosylation Bernstein et al. (Bernstein et al., 1994) found evidence for the
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modification of gpl20 by O-linked carbohydrates in addition to N-linked
carbohydrates. Unlike N-linked glycosylation there is no defined sequence for O-
linked glycosylation and the sites for carbohydrate addition were not
experimentally determined. However, studies of simian immunodeficiency virus
(SIV) have documented extended sequences, in the region homologous to VI in
gpl20 of HIV-1, rich in serine and threonine residues (TTTSTTT), that resemble
known O-linked glycosylation sites in other proteins (Jentoft, 1990; Overbaugh et
al., 1992). In this study serine/threonine rich insertions were observed in the VI
region which, although differing in sequence to those found in variants of SIV,
may lead to the addition of O-linked as well as N-linked carbohydrates. This may
be an important factor for the infectivity of HIV-1 as a number of diverse functions
have been attributed to carbohydrate post translational modifications including cell
recognition and cell adhesion (Paulson, 1989; Brandley et al., 1986), escape from
immunological constraints (Ezekowitz et al., 1989) and reduced ability to bind
antibody (Davis et al., 1990). Syncytium formation by HIV-1 has also been shown
to be blocked by antibodies to O-linked carbohydrate structures (Hansen et al.,
1991). Therefore, glycosylation of hypervariable regions may play an important
role in the infectivity and pathogenicity of HIV-1.
4.4.2 RELATIONSHIP BETWEEN VI AND V2 SEQUENCES AND TISSUE
DISTRIBUTION.
To examine the tissue distribution of these variants unrooted neighbour-
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joining trees were constructed. Numerous independent lineages were observed
containing sequences from non-lymphoid tissues such as brain and lung mixed with
those from lymphoid tissues. A number of these groupings were confirmed by
bootstrap resampling analysis (Fig 19A-19C). This lack of tissue specific groupings
of V1/V2 domains was consistent with a previous study of the evolutionary
analysis and tissue distribution of the pl7gag region and flanking regions of VI and
V2 from the same three individuals (Hughes et al., 1997). In this previous study I
found multiple evolutionary lineages in both of these regions of the HIV-1 genome.
Using the pl7gag region the time of diversification of in vivo variants from brain
tissue was estimated at 4.1 to 6.2 years, suggesting infection of brain tissue may
occur as an early event in disease preceding the onset of AIDS. The lack of organ
specific groupings contrasts with previous comparisons in the V3 region in both
my own and other investigations (Niedrig et al., 1994; Reddy et al., 1996; Ball et
al., 1994; Power et al., 1994; Epstein et al., 1991; Donaldson et al., 1994) and may
reflect different rates of sequence turnover in different tissues, combined with
different constraints on the sequence of V3 for infectivity in different cell types
(see chapter 3). This explanation would suggest that due to the lack of segregation
of VI and V2 sequences observed in this study, these two regions of the HIV-1
genome do not influence the tropism of HIV-1 to the same extent as V3 or do so
in such a way that is not apparent from comparisons of primary amino acid
sequences (see below).
Many phenotypic differences between isolates of HIV-1, such as syncytium
induction have been mapped to V3, where it has been shown that SI variants
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generally have a higher overall charge and a greater number of amino acid
differences from the consensus subtype B sequence (Millich et al., 1993).
However, there is currently a consensus view that V2 (and VI) sequences of NSI
and SI variants do not consistently differ from each other in overall charge, length
or number of potential glycosylation sites (Fouchier et al., 1995; Palmer et al,
1996; Wang et al., 1995; Cornelissen et al., 1995). In this study, a similar lack of
correlation was found between charge, length and number of potential glycosylation
sites amongst variants amplified from different tissues. There was no evidence for
any specific amino acid motif that correlated with tissue origin in either the VI or
V2 domains, nor a difference in length of V2 between pre-symptomatic and AIDS
study subjects, despite the greater frequency of isolation of SI variants from the
latter group.
These findings suggest that both VI and V2 may be irrelevant to tissue
tropism of HIV-1 or may contribute in a more subtle way undetectable by
examination of primary sequences. For example, several studies have shown that
VI and V2 domains may co-operate with other regions of the envelope protein in
determining cellular tropism of HIV-1 (McKeating et al., 1993; Sullivan et al.,
1993; Koito et al., 1995; Wyatt et al., 1995; Andeweg et al., 1993; Freed et al.,
1994; Koito et al., 1994; Carrillo et al., 1996; Groenink et al., 1993). It seems
unlikely that genomic regions which have been shown to influence viral infectivity
and post binding events should not somehow influence cytopathology and tissue
tropism. However, the evident degree of sequence flexibility tolerated by the virus
in these regions may obscure the residues that determine these properties.
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Comparison of the rates of synonymous and nonsynonymous substitutions
in the VI and V2 regions of env produced dN/ds ratios of 0.75, 0.73 and 0.97 for
p4, p5 and p6 respectively. Similar values for the VI and V2 regions were found
in a previous study examining the relationship of HIV-1 infection between maternal
and infant strains (Lamers et al., 1993). These ratios do not suggest strong positive
or negative selection for sequence change acting on this region overall, being
similar to previous estimates for the whole env gene (Wolfs et al., 1990; Li et al.,
1988). The ratios are higher than previous estimates of around 0.4 in these study
subjects (Hughes et al., 1997) and others (Gojobori et al., 1990b; Myers et al.,
1992b; Li et al., 1988b; Kasper et al., 1995b) for pl7gag, a region characterised by
a high frequency of silent substitutions and conservative amino acid replacements.
Ratios substantially greater than 1.0 imply positive selection, for example sequence
comparisons of the V3 region has produced ratios of 1.5 to 2.9 (Lukashov et al.,
1995; Simmonds et al., 1990). However, it is difficult to base conclusions for VI
and V2 on a single figure as the region probably contains a combination of
functionally critical amino acids (such as the cysteine residues), those where
variation is neutral in effect and those which may be subject to positive selection.
Immune recognition may play a major role in positive selection for
antigenic variants of HIV-1, not only for cytotoxic T cell recognition (Phillips et
al., 1991), but also from neutralising antibody recognising antigenic determinants
in gpl20. It has previously been suggested that the frequent insertions and deletions
within V4 and V5 and the variability in the position and number of glycosylation
sites may be mechanisms by which peptide epitopes are shielded from an evolving
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immune response (Simmonds et al., 1990b). This hypothesis appears even more
likely for VI and V2, given the existence of neutralising epitopes in this region
(Warrier et al., 1994; Ho et al., 1991; Yoshiyama et al., 1994; Moore et al., 1993;
Gorny et al., 1994; Sullivan et al., 1993; Fung et al., 1992; van Tijn et al., 1989).
4.4.3 DOES THE DIVERSITY OF VI AND V2 SEQUENCE VARIANTS
CORRELATE WITH DISEASE PROGRESSION?
A method to compare populations of HIV variants by high resolution gel
electrophoresis of DNA sequences amplified across the V4 and V5 hypervariable
regions has previously been described (Simmonds et al., 1990b). Length profiles
obtained in this way correlated well with the length obtained by sequencing of
single molecules isolated at limiting dilution. In the current study, I applied the
method of LPA to the VI and V2 domains on variants amplified from non-
lymphoid and lymphoid tissues from the three study subjects. Different length
variants amplified from single molecules were equally represented in the analysis
of length polymorphisms (Fig 20).
LPA provides only a partial description of the variability within a sample.
Whereas each length variant represent a different amino acid sequence, often quite
diverse sequences may have the same overall length, as was the case for p4 in V2
(Fig 21B). However, because such a large population can be amplified, less
frequent variants visible as minor bands on the gel were frequently detected using
LPA that were not detected by the amplification of single molecules, and in this
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respect the method therefore provides a more complete analysis of diversity than
sequencing based approaches (Table 9; Fig 20). Furthermore, LPA allows the rapid
comparison of a large number of samples, providing a method to investigate the
relationship between disease progression and tissue origin with population diversity
on a greater range of samples than previously attempted. Although specific amino
acid changes can not be detected by LPA, related techniques such as the
heteroduplex mobility assays (Delwart et al., 1993) that have been used to
investigate in vivo variability do not differentiate between the majority of
substitutions that are silent from those that change amino acid sequences.
Variability in these assays can therefore also not be precisely equated to changes
that influence virus phenotype.
Previous studies have observed an association between the isolation of SI
variants with an increased rate in disease progression (Tersmette et al., 1988;
Richman et al., 1994; Connor et al., 1994). However, to date, sequence
comparisons of variants in vivo have found little evidence for the existence of high
frequencies of variants with an predicted SI phenotype based upon sequence
comparisons in V3 (Lukashov et al., 1995; Wolinsky et al., 1996), including those
of the study subjects described here (Donaldson et al., 1994a). Wolinsky et al.,
found no specific amino acid motifs associated with the appearance of variants
with an SI phenotype in the V3 region from study subjects with evidence of both
rapid T cell loss and stable T cell counts (Wolinsky et al., 1996). Therefore,
although in vitro studies have suggested an increase in viral virulence may
predetermine the rate of disease progression there seems to be little in vivo
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evidence to corroborate this hypothesis.
The "antigenic diversity threshold" model was proposed to explain viral
diversity and disease progression (see introduction, section 1.5.3; Nowak et al.,
1991a). This theory predicts that during disease progression viral diversity is driven
by an active immune response, resulting in escape mutants. This generation of
antigenic diversity is thought to eventually overwhelm the immune system creating
an anomaly whereby the active host immune response is intrinsically involved in
its destruction. Wolinsky et al., have shown relatively homogenous populations to
be present, over a period of approximately three years, in individuals with rapidly
declining T cell counts (associated with rapid progression to disease) and
comparably higher diversity in patients with stable T cell counts and moderately
declining T cell counts (associated with a slower progression to disease; Wolinsky
et al., 1996). A number of other studies have corroborated this finding, showing a
decline in population diversity upon disease progression in regions of env that
include VI and V2 (McDonald et al., 1997; Lukashov et al., 1995; Delwart et al.,
1994; Ganeshan et al., 1997). In this study, however I have shown that VI and V2
viral variants were equally diverse in pre-symptomatic individuals and those dying
in AIDS. I was therefore unable to experimentally confirm the findings of these
previous studies for a decline in population diversity upon disease progression.
One of the difficulties of interpreting my own and published sequence
comparisons is distinguishing between actively replicating HIV populations and
those that may have infected cells latently or non-productively in the past.
Evidence for variable persistence of non-expressing, "older" populations of HIV
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have been obtained by comparisons of PBMC sequences in sequential samples
from acutely infected individuals (where persistence may be extremely long;
Simmonds et al., 1991), or by monitoring the appearance of resistant populations
following antiviral treatment (where one third of the PBMC populations remained
wild type 6 months after the onset of treatment; Wei et al., 1995). In these two
studies, rapid and complete replacement of populations was observed only in the
plasma virus population, which was generally less diverse than those in PBMCs for
this reason. A recent study by Wong et al., found evidence for extremely slow
turnover of variants infecting brain tissues from sequence comparisons of the pol
gene (see chapter 3: section 3.6.4; Wong et al., 1997). Thus, particularly for the
brain and other tissues where turnover of HIV populations may be slow, a clearer
indication of the relationship between diversity and disease progression may be
obtained by comparisons of the specifically transcriptionally active variants within
the populations.
In summary, this study has shown no correlating factors between VI and
V2 with either an increase or decrease in diversity from pre-symptomatic and
symptomatic individuals. No specific amino acid motifs were detected in either
region which correlated with viral phenotype and no distinction could be made,
from examining primary sequences, between variants found in different tissues.
Therefore, there were no parameters in VI or V2 that correlated with biological
properties of the virus. If, as previously proposed, these two regions act in concert
with other regions of gpl20 to influence biological properties of HIV-1, this
process remains undeterminable by analysis of their primary sequences.
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CHAPTER 5: GENERAL DISCUSSION.
215
Since AIDS was first recognized in the early 1980s, the natural history of
HIV-1 infection and clinical manifestations during progression of this disease have
been elucidated. It is now recognized that HIV-1 infection induces a chronic and
progressive disease process with a broad spectrum of clinical manifestations from
acute primary infection to AIDS where a number of life threatening opportunistic
infections and malignancies are observed. The course of disease is marked by
increasing levels of viral replication, emergence of more virulent strains in vitro in
approximately 50% of infected individuals, and progressive destruction of the
immune system, primarily due to the resulting dysfunction and depletion of CD4
cells upon HIV-1 infection. Clinical AIDS is recognized as a combination of
cytopathic infection, due to the direct action of HIV-1, and secondary or
opportunistic infections primarily due to the suppression of the immune system. In
the CNS, evidence of the cytopathic effect of HIV-1 occurs with increasing
frequency and severity as immune defences are depleted (AIDS dementia
complex/encephalitis), as do both minor (herpes zoster) and major (progressive
multifocal leukoencephalopathy, toxoplasmosis and tuberculosis) opportunistic
infections. This dichotomy of direct and indirect clinical manifestations is also
observed in other tissues such as the gastrointestinal system, liver and heart during
disease progression.
In order to investigate whether the spread of HIV-1 infection from
lymphoid to non-lymphoid tissues occurs prior to immunosuppression (as an early
event) or after an individual has progressed to full blown AIDS (a late event) I
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have analysed the nucleic acid sequences of the pl7gag region from a number of
lymphoid and non-lymphoid tissues obtained from individuals dying in AIDS. Also
in order to determine whether the VI or V2 hypervariable regions determine
infection of such tissues I have analysed both primary amino acid sequences and
nucleic acid sequences from tissue samples from the same patients. During disease
progression an increase in infected tissues and clinical manifestations is evident. To
investigate whether this is related to the degree of diversity of HIV-1 I have
analysed brain and lymph node tissue from a wide range of symptomatic and pre-
symptomatic patients.
Phylogenetic analysis of the pl7gag region revealed polyphyletic lineages of
lymphoid and non-lymphoid tissues with obvious mixing between all tissues
examined in three of the four patients analysed (p4, 5 and 6). The observation of
polyphyletic lineages in brain provides no evidence for a specifically neurotropic
variant of HIV, adapted for infection of brain tissue, where the expectation would
be for variants recovered from brain to be monophyletic.
One of the surprising findings in the course of this study was the high
diversity of the viral population in the brain. Mean synonymous pairwise distances
were calculated using the pl7gag region to estimate the average time of divergence
of variants within each tissue. The average time of divergence between sequences
from brain from patient 4, 5 and 6 (4.1 to 6.5 years) was found to be significantly
higher than that estimated for lymphoid variants (2.65 to 6.5 years) suggesting
infection of brain occurred relatively early in infection.
The restricted diversity observed in lymphoid tissue suggests that complete
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population replacements may have occurred due to a more rapidly diverging
population. This hypothesis is compatible with recent findings which have shown a
rapid turnover of virus and CD4 lymphocytes in the peripheral circulation
throughout infection (Ho et al., 1995; Wei et al., 1995). However, diversification
of variants within brain tissue may be facilitated by the lack of cellular mobility,
while the absence of positive selective pressure for change may continue to restrict
sequence variability (see section 3.6.1).
Within the VI and V2 regions the lack of tissue specific sequences was
reflected in the phylogenetic analysis which revealed a number of mixed lineages
containing variants from both lymphoid and non-lymphoid tissues. Further analysis
revealed no association between charge, length or number of glycosylation sites
with tissue origin, consistent with the findings of Wang et al., (Wang et al., 1995).
Therefore, there would appear to very little direct evidence from examination of
primary sequences alone to substantiate that the V1/V2 regions influence viral
tropism. Similarly, the claims that infection of brain tissue may require specific
neurotropic variants would appear to be unfounded from examination of these
regions. Amino acid differences in VI and V2 between brain and lymphoid tissues
noted in two of the three patients (p4 and 5) may be due to a lack of divergence as
a result of the absence of selective pressure from the immune system or may
simply reflect a requirement for infection of macrophage-like cells. In vitro studies
have shown that these two regions may influence infection of macrophages to some
extent (see section 4.1). However, this property may be influenced by interactions
with other regions of gpl20, and hence may be invisible from the examination of
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primary sequences.
Analysis of the V3 region has suggested that this region may also be an
important determinant of HIV-1 tropism (see section 1.4.3). Takeuchi et al.,
reported the isolation of an HIV-1 variant that infected CD4+ brain cells (HIVGUN),
and showed that a single point mutation of the highly conserved proline at the tip
of the V3 loop (GPGR) conferred an ability on this isolate to replicate in fibroblast
like cells derived from human brain (BT cells; Takeuchi et al., 1991). A
subsequent study by the same research group isolated several new variants able to
infect brain derived cells with a mutation from proline to serine, threonine or
alanine in the conserved GPGR sequence at the tip of the V3 loop, suggesting
amino acid sequences in this region may be important for infection of brain
(Shimizu et al., 1994). However, in an analysis of in vivo V3 sequences isolated
from lymphoid and non-lymphoid tissues a proline residue was observed in the tip
of the V3 loop, which was conserved in all sequences, although in three of the
patients (one asymptomatic and two symptomatic) GPGS was detected in a number
of sequences (Donaldson et al., 1994a). In the same study the major variants found
in brain tissue were also detected as minor variants in other tissues with relatively
trivial differences detected between variants from different tissues, consisting of
only one or two amino acids. Therefore, similar to my findings from analysis of
the VI and V2 sequences, there appears to be no signature sequence in the V3
region to indicate the existence of a specific neurotropic variant.
Analysis of primary sequences is a useful tool when constructing
evolutionary relationships and provides important information regarding the
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divergence of viral variants enabling us to discern when various tissues became
infected during disease progression. However, analysis of primary sequences
provides little information about the biological properties of a virus as these
sequences are treated as distinct variables and cannot be analysed with respect to
their secondary and tertiary interactions with other regions of the viral genome.
Although such interactions may be speculated upon, no definite conclusions can be
made from the examination of primary sequences alone. In the future, it is likely
that more substantial evidence will require the functional characterization of HIV
variants cloned directly from different tissues (see below).
The finding of high diversity within brain is in accordance with previous
studies that suggest HIV can be detected in the brain at all stages of disease and in
individuals without GCE (Davis et al., 1992). In contrast, a number of other
investigations have suggested a lack of productive infection of non-lymphoid
tissues prior to immunosuppression where significant levels of provirus in non-
lymphoid tissues from asymptomatic patients were not detected (Donaldson et al.,
1994b; Bell et al., 1993). In a number of patients low levels of provirus were
detected, although these levels were consistent with that expected from
contamination by residual infected blood within tissues. This contrasts the detection
of substantial levels of provirus in tissues from patients with AIDS, which were
several orders of magnitude greater than that detected in asymptomatic patients.
Furthermore, pathological examination of brain from asymptomatic patients failed
to reveal any evidence for HIV encephalitis and p24 antigen was not detected by
immunocytochemistry (Bell et al., 1993). In a subsequent larger study, a clear
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relationship between HIV encephalitis, detection of p24 antigen by
immunocytochemistry and proviral load in brain from AIDS patients was detected
(Bell et al., 1996). More recently in situ PCR has been developed for detection of
proviral sequences in tissue, and the results confirm previous findings of an
absence of detectable infected cells in asymptomatic patients, with frequent
detection of infected cells in AIDS patients with GCE (Bell et al., 1996).
Therefore, infection of brain tissue may not be productive during the asymptomatic
stage of infection, it may be present at low levels undetectable by present
techniques or be so dispersed in the brain that infection is not apparent from the
single samples normally used for PCR, or histological examination.
The mode of entry of HIV-1 into brain is not well understood. It has been
postulated that HIV-1 infected macrophages from the peripheral blood may be able
to cross the blood-brain barrier bringing with them the virus ("Trojan horse"
mechanism). This hypothesis is supported by the common origin and phenotype of
macrophages and microglia. The restricted sequence diversity in V3 suggests that
infection of brain simply may be a consequence of a requirement for macrophage-
tropism and does not represent a specifically adapted neurotropic variant. Indeed,
the existence of specific neurotropic variants would suggest that sequences of HIV
from the brain should be monophyletic, whereas this was clearly not the case in
most of the study subjects described here. Early seeding of brain (and other non-
lymphoid tissues) may occur as the result of an inadequate immune response
during primary infection with HIV-1. However, as an efficient immune response is
mounted, viral replication within tissues may be contained at a very low level
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during the asymptomatic stage. Subsequently, as disease progresses viral replication
within tissues may no longer be limited and result in the pathological and clinical
manifestations recognized in AIDS patients. In this respect, HIV-1 may be similar
to the ubiquitous JC virus which causes a subacute demyelinating disease,
progressive multifocal leukoencephalopathy (PML), infecting primarily
oligodendrocytes and astrocytes. Seroepidemiological studies have shown
approximately 70% of the population possess antibodies to JC virus (Padgett et al.,
1973), although infection remains undetectable in normal brain by modern
techniques. PML occurs almost exclusively in immunosuppressed individuals, most
often associated with lymphoproliferative disorders such as leukaemias and
lymphomas, although in recent years PML has become increasingly common
amongst AIDS patients, with the estimated incidence to be in the order of 3.8%
(Berger et al., 1987). As clinical manifestations of JC virus infection occur only in
the absence of an effective host immune response, as appears to be the case for
infection with HIV, reactivation of the latent virus may be the cause.
In order to understand the biological properties of a virus, functional studies
must be carried out to examine these properties in as close to the natural state as
possible. These generally involve in vitro culture of the virus in lymphocytes
followed by characterization of the variants present. However, this technique can
be misleading. It has been established for some time that culturing of HIV-1 selects
for the outgrowth of more virulent variants in vitro which leads to the
misrepresentation of viral populations. Also, during culturing of variants from
tissues such as brain, bowel and lung there is a high probability of contamination
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from residual lymphocytes which may be preferentially isolated upon co-culture
with PBMCs, particularly if there were marked differences in tropism in tissue
adapted variants. Even amongst variants present in PBMCs, there is evidence for
strong selection for SI variants within the first week of in vitro culture even where
the majority of the PBMC population has a predicted NSI macrophage tropic
phenotype (P. Strappe, personal communication). In this study, all of the SI
variants replicated in MT-2 cells and in each case the variants selected for had a
higher charge (+5) than PBMC populations (+3).
We have recently attempted to address the problem of in vitro selection
through a collaboration with Matthias Dittmar and colleagues (Dittmar et al.,
1997), in which variants of HIV infecting different tissues were cloned and
expressed without prior in vitro culture. Long range PCR was used to construct a
full-length provirus sequence from a primary isolate of p4 (one of the study
subjects in this thesis) obtained three months before death, into which amplified
env sequences from lymphoid and non-lymphoid tissues from the same study
subject were inserted. The resultant recombinant viruses were characterized for
biological properties such as tropism, cytopathology and co-receptor usage. This
method eliminates in vitro selection of unrepresentative populations, since these
replication competent viruses have been constructed from genomic DNA amplified
directly from tissue samples. Remarkably, initial biological characterization of the
expressed viruses from brain, lung and lymph node revealed that irrespective of
tissue origin, they could only productively infect peripheral blood mononuclear T
cells (Dittmar et al., 1997). In contrast, recombinant viruses comprising the p4
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background sequence with inserted env sequences from HIVgun and HIVSF162
(macrophage tropic variants) were able to infect primary macrophages, ruling out
the possibility that macrophage tropism was determined by parts of the genome of
this clone outwith the env gene.
Furthermore, infection of PBMC with these recombinant viruses showed
similar replication kinetics regardless of tissue origin. These findings now cast a
shadow of doubt on the hypothesis that the only requirement for infection of brain
is the ability to infect macrophages, and it is possible that there may be other
factors which can influence viral tropism for tissues of non-lymphoid origin such
as brain and lung. Although microglia are considered to be macrophage derived, a
recent in vitro study has suggested that certain isolates may replicate preferentially
in microglia (Strizki et al., 1996). Extensive passaging of such an isolate revealed
amino acid changes in the V3 loop shown to be associated with isolates from
patients with HIV dementia.
Matthias Dittmar and colleagues are currently examining the possibility that
co-receptor usage may influence infection of tissues such as brain. They intend to
analyse the chemokine receptor usage of variants from different tissues, such as
brain and lymph node, for entry into different cell types. In order to do this a
number of proviruses, generated by long range PCR, from brain and lymph node
tissue obtained from the same patient will be directly cloned and used to infect
various different in vitro cell systems such as primary macrophages, primary
dendritic cells and CD4+ lymphocytes.
In the future, functional and genetic characterization studies may provide
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more insight with regard to the disease manifestations associated with HIV
infection. Understanding the pathogenesis of HIV infection will involve the
reconciliation of both clinical and pathological observations with virological
studies. Infection of non-lymphoid tissues, such as the brain, may be a consequence
of alterations in the character of the virus (tropism), discussed above, or a result of
the ensuing immunosuppression characteristic of HIV infection. The fact that
pathological abnormalities in non-lymphoid tissues, such as HIV encephalitis occur
in the setting of immunosuppression and more active viral replication suggests that
a decline in host defences against HIV may be an important factor in allowing
infection of non-lymphoid tissues. Therefore, there is strong evidence to suggest
that the host response may be instrumental in the containment of viral spread
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Appendix I: Specified secondary infectious diseases listed in the CDC
surveillance definition for AIDS (CDC., 1986).
This group includes patients with symptomatic or invasive disease due to
one of twelve specified secondary infections listed below.





. Candidiasis (oesophageal, bronchial or pulmonary)
. Cryptococcosis
. Histoplasmosis
. Mycobacterial infection (Mycobacterium avium)
. Chronis mucocutaneous
. Disseminated herpes simplex virus infection
. Progressive multifocal leukoencephalopathy
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Appendix II: Other specified secondary infectious diseases (CDC.,
1986).
This group includes patients with one of six other specified secondary infectious
diseases listed below.
. Oral hairy leukoplakia
. Multidermatomal herpes zoster
. Recurrent salmonella bactaeremia
. Nocardiosis
. Tuberculosis
. Oral candidiasis (thrush)
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Appendix III: Secondary cancers (CDC., 1986).
This group includes patients with one or more of the specified cancers listed
below.
. Karposi's sarcoma
. non Hodgkin's lymphoma
. Primary lymphoma of the brain
. Cervical cancer
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Appendix IV: Nucleotide sequences obtained for p79.
P79BR-3A GGG AGC TAG AAC GAT TCG CAG TTA ACC CTG GCC TAT
TAG AAA CAT CAG AAG GCT GTA GAC AAA TAT TGG AAC AGC TAC
AAC CAT CCC TTC AGA CAG GAT CAA AAG AAC TTA GAT CAT TAT
ATA ATG CAA TAG CAA CTC TCT ATT GTG TGC ATC AAA GGA TAG
ATG TAA AAG ACA CCC AGG AAG CTT TAG AGA AGA TAA AGG AAG
AGC AAA ACA AAA ACC AGG AAA AAG CAC AGC AAG CAC AGC AAG
CAG CAG CTG GCA CAG GAA ACA GCA GTC AGG CCA GCC AAA ATT
ACC CTA TAG TGC AAA ACA TCC AGG ??? ??? ??? ??? ??? ???
??? ??? ??? ??? ??? ??? ??? ??? ???
P79BR-5A GGG AGC TAG AAC GAT TCG CAG TTA ACC CTG GCC TAT
TAG AAA CAT CAG AAG GCT GTA GAC AAA TAT TGG AAC AGC TAC
AAC CAT CCC TTC AGA CAG GAT CAG AAG AAC TTA GAT CAT TAT
ATA ATG CAG TAG CAA CTC TCT ATT GTG TGC ATC AAA GGA TAG
ATG TAA AAG ACA CCC AGG AAG CTT TAG AGA AGA TAA AGG AAG
AGC AAA ACA AAA ATC AGG AAA AAG CAC AGC AAG CAC AGC AAG
CAG CAG CTG GCA CAG GAA ACA GCA GTC AGG CCA GCC AAA ATT
ACC CTA TAG TGC AAA ACA TCC A?? ??? ??? ??? ??? ??? ???
??? ??? ??? ??? ??? ??? ??? ??? ???
P79BR-7A GGG AGC TAG AAC GAT TCG CAG TTA ACC CTG GCC TAT
TAG AGA CAT CAG AAG GCT GTA GAC AAA TAT TGG AAC AGC TAC
AAC CAT CCC TTC AGA CAG GAT CAA AAG AAC TTA GAT CAT TAT
ATA ATG CAG TAG CAA CTC TCT ATT GTG TGC ATC AAA GGA TAG
ATG TAA AAG ACA CCC AGG AAG CTT TAG AGA AGA TAA AGG AAG
AGC AAA ACA AAA ATC AGG AAA AAG CAC AGC AAG CAC AGC AAG
CAG CAG CTG GCA CAG GAA ACA GCA GTC AGG CCA GCC AAA ATT
ACC CTA TAG TGC AAA ACA TCC A?? ??? ??? ??? ??? ??? ???
??? ??? ??? ??? ??? ??? ??? ??? ???
P79BR-8A GGG AGC TAG AAC GAT TCG CAG TTA ACC CTG GCC TAT
TAG AAA CAT CAG AAG GCT GTA GAC AAA TAT TGG AAC AGC TAC
AAC CAT CCC TTC AGA CAG GAT CAA AAG AAC TTA GAT CAT TAT
ATA ATG CAG TAG CAA CTC TCT ATT GTG TGC ATC AAA GGA TAG
ATG TAA AAG ACA CCC AGG AAG CTT TAG AGA AGA TAA AGG AAG
AGC AAA ACA AAA ACC AGG AAA AAG CAC AGC AAG CAC AGC AAG
CAG CAG CTG GCA CAG GAA ACA GCA GTC AGG CCA GCC AAA ATT
ACC CTA TAG TGC AAA ACA TCC AG? ??? ??? ??? ??? ??? ???
??? ??? ??? ??? ??? ??? ??? ??? ???
P79BR-9A GGG AGC TAG AAC GAT TCG CAG TTA ACC CTG GCC TAT
TAG AAA CAT CAG AAG GCT GTA GAC AAA TAT TGG AAC AGC TAC
AAC CAT CCC TTC AGA CAG GAT CAG AAG AAC TTA GAT CAT TAT
ATA ATG CAG TAG CAA CTC TCT ATT GTG TGC ATC AAA GGA TAG
ATG TAA AAG ACA CCC AGG AAG CTT TAG AGA AGA TAA AGG AAG
AGC AAA ACA AAA ATC AGA AAA AAG CAC AGC AAG CAC AGC AAG
CAG CAG CTG GCA CAG GAA ACA GCA GTC AGG CCA GCC AAA ATT
ACC CTA TAG TGC AAA ACA TCC AG? ??? ??? ??? ??? ??? ???
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999 999 999 999 999 999 999 999 999
• •• ••• ••• ••• ••• ••• ••• •••
P79BR-10A GGG AGC TAG AAC GAT TCG CAG TTA ACC CTG GCC TAT
TAG AAA CAT CAG AAG GCT GTA GAC AAA TAT TGG AAC AGC TAC
AAC CAT CCC TTC AGA CAG GAT CAG AAG AAC TTA GAT CAT TAT
ATA ATG CAG TAG CAA CTC TCT ATT GTG TGC ATC AAA GGA TAG
ATG TAA AAG ACA CCC AGG AAG CTT TAG AGA AGA TAA AGG AAG
AGC AAA ACA AAA ATC AGG AAA AAG CAC AGC AAG CAC AGC AAG
CAG CAG CTG GCA CAG GAA ACA GCA GTC AGG CCA GCC AAA ATT
ACC CTA TAG TGC AAA ACA TCC AG? ??? ??? ??? ??? ??? ???
??? ??? ??? ??? ??? ??? ??? ??? ???
P79BR-12A GGG AGC TAG AAC GAT TCG CAG TTA ACC CTG GCC TAT
TAG AAA CAT CAG AAG GCT GTA GAC AAA TAT TGG AAC AGC TAC
AAC CAT CCC TTC AGA CAG GAT CAG AAG AAC TTA GAT CAT TAT
ATA ATG CAG TAG CAA CTC TCT ATT GTG TGC ATC AAA GGA TAG
ATG TAA AAG ACA CCC AGG AAG CTT TAG AGA AGA TAA AGG AAG
AGC AAA ACA AAA ATC AGG AAA AAG CAC AGC AAG CAC AGC AAG
CAG CAG CTG GCA CAG GAA ACA GCA GTC AGG CCA GCC AAA ATT
ACC CTA TAG TGC AAA ACA TCC AGG GGC AAA TGG ??? ??? ???
??? ??? ??? ??? ??? ??? ??? ??? ???
P79BR-13A GGG AGC TAG AAC GAT TCG CAG TTA ACC CTG GCC TAT
TAG AAA CAT CAG AAG GCT GTA GAC AAA TAT TGG AAC AGC TAC
AAC CAT CCC TTC AGA CAG GAT CAG AAG AAC TTA GAT CAT TAT
ATA ATG CAG TAG CAA CTC TCT ATT GTG TGC ATC AAA GGA TAG
ATG TAA AAG ACA CCC AGG AAG CTT TAG AGA AGA TAA AGG AAG
AGC AAA ACA AAA ATC AGG AAA AAG CAC AGC AAG CAC AGC AAG
CAG CAG CTG GCA CAG GAA ACA GCA GTC AGG CCA GCC AAA ATT
ACC CTA TAG TGC AAA ACA TCC AGG GGC AAA TGG TAC ATC AGG
CC? ??? ??? ??? ??? ??? ??? ??? ???
P79BR-15A GGG AGC TAG AGC GAT TCG CAG TTA ACC CTG GCC TAT
TAG AAA CAT CAG AAG GCT GTA GAC AAA TAT TGG AAC AGC TAC
AAC CAT CCC TTC AGA CAG GAT CAG AAG AAC TTA GAT CAT TAT
ATA ATG CAG TAG CAA CTC TCT ATT GTG TGC ATC AAA GGA TAG
ATG TAA AAG ACA CCC AGG AAG CTT TAG AGA AGA TAA AGG AAG
AGC AAA ACA AAA ATC AGG AAA AAG CAC AGC AAG CAC AGC AAG
CAG CAG CTG GCA CAG GAA ACA GCA GTC AGG CCA GCC AAA ATT
ACC CTA TAG TGC AAA ACA TCC AGG GGC AAA TGG TAC ATC AGG
CCA TA? ??? ??? ??? ??? ??? ??? ???
P79BR-25A GGG AGC TAG AAC GAT TCG CAG TTA ACC CTG GCC TAT
TAG AAA CAT CAG AAG GCT GTA GAC AAA TAT TGG AAC AGC TAC
AAC CAT CCC TTC AGA CAG GAT CAG AAG AAC TTA GAT CAT TAT
ATA ATG CAG TAG CAA CTC TCT ATT GTG TGC ATC AAA GGA TAG
ATG TAA AAG ACA CCC AGG AAG CTT TAG AGA AGA TAA AGG AAG
AGC AAA ACA AAA ATC AGG AAA AAG CAC AGC AAG CAC AGC AAG
CAG CAG CTG GCA CAG GAA ACA GCA GTC AGG CCA GCC AAA ATT
ACC CTA TAG TGC AAA ACA TCC AGG GGC AAA TGG AGC ATC AGG
CCA TA? ??? ??? ??? ??? ??? ??? ???
P79BR-29A GGG AGC TAG AAC GAT TCG CAG TTA ACC CTG GCC TAT
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TAG AGA CAT CAG AAG GCT GTA GAC AAA TAT TGG AAC AGC TAC
AAC CAT CCC TTC AGA CAG GAT CAG AAG AAC TTA GAT CAT TAT
TTA ATA CAG TAG CAA CCC TCT ATT GTG TGC ATC AAA AGA TAG
ATG TAA AAG ACA CCA ATG AAG CTT TAG AGA AGA TAA AGG AAG
AGC AAA ACA AAA ATC AGG AAA AAG CAC AGC AAG CAC AGC AAG
CAG CAG CTG GCA CAG GAA ACA GCA GTC AGG CCA GCC AAA ATT
ACC CTA TAG TGC AAA ACA TCC AGG GGC AAA ??? ??? ??? ???
??? ??? ??? ??? ??? ??? ??? ??? ???
P79BR-53A GGG AGC TAG AAC GAT TCG CAG TTA ACC CTG GCC TAT
TAG AAA CAT CAG AAG GCT GTA GAC AAA TAT TGG AAC AGC TAC
AAC CAT CCC TTC AGA CAG GAT CAG AAG AAC TTA GAT CAT TAT
ATA ATG CAG TAG CAA CTC TCT ATT GTG TGC ATC AAA GGA TAG
ATG TAA AAG ACA CCC AGG AAG CTT TAG AGA AGA TAA AGG AAG
AGC AAA ACA AAA ATC AGG AAA AAG CAC AGC AAG CAC AGC AAG
CAG CAG CTG GCA CAG GAA ACA GCA GTC AGG CCA GCC AAA ATT
ACC CTA TAG TGC AAA ACA TCC AGG GGC AAA TGG TAC ATC AGG
CCA TA? ??? ??? ??? ??? ??? ??? ???
P79BR-54A GGG AGC TAG AAC GAT TCG CAG TTA ACC CTG GCC TAT
TAG AAA CAT CAG AAG GCT GTA GAC AAA TAT TGG AAC AGC TAC
AAC CAT CCC TTC AGA CAG GAT CAG AAG AAC TTA GAT CAT TAT
ATA ATG CAG TAG CAA CTC TCT ATT GTG TGC ATC AAA GGA TAG
ATG TAA AAG ACA CCC AGG AAG CTT TAG AGA AGA TAA AGG AAG
AGC AAA ACA AAA ATC AGG AAA AAG CAC AGC AAG CAC AGC AAG
CAG CAG CTG GCA CAG GAA ACA GCA GTC AGG CCA GCC AAA ATT
ACC CTA TAG TGC AAA ACA TCC AGG GGC AAA TGG TAC ATC AGG
CCA TA"?v—* w* A • ••• ••• ••• ••• ••• ••• •••
P79BR-60A GGG AGC TAG AAC GAT TTG CAG TTA ACC CTG GCC TAT
TAG AAA CAT CAG AAG GCT GTA GAC AAA TAT TGG AAC AGC TAC
AAC CAT CCC TTC AGA CAG GAT CAA AAG AAC TTA GAT CAT TAT
ATA ATG CAG TAG CAA CTC TCT ATT GTG TGC ATC AAA GGA TAG
ATG TAA AAG ACA CCA AGG AAG CTT TAG AGA AGA TAA AGG AAG
AGC AAA ACA AAA ATC AGG AAA AAG CAC AGC AAG CAC AGC AAG
CAG CAG CTG GCA CAG GAA ACA GCA GTC AGG CCA GCC AAA ATT
ACC CTA TAG TGC AAA ACA TCC AGG GGC AAA TGG TAC ATC AGG
CC? ??? ??? ??? ??? ??? ??? ??? ???
P79LN-4B GGG AAC TAG AAC GAT TCG CAG TCA ACC CTG GCC TAT
TAG AAA CAT CAG AAG GCT GTA GAC AAA TAC TGG AAC AGC TAC
AAC CAT CCC TTC AGA CAG GAT CAG AAG AAC TTA GAT CAT TAT
ATA ATA CAG TAG CAA CCC TCT TTT GTG TGC ATC AAA GGA TAG
ATG TAA AAG ACA CCC AGG AAG CTT TAG AGA AGA TAA AGG AAG
AGC AAG ACA AAA GTA AGA AAA AAG CAC AGC AAG CAC AGC AAG
CAG CAG CTG GCA CAG GAA ACA GCA GTC AGG CCA GCC AAA ATT
ACC CTA TAG TGC AGA ACA TTC AGG GGC AAA TGG TAC ATC AGG
CAA TAT AAA CCT A?? ??? ??? ??? ???
P79LN-8B ??? ??? ??? ??? ??T TCG CAG TTA ACC CTG GCC TAT
TAG AAA CAT CAG AAG GCT ATA GAC AAA TAC TGG AAC AGC TAC
GGC CAT CCC TTC AGA CAG GAT CAG AAG AAC TTA GAT CAT TAT
ATA ATG CAG TAG CAA CTC TCT ATT GTG TGC ATC AAA GGA TAG
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ATG TAA AAG ACA CCC AGG AAG CTT TAG AGA AGA TAA AGG AAG
AGC AAA GCA AAA GTC AGA AAA AAG CAC AGC AAG CAC AGC TAG
TAG CAG CTA GCA CAG GAA ACA GCG GTC AGG CCA GCC AAA ATT
ACC CTA TAG TGC AAA ACA TCC AG? ??? ??? ??? ??? ??? ???
??? ??? ??? ??? ??? ??? ??? ??? ???
P79LN-13B GGG AGC TAG AAC GAT TCG CAG TTA ACC CTG GCC TAT
TAG AAA CAT CAG AAG GCT GTA GAC AAA TAT TGG AAC AGC TAC
AAC CAT CCC TTC AGA CAG GAT CAG AAG AAC TTA GAT CAT TAT
ATA ATG CAT TAG CAA CTC TCT ATT GTG TGC ATC AAA GGA TAG
ATG TAA AAG ACA CCC AGG AAG CTT TAG AGA AGA TAA AGG AAG
AGC AAA ACA AAA ATC AGA AAA AAG CAC AGC AAG CAC AGC AAG
CAG CAG CTG GCA CAG GAA ACA GCG GTC AGG CCA GCC AAA ATT
ACC CTA TAG TGC AAA ACA TCC AGG GGC AAA TGG TAC ATC AGG
CCA TAT AAA CCT A?? ??? ??? ??? ???
P79LN-15B GGG AGC TAG AAC GAT TTG CAG TTA ACC CTG GCC TCT
TAG AAA CAT TAG AAG GCT GTA GAC AAA TAT TGG AAC AGC TAC
AGC CAT CCC TTC AGA CAG GAT CAG AAG AAC TTA GAT CAT TAT
ATA ATG CAG TAG CAA CTC TCT ATT GTG TGC ATC AAA GGA TAG
ATG TAA AAG ACA CCC AGG AAG CTT TAG AGA AGA TAA AGG AAG
AGC AAA GCA AAA GTC AGA AAA AAG CAC AAC AAG CAC AGC AAG
CAG CAG CTG GCA CAG GAA ACA GCG GTC AGG CCA GCC AAA ATT
ACC CTA TAG TGC AGA ACA TTC AGG GGC AAA TGG TAC ATC AGG
CCA TAT A?? ??? ??? ??? ??? ??? ???
P79LN-20B GGG AGC TAG AAC GAT TCG CAG TCA ACC CTG GCC TAT
TAG AGA CAT CAG AAG GCT GTA GAC AAA TAT TGG AAC AGC TAC
AAC CAT CCC TTC AGA CAG GAT CAG AAG AAC TTA GAT CAT TAT
ATA ATG CAG TAG CAA CTC TCT ATT GTG TGC ATC AAA GGA TAG
ATG TAA AAG ACA CCC AGG AAG CTT TAG AGA AGA TAA AGG AAG
AGC AAA GCA AAA GTC AGA AAA AAG CAC AGC AAG CAC AGC TAG
TAG CAG CTG ACA CAG GAA ACA GCG GTC AGG CCA GCC AAA ATT
ACC CTA TAG TGC AAA ACA TCC AGG GGC AAA TGG TAC ATC AGG
CCA TAT A" ???>— \-X X JL 1 X X X 1 • • ••• ••• ••• ••• •••
P79LN-50B GGG AGT TAG AAC GAT TCG CAG TTA ACC CTA GCC TAT
TAG AAA CAT CAG AAG GCT GTA GAC AAA TAT TGG AAC AGC TAC
AAC CAT CCC TTC AGA CAG GAT CAG AAG AAC TTA GAT CAT TAT
ATA ATG CAG TAG CAA CTC TCT ATT GTG TGC ATC AAA GGA TAG
AGG TAA AAG ACA CCC AGG AAG CTT TAG AGA AGA TAA AGG AAG
AGC AAA GCA AAA GTC AGA AAA AAG CAC AGC AAA CAC AGC AAG
CAG CAG CTG ACA CAG GAA ACA GCG GTC AAG CCA GCC AAA ATT
ACC CTA TAG TGC AAA ACA TCC AGG ??? ??? ??? ??? ??? ???
??? ??? ??? ??? ??? ??? ??? ??? ???
P79LN-56B GGG AGT TAG AAC GAT TCG CAG TTA ACC CTG GCC TAT
TAG AAA CAT CAG AAG GCT GTA GAC AAA TAT TGG AAC AGC TAC
AAC CAT CCC TTC AGA CAG GAT CAG AAG AAC TTA GAT CAT TAT
ATA ATG CAG TAG CAA CTC TCT ATT GTG TGC ATC AAA GGA TAG
AGG TAA AAG ACA CCC AGG AAG CTT TAG AGA AGA TAA AGG AAG
AGC AAA GCA AAA GTC AGC AAA AAG CAC AGC AAG CAC AGC AAG
CAG CAG CTG GCA CAG GAA ACA GCG GTC AGG CCA GCC AAA ATT
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ACC CTA TAG TGC AAA ACA TCC AGG ??? ??? ??? ??? ??? ???
Ill 111 111 111 111 111 111 111 111
P79LN-62B GGG AGC TAG AAC GAT TCG CAG TTA ACC CTG GCC TAT
TAG AAA CAT CAG AAG GCT GTA GAC AAA TAT TGG AAC AGC TAC
AAC CAT CCC TTC AGA CAG GAT CAG AAG AAC TTA GAT CAT TAT
ATA ATG CAG TAG CAA CTC TCT ATT GTG TGC ATC AAA GGA TAG
ATG TAA AAG ACA CCC AGG AAG CTT TAG AGA AGA TAA AGG AAG
AGC AAA GCA AAA GTC AGA AAA AAG CAC AGC AAG TAC AGC AAG
CAG CAG CTG GCA CAG GAA ACA GCG GTC AGG CCA GCC AAA ATT
ACC CTA TAG TGC AAA ACA TCC AGG GGC AAA TGG TAC ATC AGG
CCT TAT CAC CTA GA? Ill 111 111 111
P79LN-64B GGG AGC TAG AAC GAT TCG CAG TTA ACC CTG GCC TAT
TAG AAA CAT CAG AAG GCT GTA GAC AAA TAT TGG AAC AGC TAC
AAC CAT CCC TTC AGA CAG GAT CAG AAG AAC TTA GAT CAT TAT
ATA ATG CAG TAG CAA CTC TCT ATT GTG TGC ATC AAA GGA TAG
ATG TAA AAG ACA CCC AGG AAG CTT TAG AGA AGA TAA AGG AAG
AGC AAA GCA AAA GTC AGA AAA AAG CAC AGC AAG CAC AGC AAG
CAG CAG CTG GCA CAG GAA ACA GCG GTC AGG CCA GCC AAA ATT
ACC CTA TAG TGC AAA ACA TTC AGG GGC AAA TGG TAC ATC AGG
CCA TAT CAC CTA GA? Ill 111 111 111
P79LN-68B GGG AGC TAG AAC GAT TCG CAG TTA ACC CTG GCC TAT
TAG AAA CAT CAG AAG GCT GTA GAC AAA TAT TGG AAC AGC TAC
AAC CAT CCC TTC AGA CAG GAT CAG AAG AAC TTA GAT CAT TAT
ATA ATG CAG TAG CAA CTC TCT ATT GTG TGC ATC AAA GGA TAG
ATG TAA AAG ACA CCC AGG AAG CTT TAG AGA AGA TAA AGG AAG
AGC AAA GCA AGA GTC AGA AAA AAG CAC AGC AAG CAC AGC AAG
CAG CAG CTG GCA CAG GAA ACA GCG GTC AGG CCA GCC AAA ATT
ACC CTA TAG TGC AAA ACA TCC AGG GGC AAA TGG TAC ATC AGG
CC? Ill 111 111 111 111 111 111 111
P79LN-69B GGG AGC TAG AAC GAT TCG CAG TTA ACC CTG GCC TAT
TAG AAA CAT CAG AAG GCT GTA GAC AAA TAT TGG AAC AGC TAC
AAC CAT CCC TTC AGA CAG GAT CAG AAG AAC TTA GAT CAT TAT
ATA ATG CAG TAG CAA CTC TCT ATT GTG TGC ATC AAA GGA TAG
ATG TAA AAG ACA CCC AGG AAG CTT TAG AGA AGA TAA AGG AAG
AGC AAA ACA AAA ATC AGA AAA AAG CAC AGC AAG CAC AGC AAG
CAG CAG CTG GCA CAG GAA ACA GCA GTC AGG CCA GCC AAA ATT
ACC CTA TAG TGC AAA ACA TCC AGG GGC AAA TGG TAC ATC AGG
CCA TAT 111 111 111 111 111 111 111
P79LN-7IB GGG AGC TAG AAC GAT TCG CAG TTA ACC CTG GCC TAT
TAG AAA CAT CAG AAG GCT GTA GAC AAA TAT TGG AAC AGC TAC
AAC CAT CCC TTC AGA CAG GAT CAG AAG AAC TTA GAT CAT TAT
ATA ATG CAG TAG CAA CCC TCT ATT GTG TGC ATC AAA GGA TAG
AGG TAA AAG ACA CCC AGG AAG CTT TAG AGA AGA TAA AGG AAG
AGC AAA GCA AAA GTC AGA AAA AAG CAC AGC AAG CAC AGC TAG
TAG CAG CTG GCA CAG GAA ACA GCG GTC AGG CCA GCC AAA ATT
ACC CTA TAG TGC AAA ACA TCC AGG GGC AAA TGG TAC ATC AGG
CCA TAT 111 111 111 111 111 111 111
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P70LN-72B GGG AGC TAG AAC GAT TCG CAG TTA ACC CTG GCC TAT
TAG AAA CAT CAG AAG GCT GTA GAC AAA TAT TGG AAC AGC TAC
AAT CAT CCC TTC AGA CAG GAT CAG AAG AAC TTA GAT CAT TAT
ATA ATG CAG TAG CAA CTC TCT ATT GTG TGC ATC AAA GGA TAG
ATG TAA AAG ACA CTC AGG AAG CTT TAG AGA AGA TAA AGG AAG
AGC AAA GCA AAA GTC AGA AAA AAG CAC AGC AAG CAC AGC TAG
TAG CAG CTA GCA CAG AAA ACA GCA GCC AGG CCA GTC AAA ATT
ACC CTA TAG TGC AAA ACA TCC AGG GGC AAA TGG TAC ATC AGG
CC? ??? ??? ??? ??? ??? ??? ??? ???
P79LN-74B GGG AGC TTG AAC AAT TTG AAG TTA ATC CTG GCC TAT
TAG AAA CAT CAG AAG GCT GTA GAC AAA TAT TGG AAC AGC TAC
AAC CAT CCC TTC AGA CAG GAT CAG AAG AAC TTA GAT CAT TAT
ATA ATG CAG TAG CAA CTC TCT ATT GTG TGC ATC AAA GGA TAG
ATG TAA AAG ACA CCC AGG AAG CTT TAG AGC AGA TAA AGG AAG
AGC AAA ACA AAA GTA AAA TAA AAG CAC AGC AAG CAC AGC TAG
TAG CAG CTA GCA CAG GAA ACA GCG GTC AGG CCA GCC AAA ATT
ACC CTA TAG TGC AAA ACA TCC AGG GGC AAA TAA TAC ATC AGG
CCT TAT CAC CTA GAA ??? ??? ??? ???
P79LN-76B GGG AGC TAG AAC GAT TTG CAG TTA ACC CTG GCC TAT
TAG AAA CAT CAG AAG GCT GTA GAC AAA TAC TGG AAC AGC TAC
AAC CAT CCC TTC AGA CAG GAT CAG AAG AAC TTA GAT CAT TAT
ATA ATG CAG TAG CAA CTC TCT ATT GTG TGC ATC AAA GGA TAG
ATG TAA AAG ACA CCC AGG AAG CTT TAG AGA AGA TAA AGG AAG
AGC AAA GCA AAA GTC AGC AAA AAG CAC AGC AAG CAC AGC TAG
TAG CAG CTA GCA CAG GAA ACA GCG GTC AGG CCA GCC AAA ATT
ACC CTA TAG TGC AGA ACA TCC AGG GGC AAA TGG TAC ATC AGG
CCT TAT CAC CTA GAA ??? ??? ??? ???
P79LN-78B GGG AGC TAG AAC GAT TCG CAG TTA ACC CTG GCC TAT
TAG AGA CAT CAG AAG GCT GTA GAC AAA TAT TGG AAC AGC TAC
AAC CAT CCC TTC AGA CAG GAT CAG AAG AAC TTA GAT CAT TAT
ATA ATG CAG TAG CAA CTC TCT ATT GTG TGC ATC AAA GGA TAG
ATG TAA AAG ACA CCC AGG AAG CTT TAG AGA AGA TAA AGG AAG
AGC AAA GCA AAA GTC AGC AAA AAG CAC AGC AAG CAC AGC AAG
CAG CAG CTG GCA CAG GAA ACA GCG GTC AGG CCA GCC AAA ATT
ACC CTA TAG TGC AAA ACA TCC AGG GGC AAA TGG TAC ATC AGG
CCT TAT CAC CTA GAA ??? ??? ??? ???
P79LN-60B GGG AGT TAG AAC GAT TCG CAG TTA ACC CTG GCC TAT
TAG AGA CAT CAG AAG GCT GTA GAC AAA TAT TGG AGC AGC TAC
AAC CAT CCC TTC AGA CAG GAT CAG AAG AAC TTA GAT CAT TAT
ATA ATG CAG TAG CAA CTC TCT ATT GTG TGC ATC AAA GGA TAG
ATG TAA AAG ACA CCC AGG AAG CTT TAG AGA AGA TAA AGG AAG
AGC AAA GCA AAA GTC AGA AAA AAG CAC AGC AAG CAC AGC TAG
TAG CAG CTA GCA CAG GAA ACA GCG GTC AGG CCA GCC AAA ATT
ACC CTA TAG TGC AAA ACA TCC AGG ??? ??? ??? ??? ??? ???
??? ??? ??? ??? ??? ??? ??? ??? ?1?
P79LG-3C GGG AGC TAG AAC GAT TCG CAG TTA ACC CTG GCC TAT
TAG AGA CAT CAG AAG GCT GTA GAC AAA TAC TGG AAC AGC TAC
AAC CAT CCC TTC AGA CAG GAT CAG AAG AAC TTA GAT CAT TAT
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ATA ATG CAG TAG CAA CTC TCT ATT GTG TGC ATC AAA GGA TAG
AGG TAA AAG ACA CCC AGG AAG CTT TAG AGA AGA TAA AGG AAG
AAC ACA GCA AAA GTC AGA AAA AAG CAC AGC AAG CAC AGC TAG
TAG CAG CTG ACA CAG GAA ACA GCG GTC AGG CCA GCC AAA ATT
ACC CTA TAG TGC AAA ACA TCC AG? ??? ??? ??? ??? ??? ???
??? ??? ??? ??? ??? ??? ??? ??? ???
P79LG-4C GGG AGC TAG AAC GAT TCG CAG TTA ACC CTG GCC TAT
TAA AAA CAT CAG AAG GCT GTA GAC AAA TAC TGG AAC AGC TAC
AAC CAT CCC TTC AGA CAG GAT CAG AAG AAC TTA AAT CAT TAT
TTA ATA CAG TAG CAA CCC TCT ATT GTG TGC ATC AAA GGA TAG
ATG TAA AAG ACA CCA ATG AAG CTT TAG AGA AGA TAA AGA AAA
AGC AAA ACA AAA GTA AGA AAA AAG CAC AGC AAG CAC AGC AAG
CAG CAG CTG GCA CAG GAA ACA GCA GTC AGA CCA GCC AAA ATT
ACC CTA TAG TGC AAA ACA TCC AGG GGC AAA TGG TAC ATC ???
??? ??? ??? ??? ??? ??? ??? ??? ???
P79LG-9C GAG AGC TAG AAC GAT TCG CAG TTA ACC CTG GCC TAT
TAG AGA CAT CAG AAG GCT GTA GAC AAA TAT TGG AAC AGC TAC
AAC CAT CCC TTC AGA CAG GAT CAG AAG AAC TTA GAT CAT TAT
ATA ATA CAG TAG CAA CCC TCT ATT GTG TGC ATC AAA GGA TAG
AGG TAA AAG ACA CCA ATG AAG CTT TAG AGA AGA TAA AGG AAG
AGC AAG ACA AAA GTA AGA AAA AAG CAC AGC AAG CAC AGC AAG
CAG CAG CTG GCA CAG GAA ACA GCG GTC AGG CCA GCC AAA ATT
ACC CTA TAG TGC AAA ACA TCC AGG GGC AAA TGG TAC A?? ???
??? ??? ??? ??? ??? ??? ??? ??? ???
P79LG-10C GGG AGC TAG AAC GAT TCG CAG TTA ACC CTG GCC TAT
TAG AAA CAT CAG AAG GCT GTA GAC AAA TAT TGG AAC AGC TAC
AAC CAT CCC TTC AGA CAG GAT CAG AAG AAC TTA GAT CAT TAT
ATA ATG CAG TAG CAA CTC TTT ATT GTG TGC ATC AAA GGA TAG
ATG TAA AAG ACA CCA GGG AAG CTT TAG AGA AGA TAA AGG AAG
AGC AAA GCA AAA GTC AGA AAA AAG CAC AGC AAG CAC AGC AAG
CAG CAG CTG GCA CAG GAA ACA GCG GTC AGG CCA GCC AAA ATT
ACC CTA TAG TGC AAA ACA TCC AGG GGC AAA TGG TAC A?? ???
??? ??? ??? ??? ??? ??? ??? ??? ???
P79LG-13C GGG AGC TAG AAC GAT TCG CAG TTA ACC CTG GCC TAT
TAG AAA CAT CAG AAG GCT GTA GAC AAA TAT TGG AAC AGC TAC
AAC CAT CCC TTC AGA CAG GAT CAG AAG AAC TTA GAT CAT TAT
ATA ATG CAG TAG CAA CTC TTT ATT GTG TGC ATC AAA GGA TAG
ATG TAA AAG ACA CCA GGG AAG CTT TAG AGA AGA TAA AGG AAG
AGC AAA GCA AAA GTC AGA AAA AAG CAC AGC AAG CAC AGC AAG
CAG CAG CTG GCA CAG GAA ACA GCG GTC AGG CCA GCC AAA ATT
ACC CTA TAG TGC AAA ACA TCC AGG GGC AAA TGG TAC A?? ???
??? ??? ? ? ? 111 111 111 111 111 111
P79LG-15C GGG AGC TAG AAC GAT TTG CAG TTA ACC CTG GCC TAT
TAG AAA CAT CAG AAG GCT GTA GAC AAA TAT TGG AAC AGC TAC
AAC CAT CCC TTC AGA CAG GAT CAG AAG AAC TTA GAT CAT TAT
ATA ATG CAG TAG CAA CTC TCT ATT GTG TGC ATC AAA GGA TAG
AGG TAA AAG ACA CCA GGG AAG CTT TAG AGC AGA TAA AGG AAG
AGC AAA ACA AAG GTA AGA AAA AAG CAC AGC AAG CAC AGC AAG
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CAG CAG CTG GCA CAG GAA ACA GCG GTC AGG CCA GCC AAA ATT
ACC CTA TAG TGC AAA ACA TCC AGG GGC AAA TGG TAC ??? ???
??? ??? ??? ??? ??? ??? ??? ??? ???
P79LG-25C GAG AGC TAG AAC GAT TCG CAG TTA ACC CTG GCC TAT
TAG AAA CAT CAG AAG GCT GTA GAC AAA TAT TGG AAC AGC TAC
AAC CAT CCC TTC AGA CAG GAT CAG AAG AAC TTA GAT CAT TAT
ATA ATG CAG TAG CAA CTC TTT ATT GTG TGC ATC AAA GAA TAG
ATG TAA AAG ACA CCA GGG AAG CTT TAG AGA AGA TAA AGG AAG
AGC AAA GCA AAA GTC AGA AAA AAG CAC AGC AAG CAC AGC AAG
CAG CAG CTG GCA CAG GAA ACA GCG GTC AGG CCA GCC AAA ATT
ACC CCA TAG TGC AAA ACA TCC AGG GGC AAA TGG TA? ??? ???
??? ??? ??? ??? ??? ??? ??? ??? ?;?
P79LG-29C GAG AGC TAG AAC GAT TCG CAG TTA ACC CTA GCC TAT
TAG AGA CAT CAG AAG GCT GTA GAC AAA TAT TGG AAC AGC TAC
AAC CAT CCC TTC AGA CAG GAT CAG AAG AAC TTA GAT CAT TAT
ATA ATG CAG TAG CAA CTC TCT ATT GTG TGC ATC AAA GGA TAG
ATG TAA AAG ACA CCA GGG AAG CTT TAG AGA AGA TAA AGG AAG
AGC AAA GCA AAA GTC AGA AAA AAG CAC AGC AAA CAC AGC AAG
CAG CAG CTG GCA CAG GAA ACA GCG GTC AGG CCA GCC AAA ATT
ACC CTA TAG TGC AAA ACA TTC AGG GAC AAA TGG TA? ??? ???
??? ??? ??? ??? ??? ??? ??? ??? ?;?
P79LG-33C GGG AGC TAG AAC GAT TCG CAG TTA ACC CTG GCC TAT
TAG AAA CAT CAG AGG GCT GTA GAC AAA TAT TGG AAC AAC TAC
AAC CAT CCC TTC AAA CAG GAT CAA AAG AAC TTA AAT CAT TAT
ATA ATG CAG TAG CAA CTC TCT ATT GTG TGC ATC AAA GAA TAA
ATG TAA AAG ACA CCC AGA AAG CTT TAG AGA AAA TAA AGG AAG
AGC AAA GCA AAA GTC AGA AAA AAG CAC AGC AAG CAC AGC AAG
CAG CAG CTG GCA CAA AAA ACA GCG GTC AGG CCA GCC AAA ATT
ACC CTA TAG TGC AAA ACA TTC AGG GGC AAA TGG TA? ??? ???
??? ??? ??? ??? ??? ??? ??? ??? 7 ? ?
P79LG-36C GGG AGC TAG AAC GAT TTG CAA TTA ACC CTG GCC TAT
TAG AAA CAT CAG AAG GCT GTA GAC AAA TAT TGG AAC AGC TAC
AAC CAT CCC TTC AGA CAG GAT CAG AAG AAC TTA GAT CAT TAT
ATA ATG CAG TAG CAA CTC TCT ATT GTG TGC ATC AAA GGA TAG
ATG TAA AAG ACA CCC AGG AAG CTT TAG AGA AGA TAA AGG AAG
AGC AAA GCA AAA GTC AGA AAA AAG CAC AGC AAG CAC AGC AAG
TAG CAG CTG GCA CAG GAA ACA GCG GTC AGG CCA GCC AAA ATT
ACC CTA TAG TGC AAA ACA TCC AGG ??? ??? ??? ??? ??? ???
??? ??? ??? ??? ??? ??? ??? ??? ? ? ?
P79LG-38C GGG AGC TAG AAC GAT TTG CAG TTA ACC CTG GCC TAT
TAG AAA CAT CAG AAG GCT GTA GAC AAA TAT TGG AAC AGC TAC
AAC CAT CCC TTC AGA CAG GAT CAG AAG AAC TTA GAT CAT TAT
ATA ATG CAG TAG CAA CTC TCT ATT GTG TGC ATC AAA GGA TAG
ATG TAA AAG ACA CCC AGG AAG CTT TAG AGA AGA TAA AGG AAG
AGC AAA ACA AAA ATC AGA AAA AAG CAC AGC AAG CAC AGC AAG
CAG AAG CTG GCA CAG GAA ACA GCA GTC AGG CCA GCC AAA ATT
ACC CTA TAG TGC AGA ACA TCC AGG GGC AAA TGG TAC ATC AGG
CCT TAT CAC CTA GA? ??? ??? ??? ???
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P79LG-39C GGG AGC TAG AAC GAT TCG CAG TTA ACC CTG GCC TGT
TAG AGA CGT CAG AAG GCT GTA GAC AAA TAT TGG AAC AGC TAC
AAC CAT CCC TTC AGA CAG GAT CAG AAG AAC TTA GAT CAT TAT
ATA ATG CAG TAG CAA CTC TCT ATT GTG TGC ATC AAA GGA TAG
ATG TAA AAG ACA CCC AGG AAG CTT TAG AGA AGA TAA AGG AAG
AGC AAA GCA AAA GTC AGA AAA AAG CAC AGC AAG CAC AGC AAG
CAG CAG CTG GCA CAG GAA ACA GCG GTC AGG CCA GCC AAA ATT
ACC CTA TAG TGC AAA ACA TCC AG? ??? ??? ??? ??? ??? ???
??? ??? ??? ??? ??? ??? ??? ??? ???
P79LG-40C GGG AAC TAG AAC AAT TCG CAG TTA ACC CTG GCC TGT
TAG AAA CAT CAG AAG GCT GTA GAC AAA TAT TGG AAC AGC TAC
AAC CAT CCC TTC AGA CAG GAT CAG AAG AAC TTA GAT CAT TAT
ATA ATG CAG TAG CAA CTC TCT ATT GTG TGC ATC AAA GGA TAG
ATG TAA AAG ACA CCC AGG AAG CTT TAG AGA AGA TAA AGG AAG
AGC AAA ACA AAA ATC AGA AAA AAG CAC AGC AAG CAC AGC AAG
CAG CAG CTG ACA CAG GAA ACA GCA GTC AGG CCA GCC AAA ATT
ACC CTA TAG TGC AGA ACA TCC AG? ??? ??? ??? ??? ??? ???
??? ??? ??? ??? ??? ??? ??? ??? ???
P79LG-41C GGG AGC TAG AAC AAT TTG CAG TTA ACC CTG GCC TGT
TAG AAA CAT CAG AAG GCT GTA GAC AAA TAT TGG AAC AGC TAC
AAC CAT CCC TTC AGA CAG GAT CAG AAG AAC TTA GAT CAT TAT
ATA ATG CAG TAG CAA CTC TCT ATT GTG TGC ATC AAA GGA TAG
ATG TAA AAG ACA CCC AGG AAG CTT TAG AGA AGA TAA AGG AAG
AGC AAA GCA AAA GTC AGA AAA AAG CAC AGC AAG CAC AGC AAG
CAA CAG CTG ACA CAG GAA ACA GCG GTC AGG CCA GCC AAA ATT
ACC CTA TAG TGC AGA ACA TCC AGG ??? ??? ??? ??? ??? ???
??? ??? ??? ??? ??? ??? ??? ??? ? ? ?
P79LG-43C GGG AGC TAG AAC GAT TCG CAG TTA ACC CTG GCC TGT
TAG AGA CAT CAG AAG GCT GTA GAC AAA TAT TGG AAC AGC TAC
AAC CAT CCC TTC AGA CAG GAT CAG AAG AAC TTA GAT CAT TAT
ATA ATG CAG TAG CAA CTC TCT ATT GTG TGC ATC AAA AGA TAG
ATG TAA AAG ACA CAC AGG AAG CTT TAG AGA AGA TAA AGG AAG
AGC AAA GCA AAA GTC AAA AAA AiiA CAC AGC AAG CAC AGC TAG
TAG CAG CTA GCA CAG GAA ACA GCG GTC AGG CCA GCC AAA ATT
ACC CTA TAG TGC AAA ACA TCC AGG ??? ??? ??? ??? ??? ???
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Appendix V
Data Origin Sequence Phenotype VI Charge VI Length VI CHO Sites
Wang et al„1995 CASE.B N -21 26 3
AD11 N 1 26 3
BABYA N -1 25 3
HU N -1 32 3
X47 N 0 26 4
ACTG6 N 2 36 4
ACTG11 N -1 31 4
X56 N -1 32 4
MR N -2 29 3
X44 N -5 26 3
AD6 N -1 27 3
ACTG10 N -1 36 3
ACTG8 N 0 29 3
EJ N -1 30 4
76B N 0 26 4
CASE.C N -1 30 4
AD10 N -2 29 4
AD13 N -2 29 3
RT N 1 32 3
JCS010 N -3 32 4
CASE.D1 N -1 35 5
CASE.D7 N -3 27 3
AD8 N 0 39 3
N70 N -1 42 8
277B S 0 17 2
ACTG1 S 0 19 2
X57 s -1 27 3
CASE.A2 s -1 36 5
CASE.AT s -1 27 3
X42C s -3 28 4
ACTG3 s -2 31 3
JSH S -2 29 4
X50C s 0 37 4
X49 s -2 48 8
*
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Data Origin Sequence Phenotype V2 Charge V2 Length V2 CHO Sites
Wang et al.,1995 CASE.B N 0 42 2
ADIT N -1 44 3
BABYA N -1 42 2
HU N 2 42 3
X47 N 1 44 2
ACTG6 N 1 41 2
ACTG11 N 1 41 1
X56 N -1 41 2
MR N -1 40 2
X44 N -3 40 3
AD6 N 3 45 1
ACTG10 N 0 43 3
ACTG8 N 2 40 2
EJ N -1 46 2
76B N 3 46 1
CASE.C N 0 40 2
AD10 N 0 43 3
AD13 N 2 40 2
RT N -2 42 2
JCS010 N 0 40 2
CASE.D1 N 1 47 4
CASE.D7 N 2 41 2
AD8 N L 40 2
N70 N 2 40 2
277B S 0 42 2
ACTG1 S 1 46 3
X57 S 0 41 3
CASE.A2 S 2 42 2
CASE.At S 4 43 2
X42C S 0 41 2
ACTG3 s 2 41 1
JSH S 1 46 3
X50C S -1 41 2
X49 s 1 40 2
Groenink et al.,1993 ACH-239.11 N -1 40 2
Ama-44 N 1 40 2
Ama-168.2 N 3 40 3
Ama-96.1 N 1 40 2
ACH-424 N 0 40 2
Ama-24 N 2 40 1
ACH-15.9 N -1 40 2
ACH-172.1 N 3 42 3
ACH-525 N -1 42 2
ACH-638 N 3 39 2
Ama-179 N 1 40 2
Ama-180 N 2 41 2
Ama-181 N 3 39 2
Ama-182 N 2 oCO 2
Ama-161.15 S 1 49 3
ACH-320.2A.1.1 s 1 48 3
Ama-16.2 S 3 43 2
ACH-39,14.2 s 1 47 3
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Ama-72.3.3 S 0 42 2
ACH-224.25.5 S 2 41 3
ACH-571.16,2 S 1 42 2
Ama-169.2 S 3 47 2
ACH-479.5 S 2 45 2
ACH-168.7 S 2 40 2
Ama-55 S 2 43 2
ACH-704.2 S -2 40 1
ACH-373.38 S 0 40 2
Ama-32 S 3 43 2
Ama-127.4.2 S 3 42 3
Cornelissen et al.,1995 BR03 N 1 38 2
BR04 N 1 40 2
BR1 7 N -1 43 3
BR18C N 0 43 3
BR19 N 0 39 2
BR20cl N -1 40 1
BR20c2 N 0 38 1
BR21 N 0 40 2
BR23 N 3 40 2
BR28cl N 2 40 3
BR28c2 N 0 40 2
BR30 N 2 40 3
TH14 N 0 39 2
TH26 N 1 39 1
AMC-Olc N 0 40 1
AMC-03 N 2 40 2
AMC-04 N 1 50 4
AMC-06 N 1 38 1
AMC-12 N 1 42 2
AMC-14 N 3 44 2
AMC-15 N 0 46 3
AMC-18 N 2 40 2
BR14c S 2 38 1
AMC-02 S 0 40 2
AMC-05 S -1 61 5
AMC-07C S 4 40 2
AMC-8 S 2 39 1
AMC-9 S 1 40 1
AMC-10 S 0 45 1
AMC-19 S 3 40 1
AMC-20C1 S 0 41 2
AMC-20c2 S -1 40 2
AMC-21 S 4 40 2
AMC-22 S 2 40 2
AMC-24 S 0 38 1
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Appendix VI
Patient No. Origin VI charge VI length VI CHO Sites V2 charge V2 length V2 CHO Sites
5 BR-1 -1 30 2 1 40 2
5 BR-2 -1 30 2 2 40 3
5 BR-3 -1 30 2 1 40 2
5 BR-4 0 30 3 1 40 2
5 BR-5 -2 30 3 -1 40 2
5 BR-6 -1 30 2 1 40 2
5 BR-7 -1 30 2 2 40 3
5 BR-8 0 30 3 1 40 2
5 BR-9 -1 30 2 1 40 2
5 BR-10 -1 30 2 2 40 3
5 BR-11 -1 30 2 1 40 2
5 BR-12 0 30 3 2 40 2
5 LN-1 2 30 3 2 40 2
5 LN-2 -1 30 2 1 40 2
5 LN-3 0 30 3 -1 40 2
5 LN-4 0 30 2 2 40 2
5 LN-5 0 30 3 0 40 2
5 LN-6 0 30 3 2 40 2
5 LN-7 0 30 2 1 40 2
5 LN-8 1 30 2 2 40 2
5 LN-9 0 30 2 2 40 2
5 LN-10 1 30 3 1 40 2
5 LG-1 -1 30 3 0 40 2
5 LG-2 0 30 3 0 40 2
5 LG-3 0 30 3 0 40 2
5 LG-4 0 30 3 1 40 2
5 LG-5 -1 30 3 0 40 2
5 LG-6 -1 30 3 0 40 2
5 LG-7 0 30 3 0 40 2
5 LG-8 1 30 3 0 40 2
5 LG-9 0 30 3 -1 40 2
5LG-10 1 30 3 1 40 2
5 LG-11 0 30 3 0 40 2
5 LG-12 1 30 3 3 40 2
5 LG-13 0 30 3 1 40 2
5 LG-14 0 30 3 2 40 2
5 LG-15 0 30 3 1 40 2
9 BR-1 2 31 2 0 43 2
9 BR-2 1 30 4 2 43 2
9 BR-3 2 32 4 1 43 2
9 BR-4 -1 31 4 2 43 2
9 BR-5 0 35 4 2 43 2
9 BR-6 0 32 4 1 43 2
9 BR-7 0 32 4 3 43 2
9 BR-8 1 31 4 3 44 3
9 BR-9 2 27 4 1 48 4
9 BR-10 3 38 5 3 43 2
9 BR-11 0 38 5 2 43 2
9 LN-1 0 38 5 0 47 5
9 LN-2 1 31 5 0 47 5
9 LN-3 0 38 5 -1 47 5
9 LN-4 1 31 4 0 47 5
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9 LN-5 o 31 5 0 47 5
9 LN-6 1 31 4 0 47 5
9 LN-7 -4 31 4 0 43 2
9 LG-1 -1 38 5 3 44 3
9 LG-2 0 31 5 1 47 4
9 LG-3 0 38 5 0 47 5
9 LG-4 0 38 5 1 47 4
9 LG-5 1 32 4 -1 48 3
9 LG-6 1 31 4 -1 48 3
9 LG-7 0 32 4 0 47 5
9 LG-8 0 38 5 1 49 4
9 LG-9 0 38 5 1 48 3
9 LG-10 0 38 5 0 48 4
11 BR-1 0 40 3 1 40 2
11 BR-2 -1 42 5 1 40 2
11 BR-3 1 31 4 2 40 1
11 BR-4 0 31 4 2 40 1
11 BR-5 0 31 4 2 40 1
11 BR-6 0 31 4 2 40 1
11 BR-7 0 31 4 2 40 1
11 BR-8 0 31 4 2 40 1
11 BR-9 1 30 4 2 40 1
11 BR-10 0 31 4 2 40 1
11 BR-11 0 30 4 1 38
11 LN-1 1 30 4 2 40 1
11 LN-2 0 31 4 2 40 1
11 LN-3 0 31 4 2 40 1
11 LN-4 2 42 4 1 40
11 LB-5 -1 42 5 1 40
11 LN-6 0 30 4 2 38 1
11 LN-7 -1 31 4 2 40 1
11 LN-8 0 41 4 0 40
11 LN-9 0 31 4 1 40 1
11 LN-10 0 31 4 1 40 1
11 LN-11 -1 42 5 1 40 2
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Appendix VII
Patient Disease Status CD4 count VI No. LN VI No. BR V2NO. LN V2 No. BR
4 S 8 1 1| 1 1
5 S 95 5 3 3 3
6 S 10 6 3 3
15 S 5 1 2 1 1
21 S 6 2 3 1 1
26 |S 8 5 3 2 2
30 S 0 2 2| 1 1
32 S 11 5 2 1 1
42 S 28 3 3 2 1
44 S 19 2 1! 3 1
51 S 10 6 3 2
63 S 2 1 2 2
69 S 90 2 3| 2 1
10 S 6 2 2
16 S 4 5 3
17 S 12 3 3
18 S 10 4 3
24 S 19 4 4
25 S 93 6 2
27 S 5 7 2
28 S 105 10 2
36 S 15 3 5
37 S 2 4 2
38 S 40 3 2
39 S 170 2 4
45 S 5 2 3
48 S 40 5 2
54 S 13 4 4
62 S 2 2 5
64 S 2 3 3
68 S 155 7 5
72 S 140 2 3
77 S 3 3 3
78 S 0 2 2
1 P 115 1 4
2 P 140 4 2
3 P 370 3 3
19 P 33 3 2
34 P 240 1 2
35 P 180 6 2
40 P 50 3 1
76 P 802 2 4
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Patient Disease status Tissue origin Actual length Genomic region CD4 count GCE
4 S LN 30 VI 8 X
4 S BR 30 VI 8 X
5 S LN 31 VI 95 X
5 S LN 32 VI 95 X
5 S LN 36 VI 95 X
5 S LN 38 VI 95 X
5 S LN 40 VI 95 X
5iS BR 31 VI 95 X
5 S BR 38 VI 95 X
5 S BR 40 VI 95 X
6iS LN 30 VI 10 X
_ 6S LN 31 VI 10 X
6 S LN 32 VI 10 X
6 S LN 40 VI 10 X
6 S LN 41 VI 10 X
6 S LN 42 VI 10 X
6 S BR 30 VI 10 X
6 S BR 32 VI 10 X
6 S BR 42 VI 10 X
15 S LN 30 VI 5 X
15 S BR 30 VI 5 X
15 S BR 36 VI 5 X
21 S LN 35 VI 6 X
21 S LN 39 VI 6 X
21 s BR 31 VI 6 X
21 s BR 35 VI 6 X
21 s BR 42 VI 6 X
26 S LN 31 VI 8 X
26 S LN 32 VI 8 X
26 S LN 39 VI 8 X
26 S LN 49 VI 8 X
26 S LN 50 VI 8 X
26 S BR 31 VI 8 X
26 S BR 32 VI 8 X
26 S BR 39 VI 8 X
30 S LN 31 VI 0 X
30 S LN 39 VI 0 X
30 S BR 31 VI 0 X
30 S BR 39 VI 0 X
32 S LN 00CM VI 11 X
32 S LN 32 VI 11 X
32 S LN 36 VI 11 X
32 S LN 37 VI 11 X
32 S LN 39 VI 11 X
32 S BR 28 VI 11 X
32 S BR 37 VI 11 X
34 p LN 30 VI O"vTCM o
40 S LN 31 VI 50 X
40 S LN 33 VI 50 X
40 S LN 39 VI 50 X
40 S BR 31 VI 50 X
40 S BR 39 VI 50 X
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40 s br 40 vi 50 x
42 s ln 27 vi 28 x
42 s ln 30 vi 28 x
42 s Tn 34 vi 28 x
42 s br 27 vi 28 x
42 s br 34 vi 28 x
42 s br 37 vi 28 x
44 s ln 27 vi 19 o
44 s ln 34 vi 19 o
63 s ln 31 vi 2 x
63 s br 31 vi 2 x
63 s br 39 vi 2 x
69 s ln 22 vi 90 x
69 s ln 29 vi 90 x
69 s br 27 vi 90 x
69 |s br 30 vi 90 x
69 s br 38 vi 90 x
77 s ln 26 vi 3 o
77 s ln 27 vi 3 o
77 s ln 33! vi 3 o
78js ln 36 vi 0 o
78 s ln 46 vi 0 o
10 s ln 37< vi 6 o
10 s ln 47 vi 6 o
1 p ln 30 vi 115 o
1 p ln 31 vi 1150
1 p ln >COCO 115 o
1 p ln 39 vi 115 o
3 p ln 30 vi 370 o
3 p ln 31 vi 370 o
3 p ln 38 vi 370 o
16 s ln 34 vi 4 o
16 s ln 38 vi 4 o
16 s ln 41 vi 4 o
17 s ln 36 vi 12 o
17 s ln 42 vi 12 o
18 s ln 24! vi 10 o
18 s ln 25 vi 10 o
18 s ln 30 vi 10 o
18 s ln 42 vi 10 o
19 p ln 27 vi 33 o
19 p ln 36 vi 33 o
2 p ln 29 vi 140 o
2 p ln 34 vi 140 o
2 p ln 39 vi 140 o
2 p ln 45 vi 140 o
24 s ln 26 vi 19 o
24 s ln 27 vi 19 o
24 s ln 29 vi 19 o
24 s ln 36 vi 19 o
25 p ln 37 vi 93 o
25 p ln 38 vi 93 o
25 p ln 40 vi 93 o
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25 P LN 43 VI 93 O
25 P LN 44 VI 93 O
27 S LN 25 VI 5 O
27!S LN 27 VI 5 O
27 S LN 28 VI 5 O
27;s LN 32 VI 5 O
27 S LN 00CO VI 5 O
27 S LN 40 VI 5 O
35 P LN 29 VI 180 O
35 P LN 31 VI 180 O
35 P LN 33 VI o00 O
35 P LN 36 VI o00 o
35 P LN 37 VI o00 o
35 P LN 38 VI 180 o
36 s LN 30 VI 15 o
36 |S LN 36 VI 15 o
37 i S LN 35 VI 2 o
37^S LN 36 VI 2 o
37 S LN 43 VI 2 o
37 S LN 44 VI 2 o
38 S LN 24 VI 40 O
38 S LN 30 VI 40 O
38 S LN 37 VI 40 O
39 S LN 36 VI 170 o
39 S LN 38 VI 170 O
45 S LN 30 VI 5 o
45 s LN 37 VI 5 o
48 S LN 28 VI 40 O
48 S LN 31 VI 40 o
48 S LN 35 VI 40 O
48 s LN 38 VI 40 O
48 S LN 39 VI 40 o
54 S LN 29 VI 3 o
54 S LN 36 VI 3 o
54 S LN 39 VI 3 o
54 S LN 43 VI 3 o
62 S LN 30 VI 2 o
62 S LN 37 VI 2 o
64 S LN 36 VI 2 o
64 S LN 37 VI 2 o
64 S LN 44 VI. 2 o
68 S LN 35 VI 155 O
68 S LN 36 VI 155 O
68 S LN 39! VI 155 O
68 S LN 41 VI 155 O
68 S LN 42 VI 155 O
68 S LN 43 VI 155 O
68 S LN 44 VI 155 O
72 S LN 27 VI 140 O
72 S LN 35 VI 140 O
76 P LN 43 VI 802 O
4 S BR 40 CN> 8 X
4 S BR 40 V2 8 X
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5 S LN 41 V2 95 X
5 s LN 43! V2 95 X
5 s LN 44 V2 95 X
5 s LN 47 C\l> 95 X
5 s BR 43 V2 95 X
5 s BR 44 V2 95 X
5 s BR 48 V2 95 X
6 S LN 38 V2 10 X
6 S TN 40 V2 10 X
6 s LN 41 V2 10 X
6 s BR 38 V2 10 X
15 S LN 41 V2 5 X
15S BR 41 V2 5 X
21 s LN 41 V2 6 X
21 s BR 41 V2 6 X
26 s LN 42 V2 8 X
26 s LN 48 V2 8 X
26 s BR 46 V2 8 X
26 S BR 00 CN> 8 X
30 S LN 41 V2 0 X
30 S BR 41 V2 0 X
32 S LN 42 V2 11 X
32'S BR 43 V2 11 X
34 p LN 37 V2 240 O
34 p LN 40 V2 240 O
40 S LN 40 V2 50 X
40 S BR Co 00 V2 50 X
42 S LN 00CO V 2 28 X
42 S LN 40 V2 28 X
42 S BR 40 V 2 28 X
44 s LN 41 V2 19 o
44 S LN 43 V2 19 o
44 S LN 44 V2 29 O
51 s LN 39 V2 10 X
51 s LN 43 V2 10 X
51 s BR 39 V2 10 X
51 s BR 43 V2 10 X
63 S LN 37V2 2 X
63 S LN 40 V2 2 X
63 s BR 40 V2 2 X
69 s LN 40 V2 90 X
69 s LN 42 !V2 90 X
69 S BR 40 V2 90 X
77 S LN 43 !V2 3 o
77 S LN 44 V2 3 o
77 S LN 45 V2 3 o
78 s LN 42 V2 0 o
78 s LN 45 V2 0 o
10 s LN 41 V2 6 O
10 s LN 44 V 2 6 O
1 p LN 36 V2 115 O
1 p LN 39 V2 115 O
1 p LN 41 V2 115 O
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1 P LN 43 V2 115 O
3 P LN 41 V2 370 O
3 P LN 49 V2 370 O
16 S LN 36IV2 4 O
16 S LN 37 V2 4 O
16 S LN 40 ;V2 4 O
17 S LN 37 V2 12 O
17 S LN 00oo V 2 12 O
17 |S LN 41 V2 12 O
18 S LN 35 V2 10 O
18 S LN 36 V2 10 O
18 S LN 38 V2 10 O
19 P LN 37 V2 33 O
19 P LN 40 V2 33 o
2 P LN 37 V2 140 o
2 P LN 40 V2 140 o
24 s LN 37 V2 19 o
24;s LN 39 V2 19 o
24 S LN 40 V2 19 o
24 S LN 44: V2 19 o
25 p LN 38 V2 93 o
25 p LN 40 V2 93 O
27 S LN 38 V2 5 O
27 S LN 40 V2 5 O
35 P LN 46 V2 180 O
35 P LN 49 V2 180 O
36 S LN 38 V2 15 O
36 S LN 39 V2 15 o
36 S LN 40 V2 15 O
36 S LN 41 V 2 15 p
36 S LN 43 V2 15 O
37 S LN 38 V2 2 O
37 S LN 40 V2 2 o
38 S LN 40 V2 40 o
38 S LN 42 V2 40 o
39 S LN 38 V2 170 o
39 S LN 40 V2 170 O
39 S LN 41 V2 170 O
39 S LN 43 V2 170 O
45 S LN 34 V2 5 O
45 S LN 37 V2 5 O
45 S LN 39; V2 5 O
48 S LN 36 V2 40 O
48 S LN 39 V2 40 O
54 S LN 34: V2 3 O
54 S LN 36: V2 3 O
54 S LN 38:V2 3 O
54 S LN 41 V2 3 O
62 S LN 34 V 2 2 O
62 S LN 36 V2 2 O
62 S LN 38 V 2 2 O
62 S LN 41 V2 2 O
62 S LN 43 V2 2 O
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64 S LN 35 V2 2 O
64 S LN 37 V2 2 O
64 S LN 42 V2 2 O
68 S LN 34 V2 155 O
68 S LN 35 V2 155 O
68 S LN | 37 V2 155 O
68 S LN 40 V2 155 O
68 S LN 42 V2 155 O
72 S LN 34 V2 140 O
72 S LN 37 V2 140 O
72 S LN 40 V2 140 O
76 P LN 36 V2 802 O
76 P LN 37 V2 802 O
76 P LN 39 V2 802 O
76 P LN 42 V2 802 O
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The time of spread of human immunodeficiency virus type 1 (HIV-1) from lymphoid to nonlymphoid tissues
in the course of infection was investigated by sequence comparisons of variants infecting a range of lymphoid
and nonlymphoid tissues from three individuals with AIDS in the p\lK"K gene and regions Hanking the V1A'2
hypervariable regions. Phvlogenetic analysis in both regions revealed several lineages in each individual that
contained sequences from both lymphoid and nonlymphoid tissues such as the brain. This observation
contrasts strongly with the previously described organ-specific sequences in the V3 region in this study
population and other investigations. Although individual pairwise comparisons of relatively short sequences
such as p\lK"K are subject to considerable stochastic error, we found that the diversity of gag sequences in
variants from lymphoid tissue was consistently lower than that found among variants amplified from the brain.
By estimating mean synonymous pairwise distances in the plT8"* region, we were able to make an approximate
calculation of the ages of populations in different tissues. Those from lymphoid tissue ranged from 2.65 to 5.6
years in the three study subjects, compared with 4.1 to 6.2 years for variants in the brain. Indeed, variants
infecting the brain were no more closely related to each other than they were to variants infecting other tissues
in the body. In two of the three individuals, these times of divergence indicate that infection of the brain may
have occurred as an early event in the progression to disease, preceding the onset of AIDS by several years. This
study is the first in which it was possible to estimate times of diversification in different tissues in vivo and is
of importance in understanding the dynamics of the spread of HIV-1 into nonlymphoid tissues and its possible
adaptation for replication in different cell types.
Infection with human immunodeficiency virus (HIV) is as¬
sociated with a slow, progressive, and irreversible impairment
of the immune system, eventually leading to AIDS. Inherent in
the nature of infection with HIV type 1 (HIV-1) is the pro¬
longed asymptomatic period that precedes the development of
disease (2,11, 28, 35), where infection may be subclinical for as
long as 10 to 15 years. This phenomenon was originally hy¬
pothesized to result from viral latency, whereby viral or provi-
ral DNA became integrated into the host genome with the
simultaneous cessation of viral expression and independent
replication (2). The ensuing progression to AIDS would then
result from subsequent reactivation of virus replication by var¬
ious factors acting upon infected cells, such as antigens, mito¬
gens. and transcriptional factors produced by other viruses.
However, it has been recently shown that from the time of
seroconversion, there is active replication of the virus in lym¬
phoid tissues (11, 28, 35). There are few convincing demon¬
strations of active infection of nonlymphoid tissues until later
in infection, and this change in distribution may be associated
with increased immunosuppression in AIDS (9). Alternatively,
it is possible that variants detected in nonlymphoid tissues such
as the brain in patients with AIDS have been continuously
present from initial infection but that infection becomes clin¬
ically significant only during severe immunosuppression. In this
model. HIV encephalitis could be regarded as reactivation
rather than de novo infection.
* Corresponding author. Mailing address: Department of Medical
Microbiology, University of Edinburgh, Teviot Place, Edinburgh EH8
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This study was undertaken to estimate the time of spread of
HIV-1 to nonlymphoid tissues to determine whether reactiva¬
tion or actual virus spread was responsible for the pathology
observed in nonlymphoid tissues in AIDS. In order to do this,
we obtained sequences from the p\T"s region and V1/V2
flanking regions of HIV-1. The p\lgag region was chosen be¬
cause most nucleotide differences in this region are synony¬
mous and therefore are not subject to positive selection pres¬
sures for sequence change, such as those that may be
encountered by immunological recognition by antibody or cy¬
totoxic T cells (36). Variations at silent sites occur at frequen¬
cies similar to those in the rest of the genome, and it has
already been demonstrated in previous epidemiological studies
that sequence relationships in this region reflect the evolution¬
ary history of the virus (15, 17, 20). The rate of sequence
change of this region (plT^) has previously been determined
from hemophiliacs infected from a common source (20), al¬
lowing the time of divergence between any pairs of sequences
to be determined. This region is therefore of use in recon¬
structing epidemiological relationships between HIV-1-in-
fected individuals (17) and can be extended to the comparison
of variants within different cell types within a single infected
individual.
Tissues from various lymphoid and nonlymphoid organs
were obtained at autopsy from a number of HIV-l-positive
patients known to have a high viral load in the brain and
evidence of giant cell encephalitis by pathology. Phylogenetic
analyses of both p 1 lgag and V1/V2 flanking regions were car¬
ried out in order to explore the relationships among the vari¬
ous lineages present and the spread of infection to nonlym¬
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FIG. 1. Clinical and laboratory markers of disease progression in the three study patients in the 5 years before death. The duration of infection in each individual
was estimated to be 9 or 10 years. Each CD4 count shown is the mean count for the indicated year. Abbreviations: AZT. zidovudine; PCP. Pneumocystis carinii
pneumonia; OHL. oral hairy leukoplakia.
between lymphoid and nonlvmphoid tissues, allowing us to
determine the length of time prior to death at which noniym-
phoid tissues become infected.
MATERIALS AND METHODS
Patient samples. Tissues from various organs were obtained at autopsy, car¬
ried out within 3 days of death, from three individuals who died with AIDS-
dehning illnesses. All individuals showed evidence of HIV infection of the brain
upon postmortem examination, as determined by the histological appearance of
giant cells, the detection of p24 by immunocytochemistry, and the finding of high
provira! loads in the brain by quantitative PCR (9). Pathological examination of
the fixed brains revealed evidence of atrophy on external examination, and this
was confirmed on section by the presence of ventricular dilatation and opening
up of the sulci in all three patients. In one case (P6), a focal 1-cm-diameter lesion
was identified on macroscopic inspection in the right basal ganglia. Histological
examination of this lesion showed that it was a primary central nervous system
lymphoma. Neither of the other two patients showed macroscopic focal lesions
of the brain. Histological examination in all three patients displayed evidence of
quite florid HIV encephalitis and leukoencephalopathy, characterized by giant
cells and focal collections of macrophages and microglial cells, associated with
myelin damage. There was no evidence of perivascular or leptomeningeal in¬
flammatory infiltrates, and, in particular, lymphocytes were not identified within
the central nervous system parenchyma. Further results of the pathological
examinations of these three individuals and quantitation of HIV DNA sequences
in brain and other tissues have been reported previously (8, 9). Clinical infor¬
mation in addition to the previous description (9) for the 4 or 5 years prior to
death is summarized in Fig. 1. Samples of brain (left frontal lobe), spinal cord,
lymph node (mesenteric), lung, and colon tissues from these patients were
dissected into 1- to 2-cm pieces and stored at -70°C.
Preparation of DNA. Extraction of DNA from these tissues was carried out by
resuspending small pieces of tissue in 500 p.1 of lysis buffer (50 mM Tris hydro¬
chloride [pH 8.0], 100 mM NaCl, 50 mM EDTA, 1% sodium-n-lauroylsarcosine,
100 pg of proteinase K per ml). The digestion process was allowed to continue
for 2 h at 65°C. This was followed by phenol-chloroform extraction and ethanol
precipitation. DNA pellets were dried and resuspended in 100 to 200 pi of
distilled water. The concentration of DNA in each sample was determined by
UV absorbance at wavelengths of 260 and 280 nm.
Detection of provirus. Proviral DNA was amplified and quantified bv a pre¬
viously described limiting dilution and nested PCR method (43). Amplification
of DNA was carried out with primers flanking hypervariable regions 1 and 2 from
env and pl7 from gag. The nucleotide sequences of the primers were as follows:
for V1./V2, a, GAG GAT ATA ATC AGT TTA TGG, + (sense), 6539: b, GA
TCA AAG CCT AAA GCC ATG, +, 6560: c. TTG AAA GAG CAG TTT, -
(antisense), 6677; d, T(G/A)A AAA ACT GCT CTT TCA A, +, 6684; e, CAA
TAA TGT ATG GGA ATT GG, -, 6857; and f, AAT GTA CTG TGC TGA
CAT T. -, 6944; for gag. g, GCG AGA GCG TCA GTA TTA AGC GG, +, 795;
h. GGG AAA TTC GGT TAA GGC C, +, 835; i, CTT CTA TTT TTA CCC
ATG C, -, 1248; and j. TCT GAT AAT GCT GAA AAC ATG GG, -, 1296 (all
positions numbered according to the HXB2 genome [33]). Amplification of
target DNA was accomplished by using a thermal cycle of 36 s at 94°C, 42 s at
50°C for gag or 46°C for V1/V2, and 40 s at 72°C for strand extension. Each
template strand was subjected to 25 cycles of amplification.
Sequence analysis. Single molecules of HIV provirus were isolated by limiting
dilution and amplified in a nested PCR to produce sufficient DNA to allow direct
sequencing of the PCR products. Direct sequencing of amplified DNA was
achieved by using a solid-phase sequencing method. The second PCR was per¬
formed in a 100-pl volume with one biotin-labelled primer and one unlabclled
primer (5 to 10 pmol per reaction mixture), generating a PCR product with one
strand having a biotin moiety at either the 5' or 3' end. PCR products were
immobilized on streptavidin-coated magnetic beads (Dvnal), and single strands
of DNA were purified by magnetic separation and sequenced according to the
manufacturer's (Sequenase version 2.0) protocol. After this sequencing reaction,
5 to 6 pi of the reaction product was then electrophoresed on a denaturing
polyacrylamide gel (6% acrvlamide, 0.3% A''JV-bisacrylamidc. 8 M urea. 0.089 M
Tris, 0.089 M boric acid, 0.002 M EDTA. pH 8.3). Gels were fixed, dried, and
exposed overnight on X-Omat film.
Phylogenetic analysis. Sequence comparisons between viruses from the three
study patients were made for the pl7w gene and hypervariable flanking regions
of VI and V2 of the env gene of HIV-1. The amplified pi?""* region began at
nucleotide 795 of HXB2 and extended to position 1319. The amplified V1/V2
region began at position 6539 of HXB2 and extended to position 6976. The
length of the gag region used for sequence comparisons was 413 nucleotides, and
that of the V1/V2 region was 297 nucleotides. An unrooted phylogenetic tree for
all 85 pl7-mx nucleotide sequences and 99 V1/V2 nucleotide sequences obtained
from lymph node, brain, and lung samples was constructed by the neighbor-
joining method using the NEIGHBOR program in the PHYLIP package (ver¬
sion 3.5) (12). Distances between each pair of sequences were estimated by using
the DNADIST program in the PHYLIP package (version 3.5) (12). Rooted trees
were constructed for each patient by bootstrap resampling (500 replications)
using the MEGA package with the sequence of HIVMN as an outgroup (25).
Phylogenetic analysis of the env region was confined to regions flanking the VI
and V2 hypervariable regions because of the indeterminate and often arbitrary'
alignment of the hypervariable sequences.
Nucleotide sequence accession numbers. The sequences obtained in this study
have been submitted to GenBank and assigned accession numbers U79785 to
U79869 (gag) and U79870 to U79957 (U1/U2).
RESULTS
Rate of sequence change in pl7A<JA' regions. An unrooted
neighbor-joining tree was constructed by using 85 sequences
from the pl7gas region (positions 835 to 1270 in the HXB2
clone [33]) from a range of lymphoid and nonlymphoid tissues
of three HIV-infected individuals dying from AIDS. The se¬
quences from each of the three study patients were distinct,
grouping separately into three clades. Bootstrap resampling
supported the distinction of three separate groups (Fig. 2).
All three study subjects were infected with HIV through
drug abuse in 1982 or 1983. Previous phylogenetic studies have
implicated a common source of infection for the majority of
drug users in Edinburgh, United Kingdom, including the three
described here (15). The current sequence differences between
!_/-+ nuunu m AL.
FIG. 2. Neighbor-joining tree of sequences from the pi?1'"1' region of the
three study subjects. Bootstrap values indicate the percentages of trees showing
the observed patient-specific groupings.
the study subjects therefore must have originated from a pro¬
cess of divergent sequence change over a period of between 9
and 10 years. By using a mean figure of 9.5 years (or 19 years
of divergent sequence change), the mean synonymous pairwise
distances in thegng region between individual (0.149) indicated
a rate of sequence change of 0.0077 per site per year. The rate
of sequence change between pairs of individuals was similar,
ranging from 0.006 to 0.009 (Table 1; Fig. 3A through C). This
estimate was similar to those obtained in previous studies; For
example, sequence comparisons in the \)llgag region of plasma
RNA sequences from hemophiliacs infected from a common
source indicated a mean rate of synonymous substitution in
p\Tag of 0.006 to 0.0072 substitutions/site/year (21).
The mean rate of nonsynonvmous substitution between the
study subjects was 0.0058, lower than the silent rate. The mean
dNlds ratio of 0.41 indicated a bias toward silent substitutions
in this region of the gag gene, consistent with previous esti¬
mates (13, 20, 26, 34).
In this study, we also determined the sequences of the VI
and V2 hypervariable regions and flanking regions in the env
region from the three study patients (positions 6560 to 6876).
Between individuals, the mean pairwise synonymous distance
between sequences from the flanking regions (but omitting the
hypervariable regions between positions 6623 to 6679 [VI] and
6701 to 6796 [V2]) was 0.104, lower than for the pi7s"* region.
In contrast, the rate of nonsynonymous substitution in the
V1/V2 flanking region was higher (0.083), producing an overall
TABLE 1. Sequence comparisons between study subjects in the
pl7.e«s region
Mean rate of
Patient pair Divf^nce No' °f P™ substhut'on(yr) comparisons sj,em Nonsilent ratio ^
sites sites
P4 and P5 19 960 0.152 0.053 0.35 0.008
P4 and P6 18 736 0.112 0.052 0.47 0.006
P5 and P6 19 689 0.184 0.070 0.38 0.009
All 18.7 795 0.149 0.058 0.39 0.0077
" Based upon infection from a common source in 1982 (see Results).
h Silent substitution rate of sequence change (in substitutions per site per year)
between study subjects.
dN/ds ratio of 0.80, similar to previous estimates for the em-
region (26, 48).
In this study, we used the measured rate of sequence change
in the p]78"8 region at silent sites to estimate the time of
divergence between variants infecting different tissues within
an infected individual. These data should indicate when the
spread of HIV into nonlymphoid tissues occurred (9).
Phylogenetic analysis of variants from different tissues. Phy-
logenetic analyses using sequences from the p\78"8 region and
VI and V2 flanking regions from a range of lymphoid and
nonlymphoid tissues were carried out to determine the reiat-
edness of variants between each tissue (e.g., lymph node, brain,
and lung) (Fig. 4). Bootstrap resampling using 500 replicate
trees was carried out to estimate the robustness of observed
groupings.
In none of the patients was there consistent phylogenetic
grouping by tissue origin. For example, p 1 78"8 sequences from
lymph node samples of patient P4 were found in two distinct
lineages, both of which contained a variety of sequences from
other tissues (lung and spleen) (Fig. 4A). Similarly, sequences
from brain samples were interspersed with those from colon,
lung, and spinal cord samples. In the V1/V2 flanking regions,
there was an even more marked splitting of sequences into
different lineages separated by high bootstrap values (Fig. 4D).
For example, sequences from the brain were found in lineages
a, b, and d, of which the latter two include sequences from
lymphoid tissues (lymph nodes and spleen).
Similar mixing of sequences from lymphoid and nonlym¬
phoid tissues was observed among sequences from the other
two study subjects (Fig. 4B, C, E, and F). For example, p 1 78"8
sequences from both brain and lymphoid tissue samples of
patient P5 were found on lineages a and b, separated from
each other by high bootstrap values (Fig. 4B). In patient P6,
sequences were obtained only from brain and lymph node
samples but each of the lineages contained sequences from
both sources (Fig. 4C and F).
Times of divergence of HIV variants in different tissues.
Pairwise synonymous distances between sequences from the
p\78"8 region from each patient were calculated to estimate the
time of divergence of variants within each tissue. The previ¬
ously established rate of sequence change in the p\78"8 region
of 0.0066 substitutions per site per year was used (20), although
similar results would have been obtained if we had used the
synonymous substitution rate observed in this study (mean of
three study individuals, 0.0077).
Mean synonymous pairwise sequence distances within study
subjects were calculated by comparing sequences from all tis¬
sues with each other, as well as comparisons restricted to
variants found in particular tissues, such as brain, lymph node,
and lung tissues (Table 2; Fig. 3D through F). Comparisons of
variants found in all tissues produced a range of pairwise dis¬
tances from 0.035 to 0.086, approximately a third of the mean
interpatient silent distance. These distances implied times of
divergence of 2.6 to 6.5 years (Table 2).
For all three patients, the mean distance between sequences
from brain tissue was greater than the mean distance between
variants in lymphoid tissue (Table 2; Fig. 5), reflecting their
wide distribution in multiple lineages by phylogenetic analysis
(Fig. 4). For example, the mean synonymous pairwise distances
calculated for brain tissues ranged from 0.054 to 0.086 years
while those for lymphoid tissues ranged from 0.035 to 0.074
years (P < 0.001). These distances translate into approximate
mean divergence times of 4.1 to 6.5 years and 2.65 to 5.6 years
for brain and lymphoid variants, respectively. Overall, se¬
quences between variants found in the brain were no more
similar to each other (0.080 for the three study patients [Table
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FIG. 3. Frequency histograms of silent pairwise distances in the pl7s"s region between study subjects P4 and P5 (A), P4 and P6 (B), and P5 and P6 (C) and within
study subjects between sequences obtained from different tissues of P4 (D), P5 (E). and P6 (F). The median values for distributions are shown in Tables 1 and 2.
2]) than they were to those present in lymphoid tissue (mean
silent pairwise distance between brain and lymph node se¬
quences, 0.070).
Mean nonsvnonymous pairwise distances were also calcu¬
lated and were found to be lower than the distances at silent
sites only. Nonsynonymous distances calculated for brain tissue
ranged only from 0.010 to 0.042 years and were higher than
those observed between variants in lymphoid tissue of the
three study individuals (0.012 to 0.020; P < 0.001). Subse¬
quently, these values produced dN/ds ratios of between 0.158
and 0.49 for brain tissue only and between 0.16 and 0.46 for
lymphoid tissue only, similar to those observed previously for
interpatient comparisons. These ratios indicate that most of
the substitutions which occurred within an individual in the
pil8"* region were silent.
DISCUSSION
Rate of sequence change of HIV in vivo. In this study, we
used published rates as well as estimates based upon the se¬
quences recovered from the study patients to estimate the
times of divergence of variants infecting different tissues in
vivo. Measurement of the rate of sequence change was possible
for the study patients because it was known that all three
patients were originally infected with HIV from a common
source in an outbreak around 1982 or 1983, so each was in-
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FIG. 4. Phyiogenetic analysis of sequences obtained from different tissues of
the three study subjects (P4 [A and D], P5 [B and E], and P6 [C and F]) in
different subgenomic regions (pl7s"fi region [A through C] and VlA/2 flanking
regions [D through F]). Trees are shown in rooted form, with the unrelated
subtype B sequence of HIVMN as an outgroup. Bootstrap values of >75% for
branches are in bold. Symbols: +, brain; ♦. spinal cord; •. lung; ■. colon: □,
lymph node; O, spleen.
fected for approximately 9 or 10 years prior to death. There¬
fore, between any two individuals, there were approximately 19
years of divergent sequence change. Synonymous rates of sub¬
stitution were calculated for each patient in pi?8"* (Table 1)
and ranged from 0.006 to 0.009 substitutions per site per year
(mean, 0.0077), while the rate for the V1/V2 flanking regions
was slightly lower (mean, 0.0056 substitutions per site per
year).
One assumption that must be made when calculating times
of divergence from sequence distances is that the rate of se¬
quence change remains constant throughout the course of in¬
fection, and there is little direct evidence of whether this is
justified. Although higher levels of virus replication clearly
occur later in the course of disease, this does not necessarily
imply that the rate of sequence change should be higher. The
rate of sequence change is proportional to the number of
replication cycles, whose length is determined by the replica-
tive processes within the cell, unless a substantial proportion of
the sampled population originates from virus that has reacti¬
vated from latently infected cells, where viral replication may
not have occurred for several years.
Empirically, however, the rate of sequence change at silent
sites in pl7*"* over the first 2 years of infection in hemophiliacs
(0.0066 per site per year [20]) was similar to that observed in
the study patients (0.0077), in which the period of infection was
9 or 10 years, covering primary infection to death from AIDS.
These figures are in turn within the range of rates of change
estimated for viral isolates from several other studies (13, 26,
48).
Although the rate of nonsilent sequence change in the gag
region was lower than the synonymous rate, times of diver¬
gence based on nonsilent sites were similar to times of diver¬
gence of variants in different tissues (mean time of divergence
of variants within each subject, 3.1 years, compared with 3.7
years by using the published rate of silent sequence change in
pl78"* [20]). This is in spite of the theoretical possibility that
the rate would be affected by phenotypic selection of variants
with changes in the pl7*"* region.
By using the mean synonymous rate of substitution for
pl7*"*of 0.0066 substitutions per site per year (20), the average
time of divergence between brain and lymph node variants
within an individual patient were calculated (Table 2) and a
range of 3.5 to 6.5 years was obtained. In lymphoid tissue, the
mean diversity of gag sequences implied an approximate pop¬
ulation age of 2.65 to 5.6 years, while those infecting the brain
were significantly more variable, suggesting an even earlier
time of diversification (4.1 to 6.2 years). Despite the large
potential inaccuracies in calculating times of divergence based
upon sequence distances, it is clear that compared with the
total duration of infection within these patients (9 or 10 years),
the observed diversity within brain tissue suggests infection
relatively early in the course of HIV infection and clearly
preceding the onset of AIDS in two of the three study individ¬
uals (Fig. 1).
Organ-specific differences of HIV in the V3 region. Popula¬
tions of HIV variants infecting different tissues in vivo are
generally distinct in the V3 hvpervariable region of env (1, 23.
37) including the three study patients in the current study (8).
For example, for P5, none of the V3 sequences of either the
major population (15 of 17) or minor population (2 of 17)
found in the brain were found among those from lung, periph¬
eral blood mononuclear cell, and lymph node samples; these
tissues were dominated by a variant with a substitution at
position 28 (35 of 42). Similarly, for P6, variants in the brain
were uniform and differed from lymph node variants in all but
one case by 1 to 3 amino acids. The diversity of sequences in
the V3 region of P4 made comparison more difficult, but again
, the main variants in the brain (14 of 17) were not found in
peripheral blood mononuclear cell or spleen samples (n = 16)
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TABLE 2. Sequence comparisons of variants from different tissues in the p!7A'"A' region
Paticnt(s) Tissue typc(s)
No. of
Silent sites Nonsilenl sites
sequences Mean distance Mean divergence (yr) P" Mean distance I" r/N/(fsratio
All All 75 0.049 3.72 0.019 0.390
Brain 35 0.080 6.06 0.031 0.390
Lymph node 21 0.055 4.20 <0.001 0.081 <0.001 0.270
Lung 15 0.049 3.72 <0.001 0.013 <0.001 0.270
P4 All 20 0.042 3.18 0.018 0.430
Brain 7 0.054 4.10 0.010 0.185
Lymph node 7 0.035 2.65 0.004 0.016 0.002 0.460
Lung 6 0.070 5.30 0.058 0.013 0.184 0.190
P5 All 30 0.045 3.40 0.020 0.440
Brain 13 0.082 6.20 0.023 0.280
Lymph 6 0.048 3.60 0.069 0.020 0.533 0.420
Node
Lung 11 0.043 3.25 <0.001 0.015 <0.001 0.350
P6 All 23 0.061 4.60 0.020 0.330
Brain 15 0.086 6.50 0.042 0.490
Lymph node 8 0.074 5.60 0.113 0.012 <0.001 0.160
" Significance of difference between pairwise distances among brain variants compared with those in other tissues by nonparamctric K.ruskall-\Vallis test.
or. with a single exception, in lymph node samples (15 sequenc¬
es).
On the basis of this apparent tissue-specific distribution of
variants in V3, it has been suggested that these population
differences have adaptive significance and reflect different tro-
pisms for the different infected cell types in different tissues.
The involvement of V3 would be consistent with the previous
observation of its role in determining the ability of HIV to
replicate in different cell types in vitro (29). Within macroph-
agetropic isolates, an acidic amino acid or alanine was predom¬
inantly seen at position 25, while a basic or uncharged amino
acid at this position was associated with nonconservative basic
amino acid substitutions at positions 11, 24, and 32, correlating
with T-cell tropism, consistent with the findings of other stud¬
ies (5, 18, 19, 31, 41, 42, 47). Extending this work, Power et al.
(37) compared cloned sequences from the brains and spleens
of demented and nondemented patients and found evidence
for specific amino acid substitutions at two positions in the V3
loop (histidine at position 305 and proline at position 329) that
correlated with neurotropism and the clinical expression of
HIV dementia. However, while other studies have also found
populations infecting the brain separate from those infecting
lymphoid tissues, there appear to be no conserved features of
the V3 loop that correlate with neurotropism (7,10, 21. 23, 27,
39).
Furthermore, there is no evidence for a correlation between
tissue distribution with the predicted phenotype of such V3
sequences in vitro. For example, in our previous study of the
three study patients and others (8), we found that each tissue
was predominantly infected with variants with a predicted non-
syncvtium-inducing (NSI)- or macrophagetropic phenotype,
regardless of tissue origin. In these cases, the observed amino
acid differences between brain and lymphoid tissues were rel¬
atively few and probably unlikely on their own to alter the
phenotype of the virus (8) (see below).
Other studies support the conclusion that the V3 region is to
some extent involved in tissue tropism but that interaction with
other regions in the HIV-1 genome is required for infectivity
(3, 4. 22, 44). Stamatos and Cheng-Mayer (44) have suggested
that mutations altering the structure of the V3 loop can affect
the conformation of gpl20 and that in turn the structure of the
V3 loop is influenced by the conformation of other regions in
gpl20. Carrillo and Ratner (3) have suggested that an inter¬
action of the V3 loop with a small region of the C4 domain is
required for infectivity of Jurkat T-cell lines, and previous
studies have suggested a similar association (30,32,49). There¬
fore, although it is universally accepted that restricted variabil¬
ity exists in the V3 loop of HIV-1 gpl20, there is no universal
interpretation of this observation.
Multiple evolutionary lineages in pl7s<w and VVV2 regions.
Given the previously observed organ-specific populations in
the V3 region, we were surprised to find a different relation¬
ship between variants when sequences elsewhere in the ge¬
nome were compared. In both pl7s"s and V1/V2 flanking re¬
gions, we observed numerous independent lineages containing
sequences from nonlymphoid tissues such as the brain and lung
mixed with those from lymphoid organs. Some of these group¬
ings were confirmed by bootstrap resampling analysis (Fig. 4).
Comparison of the actual VI and V2 sequences showed a
pattern of sequence variability between tissues similar to that
of the flanking regions and without evidence of tissue-specific
groupings; these data are the subject of a further study (17a).
There are at least three possible explanations for differences
in grouping in different regions of the genomes; these include
(i) different rates of sequence change in different tissues, (ii)
convergence, and (iii) recombination and are reviewed below.
The first hypothesis, originally proposed by Korber et al.
(23), is based upon the principle that infection of nonlymphoid
tissue such as the brain occurs early in the course of infection
at a time when the viral population is relatively homogeneous
in the V3 region. Therefore, variants infecting the brain would
be initially similar to variants infecting nonlymphoid tissues.
Subsequently, as disease progresses, variants found in lym¬
phoid tissues may undergo more rapid sequence change in V3
and elsewhere in the genome associated with population re¬
placements arising from immune escape or antiviral treatment.
For example, variants resistant to neutralization or to antivirals
such as zidovudine would outgrow other variants present
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FIG. 5. Distribution of pairwise distances in different tissues from the three
study patients at silent (A) and nonsilent (B) sites in the pl7s"y region.
within the lymphoid tissue. Rapid turnover and population
replacements may be facilitated by the continuous movement
of lymphocytes and other susceptible cells through lymphoid
tissue. The previously estimated high rate of turnover of HIV-
infected lymphocytes (14, 46) after antiviral treatment is con¬
sistent with the existence of a relatively dynamic lvmphoid-cell
population, whereas at least for antiviral resistance, the brain
population is not (44a).
Alternatively, variants infecting lymphoid cells may be sub¬
ject to more rapid changes over time associated with changes in
the V3 region that determine the shift in the phenotype of HIV
upon disease progression. Variants in the brain, however, may
be unable to undergo such radical changes in the V3 region
due to the continued strict requirements for replication in cells
of the brain that are largely monocyte-derived cells, i.e., infil¬
trating macrophages and microglial cells (38, 45). The survival
of the original infecting population in the brain and its replace¬
ment in lymphoid cells would explain the former's greater
diversity in all parts of the genome other than those that
determine tropism and the observed organ-specific differences
in V3 populations. This hypothesis implies early entry of HIV
into the brain, and although the V3 region is involved in tro¬
pism, it is not in the simple way it has been previously imag¬
ined.
It is possible to account for the organ-specific populations in
V3 by other processes that do not necessarily imply early entry
into the brain. For example, the organ-specific similarities in
V3 sequences among variants that are not closely related in
evolutionary terms could have originated from a process of
strong convergent evolution, whereby the V3 sequence deter¬
mines the ability of variants to grow in different cell types.
Independent evidence for the existence of positive selection
leading to convergence in V3 has been obtained from a study
of hemophiliacs infected from a common source, who showed
similarities in the pattern of sequence change in the V3 region
in different individuals (20). Similarly, a longitudinal study of a
single infected individual showed several independent occur¬
rences of certain amino acid changes in the V3 loop in variants
forming two evolutionarily distinct lineages (16).
It is unlikely that the V3 loop could be the sole determinant
of tropism, as the differences between populations infecting
brain and lymphoid tissues are often trivial and would be
unlikely on their own to affect the phenotype of the virus. For
example, all variants in the brain of P5 differed from those of
lymphoid tissue at only one position (position 28), where a
glutamate replaced an aspartate, a conservative amino acid
change. Evidence for the functional equivalence of these two
residues at this position can be inferred from their approxi¬
mately equal distribution in isolates of the NSI phenotype and
among variants infecting a range of tissues collected at autopsy
from these and other individuals (7, 10, 21, 23, 27, 37, 39).
Furthermore, if convergence were the explanation for the or¬
gan-specific grouping of V3 sequences,' we might expect to
observe general similarities between variants infecting specific
tissues from unrelated HIV-infected individuals. However,
apart from one study (37), it has generally proved impossible to
demonstrate any specific conserved sequence or motif in V3 or
elsewhere in env that correlates with the type of cell infected
(see above). On the other hand, as noted above, it is possible
that the actual V3 sequence required for replication in differ¬
ent cell types may depend upon interactions between V3 and
other regions of env so that different V3 sequences may evolve
to carry out equivalent functions in different HIV strains.
The other mechanism for different relationships in different
parts of the genome is recombination, where a requirement for
specific V3 sequences that confers an ability to infect different
tissues may favor recombination with an already divergent
preexisting population either within or without the tissue
where the variants are found. Recombination occurs fre¬
quently in retroviruses, including HIV-1, and is a mechanism
by which genetic variation can be increased (6). Recombina¬
tion requires that multiple infection of cells occurs, and al¬
though there is evidence that this may occur in vitro (24, 40),
the scarcity of HIV-infected cells in brain and other tissues
seems to suggest that it may be an unlikely event in vivo.
However, it is possible that recombinants are generated else¬
where, where high levels of replication occur (e.g., in lymphoid
tissue), producing variants that are uniquely able to enter and
replicate within the central nervous system.
Whether the similarities in V3 originated from convergence
or recombination, these hypotheses suggest that the observed
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diversity of variants within brain tissue could have originated
by a process of multiple entry from sources outside the central
nervous system. Therefore, the actual duration of infection in
the brain may be substantially shorter than can be calculated by
estimating its population diversity. Indeed, the grouping of
variants from brain and lymphoid tissues by phylogenetic anal¬
ysis of the pl7s"s and V1/V2 flanking regions is evidence for a
process of multiple entry. On the other hand, this hypothesis
does not easily explain how populations in the brain should be
consistently more diverse than those in lymphoid tissue or
other presumed sources of infection in the brain (Fig. 5). The
observed greater diversity of pl7*"s sequences in the brain is
more consistent with the first hypothesis of a lower rate of
population replacement in the brain compared with that in
lymphoid tissue.
In summary, the main findings of this study were the obser¬
vation of an unusually diverse population of HIV variants in
the brain without evidence for any closer evolutionary relation¬
ship between them than to variants infecting other tissues in
the body. Although late entry of recombinant viruses is a pos¬
sibility, it is more likely that viral entry into the brain occurs
relatively early in the course of disease, based upon observa¬
tions of its higher diversity in the brain than in other tissues
and the existence of multiple evolutionary lineages containing
sequences from the brain. These findings suggest that the loss
of immune competence is not solely required for entry into
nonlymphoid tissue, and the strong association between HIV-
induced neuropathology and disease progression may be con¬
sequent to reactivation rather than de novo infection of the
central nervous system. The finding of variants in the brain on
several different evolutionary lineages challenges the hypoth¬
esis of the evolution of a uniquely neurotropic strain. It is
possible that the only requirement for infection of the brain is
macrophage tropism and hence the possession of a V3 loop
sequence that is of low charge and shows few differences from
the subtype B consensus sequence (8).
This study represents the first attempt to use evolutionary
analysis of variants infecting different tissues. The finding of
different interrelationships between variants in different parts
of the genome, combined with uncertainty about the frequency
and site of recombination in vivo and the selection pressures
that could produce convergent evolution in V3, highlights the
complexity in trying to understand the dynamics of HIV rep¬
lication and dissemination to different tissues. However, this
research at least provides a starting point for a more rigorous
examination on the existence of HIV tropism in vivo.
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The distribution, cell tropism, and cytopathology in vivo of human immunodeficiency virus (HIV) was
investigated in postmortem tissue samples from a series of HIV-infected individuals who died either of
complications associated with AIDS or for unrelated reasons while they were asymptomatic. Proviral sequences
were detected at a high copy number in lymphoid tissue of both presymptomatic patients and patients with
AIDS, whereas significant infection of nonlymphoid tissue such as that from brains, spinal cords, and lungs
was confined to those with AIDS. V3 loop sequences from both groups showed highly restricted sequence
variability and a low overall positive charge of the encoded amino acid sequence compared with those of
standard laboratory isolates of HIV type 1 (HIV-1). The low charge and the restriction in sequence variability
were comparable to those observed with isolates showing a non-syncytiutn-inducing (NSI) and macrophage-
tropic phenotype in vitro. All patients were either exclusively infected (six of seven cases) or predominantly
infected (one case) with variants with a predicted NSI/inacrophage-tropic phenotype, irrespective of the degree
of disease progression. p24 antigen was detected by immunocytochemical staining of paraffin-fixed sections in
the germinal centers within lymphoid tissue, although little or no antigen was found in areas of lymph node
or spleen containing T lymphocytes from either presymptomatic patients or patients with AIDS. The
predominant p24 antigen-expressing cells in the lungs and brains of the patients with AIDS were macrophages
and microglia (in brains), frequently forming multinucleated giant cells (syncytia) even though the V3 loop
sequences of these variants resembled those of NSI isolates in vitro. These studies indicate that lack of
syncytium-forming ability in established T-cell lines does not necessarily predict syncytium-forming ability in
primary target cells in vivo. Furthermore, variants of HIV with V3 sequences characteristic of NSI/
macrophage-tropic isolates form the predominant population in a range of lymphoid and nonlymphoid tissues
in vivo, even in patients with AIDS.
There are several interpretations of the high degree of
observed sequence diversity between published sequences of
the envelope gene of human immunodeficiency virus type 1
(HIV-1) (subtype B) (54) and of the rapid turnover of HIV
envelope variants within infected individuals (69, 79). It has
been suggested that changes in the hypervariable domains in
the env gene (VI to V5) (52, 70, 78) may facilitate evasion of
the host immune system. This conclusion is supported by the
observation that V3 and possibly other regions are targets of
neutralizing antibodies elicited by natural infection or upon
immunization with recombinant gpl20 protein (20, 26, 32, 44,
49, 60).
However, changes in the V3 loop, and more recently in the
VI and V2 hypervariable domains, have also been shown to
influence the phenotype of variants of HIV-1 in in vitro culture
(2, 6, 11, 19, 24, 31, 72, 73). In particular, substitutions of basic
amino acids in the V2 and V3 regions change virus isolates
from non-syncytium-inducing (NSI) isolates to syncytium-in-
ducing (SI) isolates (11, 19, 24) and may confer a reduction in
* Corresponding author. Mailing address: Department of Medical
Microbiology, University of Edinburgh, Medical School, Teviot Place,
Edinburgh EH8 9AG, United Kingdom. Phone: (44) 31 650 3138. Fax:
(44) 31 650 6531.
the ability of the virus to replicate in macrophages (10, 64).
Apart from the association with arginine or lysine at positions
11 and 28 in V3, the SI phenotype has been also been shown to
correlate with increased V3 sequence heterogeneity in this
region (10, 51). V3 sequences from NSI isolates show few
sequence differences from each other or from a consensus
sequence of 133 North American isolates (40) that comprise
predominantly subtype B variants of HIV-1 (46). In contrast,
SI isolates show a broad range of substitutions, insertions, and
deletions at most positions (30 of a total of 33 to 37) between
the disulfide-bridged cysteine residues of the putative V3 loop
structure.
In early infection, HIV variants with an NSI/macrophage-
tropic (MT) phenotype predominate. Subsequently, approxi¬
mately half of those individuals who progress to AIDS show a
change in virus to a more rapidly replicating (rapid/high) and
cytopathic phenotype (3, 8, 18, 74); this switch in phenotype
has been reported to precede an accelerated loss of CD4
lymphocytes in the peripheral circulation and a more rapid
onset of AIDS than in those individuals whose isolates retain
the NSI phenotype (35). However, although most investigators
have found a close association between the properties of
syncytium induction and inability to replicate in macrophages
in vitro and vice versa (10, 12, 19, 23, 37, 63, 64, 87), others
5991
5992 DONALDSON ET AL. J. Virol.
have found that disease progression is associated with a switch
from NSI, non-MT isolates to SI/MT isolates (8).
Despite their more aggressive phenotype in vitro, the SI
isolates are less transmissible by sexual contact than are NSI
isolates (59, 87), but they are equally transmissible in cases of
mother-to-child transmission (62). To explain these apparently
contradictory findings, it has been speculated that macro¬
phages may be the first cells infected at the mucosal barrier in
the case of sexual transmission and that infection of this cell
type is responsible for the systemic dissemination of the virus
found upon primary infection (87). However, V3 sequences
typical of NSI isolates were also found to be specifically
selected for not only upon sexual contact but also in several
cases of parenteral infection (hemophiliacs exposed to HIV-
contaminated factor VIII concentrate) in which case the
initially infected cells could equally well be CD4+ lymphocytes
(85).
An important limitation of many of the previous studies of
sequence and phenotype change of HIV-1 is the reliance upon
patient blood samples as sources of virus isolates, proviral
DNA, or virion RNA as study material. However, HIV results
in systemic disease and has been shown to be capable of
infecting a wide variety of nonlymphoid tissue, including tissue
from brain, lung, and the small and large bowel (reviewed in
reference 41). It cannot be assumed that variants in blood are
representative of populations infecting other cell types in the
body. For example, isolates from brain and bowel tissues show
in vitro properties different from those derived from peripheral
blood mononuclear cells (PBMCs); the latter tend to replicate
well in macrophages and to show an NSI phenotype (25, 36,
76). In some cases, sequence differences between populations
of variants in brain tissue and those in circulating lymphoid
cells have been observed (16, 25, 33, 42, 43, 57, 71). The extent
to which sequence changes are responsible for the differences
in in vivo tropism is discussed below.
Given the evidence for changes in the in vitro phenotype of
virus isolated from PBMCs at different stages of disease
progression, it is clearly important to investigate whether
equivalent changes occur in virus populations outside the
peripheral circulation. By carrying out detailed quantitative
studies of postmortem tissue, we have recently found a highly
restricted distribution of HIV in the body preceding the onset
of AIDS, with proviral sequences apparently confined to cells
of the lymphoid system (PBMCs, spleen, and lymph nodes). In
contrast, those patients who died from complications associ¬
ated with AIDS showed significant infection of cells in the
central nervous system (CNS) and in lung and bowel tissues
(13). These results confirm a previous study in which HIV
infection was undetectable in the CNS of a large number of
individuals who died while they were asymptomatic (5).
This apparent redistribution of virus upon disease progres¬
sion occurs at the same stage of disease as the change from an
NSI to an SI phenotype. Paradoxically, while isolates become
cytopathic and often non-MT in vitro, the redistribution of
HIV in vivo involves organs such as brains and lungs and other
tissues in which the main targets of infection are reported to be
tissue macrophages, microglia (in the CNS), and other non-
lymphocyte cell types (22, 34, 47, 55, 77).
In this study, we have carried out detailed sequence com¬
parisons of the V3 loop and flanking regions of virus variants
in lymphoid and nonlymphoid tissues from a series of individ¬
uals who died while asymptomatic or as a consequence of
terminal AIDS. The inferred in vitro phenotypes were com¬
pared for individuals with differing degrees of disease progres¬
sion and for different tissue types in order to explore the
relationship between V3 variation and tissue tropism of HIV in
vivo. In many cases it was possible to directly identify the target
cells and degrees of associated cytopathology in different
tissues (in vivo phenotype) by immunocytochemical staining of
the tissues with an anti-p24 monoclonal antibody.
MATERIALS AND METHODS
Patient samples. Cardiac blood and tissue from various
organs were obtained within 3 days of patient death from 11
autopsied HIV-infected patients of whom three (patients 1 to
3) died suddenly while they were in the asymptomatic stage of
HIV infection as defined by Centers for Disease Control
criteria and four patients (patients 4 through 6 and patient 9)
who died with AIDS-defining illness. Additional lymph node
samples were obtained from four further patients who died of
complications associated with AIDS (patients 10 through 13)
for further sequence comparisons of sequences in the V3 and
gag regions. Clinical information and laboratory investigations
pertaining to patients 1 to 6 have been detailed as part of an
earlier study (13). Patient 9 was a 59-year-old male with a
recent history of psychomotor slowing. One week prior to
death he developed a fatal atypical pneumonia, at which time
a diagnosis of full-blown AIDS was made. He received no
antiviral treatment, and the duration of his infection is un¬
known.
Samples of brain (left frontal lobe), spinal cord (mid-
thoracic), lung, large bowel, mesenteric lymph node, and
spleen tissues from these patients were dissected into 1- to
2-cm pieces and were stored at — 70°C. DNA was extracted
from tissues and whole blood to obtain total DNA from all
nucleated cells in the circulation (peripheral blood nucleated
cells [PBNCs]) as previously described (68).
Quantitation. Proviral DNA was quantified by using a
previously described limiting dilution and nested-primer PCR
approach (68). The quantitation was performed in the first
instance by using primers corresponding to the pol gene and
was performed subsequently with primers spanning the V3
region. The nucleotide sequences of the primers and the
position of the 5' base in the HXB2 genome (54) were pol a
CATGGGTACCAGCACACCGG, + (sense), position 4149;
pol b GGAGGAAATGAACAAGTAGATA, +, 4175; pol c
TCACTAGCCATTGCTCTCCAATT, - (antisense), 4290;
pol d TCTACTTGTCCATGCATGGCTTC, - ,4380; V3 e TA
CAATGTACACATGGAATT, +, 6957; V3 f TGGCAG
TCTAGCAGAAGAAG, +, 7009; V3 g CTGGGTCCCCTC
CTGAGG, -,7331; and V3 h ATTACAGTAGAAAAATTC
CCC, -, 7381.
All reactions were performed with appropriate positive and
negative controls. The number of proviral copies was estimated
by assuming a Poisson distribution for each sample by
— log(l —p)ld (where p = proportion of positive samples and d
= dilution). Likelihood ratio tests were used to determine
whether there were significant differences between sample
pairs. The likelihood function is proportional to [1— exp(A.tf)]'"
X [exp(—V/)]", where X = number of proviral copies, m =
number of positive replicates, and n = number of negative
replicates. Ninety-five percent confidence intervals for each
sample were determined by evaluating the likelihood function
incrementally over the range of possible values for the number
of proviral copies. The overall level of agreement between the
pol and env primers was assessed by using the paired t test on
the basis of the numbers of proviral copies on a log scale.
Sequence analysis. Single molecules of HIV-1 provirus were
isolated by limiting dilution and amplified in a nested PCR to
produce sufficient DNA to allow direct sequencing of the PCR
products. Direct sequencing of amplified DNA was achieved
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TABLE 1. Quantitation of proviral sequences in postmortem tissue by limiting dilution using nested primers in the pol and V3 regions:
frequency of positive results at specified dilutions of DNA
Frequency'' of positive results
Patient Primer" Lymphoid tissue Nonlymphoid tissue
Lymph node Spleen PBNCs Brain Spinal cord Lung Colon
Presymptomatic
1 E 9/20 (IE-3)" 4/20 (IE-3) 12/20 (1E-2) 0/20 (5E-1) 3/20 (5E-1) 0/20 (5E-1) 0/20 (5E-1)
P 19/60 (5E-4) ND17 18/25 (2E-2 ND ND ND ND
2 E 14/20 (IE-3) 12/20 (1E-2) 7/20 (IE-3) 2/20 (5E-1) 15/20 (5E-1) 6/20 (1E-1) 10/20 (1E-1)
P ND ND 20/50 (2E-3) ND ND ND ND
3 E 9/20 (1E-1) 7/20 (1E-2) 9/20 (1E-2) 3/20 (5E-1) 3/20 (5E-1) 3/20 (1E-1) 6/20 (5E-1)
P 2/20 (5E-2) ND 8/30 (1E-2) ND ND ND ND
Symptomatic
4 E 14/20 (5E-3) 3/20 (IE-3) 5/20 (1E-2) 3/20 (1E-2) 7/20 (1E-2) 18/20 (1E-2) 17/20 (1E-2)
P 19/30 (6E-3) 16/30 (5E-3) 21/50 (5E-2) 17/50 (2E-2) 10/25 (1E-2) 14/49 (2E-3) 18/30 (6E-3)
5 E 17/20 (IE-3) 4/20 (IE-3) 7/20 (1E-1) 4/20 (IE-3) 11/20 (1E-4) 17/20 (53-3) 7/20 (1E-1)
P 41/50 (1F.-3) ND 23/50 (1.5E-1) 16/50 (IE-3) ND 14/50 (8E-4) ND
6 E 15/20 (1E-2) 19/20 (1E-2) 4/20 (5E-1) 12/20 (1E-2) 10/20 (1E-1) 11/20 (1E-1) 11/20 (IE-3)
P 23/50 (5E-3) ND 1/20 (5E-2) 14/50 (4E-3) ND ND 12/50 (8E-4)
9 E 7/50 (2E-2) ND ND 22/49 (2.5E-4) ND ND ND
P ND ND 03/(1)" ND 2/3 (1E-2)" 0/3 (1)" 0/3 (1)"
" E, env primer quantitation; P, pol primer quantitation.
h Expressed as number positive/total number.
"Test dilution (in micrograms); IE-3 = 1 X 10 3 pg.
d ND, not done.
* p24!"'i; quantitation.
either as previously described or by using a solid-phase se¬
quencing method (30). For solid-phase sequencing, the second
PCR reaction was performed in a 100-p.l volume by using one
biotin-labelled and one unlabelled primer (5 to 10 pmol of
primer per reaction mixture), generating a PCR product with
one strand having a biotin moiety at the 5' end. PCR products
were immobilized on streptavidin-coated magnetic beads (Dy-
nal), and single strands of DNA were purified by magnetic
separation and were sequenced according to the manufactur¬
er's protocol.
A Fisher's exact test for 2 X n contingency tables (48) was
used to compare amino acid frequencies at each position in the
V3 loop (n is the number of alternative amino acids at a single
position). The test is based on exact multinomial probabilities
and is appropriate here because many values in the contin¬
gency tables were small. Comparisons of V3 loop charge and
diversity were made between sequences obtained in this study
and those of a series of isolates of HIV-1 of known biological
properties. V3 loop sequences of 30 isolates with an SI
phenotype and 29 NSI/MT isolates were obtained from refer¬
ences 10 and 19, as were corresponding sequences from MN,
RF, SF2, GUN-1, HAN-2, SF33, LAI, ADA, YU2, SF162,
JF-L, and SF-128A isolates (51, 54).
Evolutionary analysis of pl7 sequences. Sequence compar¬
isons between viruses from the 11 study patients were made in
the region of the gag gene encoding pi7, as previously de¬
scribed (29). Phylogenetic relationships between single nucle¬
otide sequences from each of the study patients and from
representative sequences obtained both in Edinburgh, United
Kingdom (29a), and from other widely separated geographical
localities (54) were estimated by using the neighbor joining
method with a bootstrap resampling program (PHYLIP pro¬
grams SEQBOOT, DNADIST, NEIGHBOR, and CON-
SENSE) (17). Branch lengths on this tree were estimated by
using the maximum-likelihood method (DNAML). Nucleotide
distances between sequences were estimated by using the
substitution model of Felsenstein (program DNADIST).
Immunocytochemical staining. Five-micrometer sections of
formalin-fixed paraffin-embedded tissue from the study organs
were stained with hematoxylin and eosin by standard methods.
p24 antigen was detected by an avidin/biotin immunocyto¬
chemical technique (5) with a monoclonal antibody to p24
(Dupont) as first antibody at a dilution of 1/200 and diantino-
benzidine as the visualizing agent. Prior to antibody incuba¬
tions, the sections were irradiated in an 800-W microwave oven
for three cycles of 5 min each while they were immersed in 0.01
M citrate buffer (pH 6.0) (Fisons).
Nucleotide sequence accession numbers. Sequences ob¬
tained in this study have been deposited into GenBank and
have accession numbers L34422 to L34541.
RESULTS
Quantitation of proviral load in different organs. The
numbers of copies of provirus per million cells in a range of
lymphoid and nonlymphoid tissues from the study patients
were determined by limiting-dilution PCR with primers from
both pol and env regions of the genome (Table 1; results
obtained with the pol primers for patients 1 to 6 have been
previously reported) (13). We found high levels of HIV in
lymphoid organs (spleen and lymph node) from all presymp-
tomatic and symptomatic individuals with both sets of primers,
whereas nonlymphoid organs were infected only in patients
who died of complications associated with AIDS. Although low
levels of provirus were found in many of the nonlymphoid
tissues of the presymptomatic patients (up to 46 copies per 10''
cells; Table 2), such virus may have originated from PBNCs in
residual blood within the organs (forming between 1 and 10%
of the extracted DNA from the tissue, depending on its
vascularity), as previously discussed (13). For example, the
sample of colon tissue from patient 2 contained 46 copies of
provirus per 10'' cells, 60 times lower than the frequency of
infected cells in peripheral blood (2,843 copies per 10'' PBNCs)
and attributable to the presence of peripheral blood in the
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postmortem tissue. In contrast, the majority of organs from the
patients with AIDS showed high levels of provirus, consistent
with actual infection of cells within the tissue by HIV. Only
samples with clear evidence of infection by these criteria were
used for comparisons of sequences in the env gene (see below).
The accuracy of quantitation by limiting dilution is depen¬
dent on the number of replicates tested and the frequency of
positive reactions. We calculated the confidence intervals for
quantitation with pol and env primers by evaluating the likeli¬
hood function for each sample (see Materials and Methods)
and found that there was no statistically significant difference
between the primers for any of those tested (Table 2). When
the samples were taken together, the frequency of provirus
quantified with env and pol primers showed a ratio of 1.18
(confidence interval, 0.94 to 1.48; Fig. 1). The correlation
coefficient for quantitation with the two sets of primers was
0.96 (P = 0.0001), and there was no evidence for an over- or
underrepresentation of env or pol sequences in either lym¬
phoid or nonlymphoid tissue. These results indicate that the
V3 primers are as efficient as pol primers in amplifying HIV
and that we did not amplify only a specific subset of variants in
our subsequent sequence comparisons (see Discussion).
Sequence variation in the V3 loop. DNA extracted from
different organs or from PBNCs was diluted until only 10 to
20% of replicates gave a PCR product, thus ensuring that
nucleotide sequences were derived from single molecules of
provirus (68). The lack of peripheral infection in the asymp¬
tomatic group restricted our sequence comparisons to virus
within lymphoid tissue only (PBNCs and lymph node). For the
patients who died of complications associated with AIDS, we
were able to carry out more extensive comparisons with a
range of samples from nonlymphoid tissues, such as those from
brain and lung tissues (Table 2). None of the 322 nucleotide
sequences in the V3 loop or flanking regions contained inac¬
tivating substitutions such as stop codons or frameshifts. Only
one sequence (from lymph node tissue from patient 3) showed
G^-A hypermutation, producing a highly unusual and proba¬
bly nonfunctional provirus. Like previous researchers who
used the limiting-dilution/direct-sequencing method of se¬
quence determination (4, 68, 85), we have found no evidence
for high rates of defective genomes in vivo.
In the asymptomatic patients, a wide range of sequence
variants were found in both PBNCs and lymph nodes (Fig. 2).
In patients 1 and 3 there were statistically significant differ¬
ences in the frequency of major and minor amino acid se¬
quences present in the two types of sample. In these two
patients, the majority form, in the PBNCs, differed from that in
the lymph nodes and vice versa, although in each case such
variants were present as minority components in the other
sample.
There was a similar diversity of V3 sequences as well as of
population differences between samples from the patients who
died of complications associated with AIDS. Extreme se¬
quence diversity in all samples from patient 4 was observed,
while samples from patient 9 were restricted to only two
different sequences in the brain and to three in the lymph
nodes. As with the presymptomatic patients, the frequencies of
different variants between some organs were statistically sig¬
nificant, although a general observation was of a common set
of sequences being present at varying frequencies throughout
the body. For example, for patient 4, the main sequence in the
brain (12 of 17) and spinal cord (6 of 7) also occurred in the
colon (5 of 16), lung (7 of 15), and lymph nodes (1 of 16).
However, there are also variants that appear to be more
restricted in distribution (e.g., the colon of patient 4, the brain
of patient 5, and the colon of patient 6). This type of analysis
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provides no evidence for the existence of a shared determinant
in the V3 loop that governs the distribution of HIV variants.
This problem is compounded by not knowing whether the
different sequences within an organ represent genuine diversity
of HIV in a single cell type, or whether they result from the
presence within the same organ of various proportions of
several different HIV-infected cell types, each bearing different
proviral variants (such as CD4+ lymphocytes, dendritic cells,
and macrophages in the lymph nodes).
To investigate in more detail the process of sequence
diversification of the V3 loop upon disease progression, we
compared the number of different V3 amino acid sequences
found within samples from the presymptomatic patient group
and from the group of patients with AIDS (Table 3). In both
cases, frequent nonidentical sequences were found; the pre¬
symptomatic patients showed a total of 21 different sequences
of 84 sampled, compared with 18 of 92 in lymphoid tissue and
23 of 146 from nonlymphoid tissue in the patients with AIDS.
Similarly, the mean evolutionary distances between nucleotide
sequences in the presymptomatic group (0.042) differed little
from distances between sequences found in the patients with
AIDS (0.038; Table 4). These comparisons also show that little
difference in diversity exists between populations of HIV
infecting lymphoid tissue and those replicating in nonlymphoid
tissue such as that from the brain, lung, and colon (Tables 3
and 4).
Prediction of in vitro phenotype from V3 loop sequences.
There exist well-defined relationships between the properties
of macrophage tropism and syncytium induction on the one
hand, and between the net V3 charge (11, 19) and similarity to
the subtype B consensus V3 sequence (10) on the other hand.
Comparison of the 54 different V3 loop sequences produced a
consensus sequence that was identical in all but one position to
the subtype B consensus (40). There was a striking similarity
between this set of sequences and a sequence set of 29 isolates
characterized in vitro as showing an MT and NSI phenotype,
not only in overall consensus sequence but also in the position
and nature of amino acid substitutions that did occur (Fig. 3).
For example, both data sets contain frequent substitutions of
asparagine (N) and proline (P) for histidine (H) at position 15
and contain either aspartate (D) or glutamate (E) at position
29, with frequent substitutions of alanine (A) or glutamine (Q).
In contrast, V3 loop sequences from a collection of SI
sequences were highly variable and contained a number of
amino acid replacements not found in the other sequences. For
example, residues 7 to 9 are invariant among the postmortem
and NSI/MT sequences but are highly polymorphic in the SI
isolates. Other residues such as that at position 12 show
differences of the consensus sequence (serine [S] in postmor¬
tem and NSI/MT sequences and arginine [R] in the SI
variants). To investigate whether the postmortem sequences
were significantly more similar to those of MT isolates, we
carried out Fisher's exact tests (see Materials and Methods) at
each amino acid position in the V3 loop. Results at each amino
acid position are not independent, so statistical results have to
be interpreted cautiously; values are listed only when P is less
than 0.01. These tests showed that between postmortem and
NSI/MT isolates, there were significant differences in the
populations of amino acids only at positions 16 (P «= 0.003) and
22 (P «= ICR4) (Fig. 4). In contrast, postmortem sequences
differed significantly at several positions from the SI variants,
the most divergent residues being 10 (P < 10~8), 12 (P <
10~8), and 29 (P < 10~6). This statistical evidence supports the
previously observed association between the presence of basic
(arginine or lysine) residues at positions 12 and 29 and the SI
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FIG. 1. Comparison of quantitation of provirus by using pol and V3
primers by limiting dilution (log scales). O, samples extracted from
lymphoid tissue (lymph node, spleen, and PBNCs); •. samples ex¬
tracted from brain, spinal cord, lung, and colon.
sites also occur specifically in the SI variants. There are also
further positions at which SI variants differ considerably from
postmortem and NSI/MT variants (positions 7 to 10, 15, 28,
and 36).
To investigate the relationship between in vitro phenotype
and V3 sequence, we have calculated the overall V3 charge
and the degree of sequence divergence from the subtype B
consensus for a series of isolates with known biological prop¬
erties (Fig. 5a). In agreement with a previous report which
used a similar method for sequence analysis of V3 (51),
NSI/MT isolates consistently showed lower charge, greater
similarity to the subtype B consensus, or both, than did SI and
non-MT variants. A diagonal line almost completely separates
the two populations. Using this analysis to predict the pheno¬
type of variants found in postmortem tissue of presymptomatic
and terminal patients with AIDS, we found that almost all
sequences were located to the left of the dividing line and that
they could therefore be predicted to be of the NSI/MT
phenotype (Fig. 5b and c). Indeed, there was a tendency for
some of the postmortem sequences, particularly those from
nonlymphoid tissue, to show a lower charge and fewer differ¬
ences from the subtype B consensus than did the "typical" NSI
isolate. The only sequences with overall charge and divergence
approaching that of SI variants were some of those found in
patients 3 and 9.
Although the sequences obtained in this study conform
closely to those previously described for MT variants in vitro,
it is possible that the restriction in sequence diversity in V3
was, at least in part, the result of sampling a population of
individuals infected with a very limited subset of H1V-1
variants. To investigate this possibility, we carried out se¬
quence comparisons in the pi?'-'''8 for all of the 11 study
patients. Phylogenetic analysis of sequences in the pi7 region
have been shown to provide a reliable indication of epidemi¬
ological relationships between variants within the same sub¬
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9).AllsequencesarecomparedwithubtypeBns suencfV3(40);perioindica sd ntityitsucons n us;mi uig ptrod cpre rvealignm n withconsensussequ ce,numberfceobserved.
Vol. 68, 1994 RESTRICTED SEQUENCE VARIABILITY OF V3 IN VIVO 5997
TABLE 3. Comparison of sequence variability in the V3 loop upon
disease progression: frequency of different sequences
No. of sequences
Patient type Lymphoid tissue Nonlymphoid Total
Total Unique Total Unique Total Unique
Presymptomatic 84 21 84 21
Symptomatic 92 18 146 23 238 31
Total 176 36 146 23 322 47
TABLE 4. Comparison of sequence variability in the V3 loop upon









Symptomatic 0.038 0.039 0.0385
Total 0.040 0.039 0.040
a Mean evolutionary distance between nucleotide sequences.
No direct epidemiological relationship was found between
viruses infecting the 11 study subjects (Fig. 6). Although many
of the subjects were infected with variants that fell within the
main (heterosexual and intravenous-drug user) cluster of
Edinburgh patients, there was no evidence of direct epidemi¬
ological contact between them. Furthermore, several variants
were separated by those of published isolates of HIV-1 from
North America and elsewhere, suggesting a distant evolution¬
ary relationship between them. This analysis confirms the
clinical impression that the patients in this study were unre¬
lated epidemiologically to each other. However, there was no
phylogenetic information within the V3 region of the env gene:
sequences showed at most six amino acid changes (patient 9)
from the subtype B consensus sequence. All but one V3
sequence (patient 10) is predicted to have an in vitro NSI/MT
phenotype according to the analysis presented in Fig. 5.
Although certain V3 sequences are more divergent than
others, this does not correlate with the underlying phylogenetic
relationships between the corresponding pils"s sequences
within the HIV-1 B subtype.
Localization and cytopathology of HIV-1 in vivo. None of
the previous investigations described in this study identify the
cells infected with HIV. It is therefore not clear whether the
predicted macrophage tropism and NSI phenotype of the
postmortem sequences reflects the tropism and cytopathology
of HIV-1 in vivo. To show this, we performed immunocyto-
chemical detection of p24 antigen to localize the infected cells
in the tissues for which we carried out the sequence analysis.
For nonlymphoid tissue, we found a very good agreement
between the detection of p24 antigen and virus load as
determined by limiting-dilution PCR (Table 5). No p24 was
found in nonlymphoid tissue of any of the presymptomatic
patients, while antigen-expressing cells were frequently found
in the brains, spinal cords, and lungs of several of the patients
with AIDS (Tables 1 and 5). For example, patient 5 showed
high levels of provirus and p24 antigen in several organs, while
antigen-expressing cells in patient 6 were confined to the brain.
The lymph node architecture of the presymptomatic patients
was relatively normal or showed hyperplasia (Fig. 7a), with
none of the evident T-cell depletion, involution, or fibrosis
which is found in the lymphoid tissue of patients with AIDS.
The interpretation of p24 antigen staining in lymph nodes and
spleen was complicated by the presence of extracellular virions
captured on the surface of follicular dendritic cells in the B-cell
areas (Fig. 7b) (15, 58). p24 antigen was confined to cellular
processes of what morphologically appeared to be follicular
POST MORTEM VARIANTS
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FIG. 3. Comparison of sequences obtained in this study from postmortem material (54 different V3 loop sequences from a total of 322) with
those of isolates of HIV-1 showing an NSI and MT phenotype (n = 29). and isolates that are SI and non-MT (n = 30). Position and frequency
(in subscript) of specific substitutions are indicated below the consensus. See Materials and Methods for sources of sequences.
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FIG. 4. Comparison of the distributions of amino acid changes at
each position in the V3 loop between postmortem sequences and those
of NSI/MT isolates (solid line) and those of SIAT-cell-tropic isolates
(dotted line) in vitro. The probability of the distribution of changes
arising by chance is indicated on the y axis on a log scale. Sequences
compared correspond to those shown in Fig. 3.
dendritic cells and was not found in the T-cell areas of either
presymptomatic or terminal patients with AIDS (Fig. 7b). The
failure to detect p24 antigen staining outside the lymphoid
follicles suggests that the provirus-bearing cells in lymphoid
tissue are largely transcriptionally inactive, although the p24
assay used in this study may not be able to detect low-level
expression of virus proteins.
Elsewhere, p24 antigen-expressing cells in vivo were found
in brain (Fig. 7c and d), spinal cord, and lung tissue (Fig. 7f and
h). In brain and spinal cord tissues of patients with AIDS, p24
antigen was detected in multinucleated giant cells (Fig. 7c), in
mononuclear macrophages, and frequently in morphologically
normal microglial cells (Fig. 7d). In general, the presence of
p24 antigen-positive cells was associated topographically with
evidence of tissue damage.
In the lung tissue of patient 4, frequent p24 antigen-
expressing lung macrophages were found, and, as in the brain,
infected cells formed pronounced multinucleated syncytia (Fig.
7f). For this patient, the predominant V3 sequence of provirus
amplified from lung tissue was identical to the major variants
infecting the brain and spinal cord and to a proportion of those
in colon tissue (Fig. 2). However, this sequence was not
represented significantly among sequences of provirus infect¬
ing lymphoid tissue from the same patient. The other patient
who by quantitative PCR (patient 5; Table 1) showed signifi¬
cant infection of the lungs showed a sharply contrasting tissue
distribution of infection. Pathological examination of the lung
revealed prominent lymphocytic infiltration into lung tissue
and formation of poorly formed lymphoid follicles adjacent to
bronchioles (Fig. 7g and h). p24 antigen was detected within
the lymphoid follicles but not elsewhere in the lung despite the
presence of some multinucleated macrophages. In this patient
the population of V3 sequences in lung tissue corresponded
closely to that in lymphoid tissue and was distinct from that of
provirus variants infecting the brain, where infection of mac¬
rophages and microglial cells was prominent (Fig. 2).
DISCUSSION
Restricted sequence variability in the V3 region. An unan¬
ticipated finding in this study was the limited sequence vari¬
ability in the V3 loop of HIV amplified from tissues in vivo.
This restriction was evident irrespective of the degree of
4 5 6
f Charge of V3 loop
f Charge of V3 loop
1 CH
•+- moo«i»ooa □ i \
1 2 3 4 5 6 7 8
+ Charge of V3 loop
FIG. 5. Comparison of V3 loop sequences on the basis of predicted
overall charge (x axis) and number of amino acid changes from the
subtype B consensus (40) (y axis), (a) Fifty-nine isolates of known
phenotype in vitro; O, NSI and MT; • SI, non-MT. See legend to Fig.
3 for sources of sequences. A diagonal line separates the two popula¬
tions. Equivalent analysis was carried out upon the nonidentical V3
loop sequences collected postmortem from three presymptomatic
individuals (b) and four patients who died from complications associ¬
ated with AIDS (c). Origins of sequences: O, PBNCs, □, lymph nodes;
+ , brain; ♦. spinal cord; •, lung; ■, colon. The V3 loop charge was
calculated by assigning a unitary positive charge to arginine and lysine
residues and a unitary negative charge to glutamate and aspartate
residues. The potential partial charge contributed by histidine residues
was discounted.
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TABLE 5. Detection" of p24 antigen in postmortem tissue
Staining result
Patient Lymphoid tissue Nonlymphoid tissue
Lymph
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+ + -
+ + + - -
"Graded from - (negative) to + + + (extensive staining, frequent antigen-
expressing cells).
h ND, not done.
disease progression and tissue origin, whether lymphoid or
nonlymphoid. Both the consensus and observed polymor¬
phisms almost exactly matched those found in a separate
analysis of isolates showing an MT/NSI phenotype in vitro, but
were quite distinct from those of SI variants (Fig. 4). The
infrequency with which variants with a predicted SI phenotype
were detected in vivo contrasts with their frequent isolation
from patients upon disease progression (3, 8, 18, 74). For
example, among the four patients with AIDS in this study, only
two variants were found to show sufficient positive charge and
divergence from the consensus sequence to place over the
dividing line that separates isolates with different properties
(Fig. 5c).
We were able to rule out two possible sources of bias in our
results, i.e., that the primers used for amplification of the V3
loop preferentially amplified NSI variants, and that we were
studying an epidemiological^ very restricted group of patients.
To address the first possibility, we compared quantitation of
proviral sequences by using primers specific for both V3 and
the well conserved pol region. Evaluating the likelihood func¬
tion to determine confidence intervals for the quantitation
method used in this study, we found no significant differences
between virus loads when we used the two sets of PCR primers.
These data make it unlikely that we failed to amplify a
significant proportion of envelope sequences and, indeed, the
close concordance between the results for pol and V3 in every
sample further suggests that each of the sequences analyzed
was derived from a complete provirus (see below).
The second potential bias was addressed by phylogenetic
analysis of pl7sas sequences from the 11 patients from whom
we obtained V3 loop sequences. This analysis suggested that
the individuals were infected with a representative range of
HIV-1 subtype B variants and that the similarities observed in
the V3 loop did not result simply from infection with relatively
homogeneous and possibly epidemiological^ related variants.
The high frequency of variants with a predicted NSI pheno¬
type is not inconsistent with the results of previous studies.
Variants with predicted NSI phenotypes were frequently de¬
tected in several published analyses of viral sequences in vivo,
in many cases from patients with advanced HIV-related dis¬
ease (16, 28, 33, 37, 51, 56, 62, 67, 80, 81, 86), although their
frequency relative to SI variants varies considerably between
patient groups. Sequence comparisons of the V3 loop of
FIG. 6. Phylogenetic analysis of sequences in the pl74'"'i gene of the study patients, and comparison with V3 loop sequence diversity. (Left
panel) Phylogenetic relationships represented by a rooted tree, with the HIV-1 subtype D sequence ELI as an outgroup. O, study patients; 9. other
HIV-infected Edinburgh patients. (Right panel) Majority amino acid sequence from PBNCs (P) or lymph node (L) of samples from study patients
in the V3 loop; only differences from the subtype B consensus sequences (40) are shown (see legend to Fig. 2).
FIG. 7. Morphology and immunocytochemical detection of p24 antigen in lymphoid and nonlymphoid tissue, (a) Lymph node of patient 2
(asymptomatic) at low magnification (X31); hematoxylin and eosin stain. Normal germinal centers are set in the lymphocyte cortex (arrows), (b)
High-magnification (X193) view of the same lymph node stained for p24 antigen, showing association of viral protein with follicular dendritic cells,
(c) High-magnification view of section of frontal lobe of the brain from patient 5, stained for p24 antigen, showing prominent virus expression in
giant (syncytial) cells (nuclei indicated by arrows; X308). (d) Same case showing p24 positivity in cells of microglial morphology (arrows; X193).
(e) Section of lung from patient 4 showing frequent macrophage syncytia (arrows) in lung alveoli filled with mononuclear macrophages and edema
6000
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sequential samples collected upon disease progression often
show a change from a predicted NSI to SI phenotype (80),
although there is no evidence for a complete replacement. For
example, in an HIV-infected hemophiliac monitored over a
period of 6 years, V3 loop sequences were NSI in early
infection and became predominantly SI between 4 and 5 years
after infection but subsequently reverted to an apparent NSI
phenotype (28, 69).
The observed restriction in sequence variability of the V3
loop can be plausibly accounted for by strong selection against
sequence change in this region, although with some tolerance
of certain amino acid replacements at specific sites (28, 51).
The mechanism of selection for these variants remains obscure
(see below), but it is significant that exactly the same restriction
in sequence diversity in the V3 loop in variants associated with
primary infection has been observed in vivo (38, 85, 87).
In vitro phenotype of HIV. Although we have not been able
to confirm the phenotype of the postmortem variants experi¬
mentally, direct evidence that variants found in the CNS were
indeed MT has been reported by others (9, 33). In one study,
it was found that almost all isolates derived from the cerebro¬
spinal fluid from a range of asymptomatic and symptomatic
individuals were capable of efficient replication in primary
macrophage culture (33); these variants showed V3 loop
sequences with low charge and little divergence, if any, from
the subtype B consensus.
Most of the published sequences of SI variants used for
sequence comparisons were derived from isolates of HIV-1
that were often passaged extensively in cell culture prior to
biological characterization. It is possible that whatever selec¬
tive constraint restricts sequence diversity in vivo is absent in
the conditions used for virus culture and that the virus is
therefore free to drift away from the subtype B consensus
sequence. It is also possible that a V3 (or V2) loop with a large
positive charge confers a growth advantage in vitro, leading to
the selective isolation of variants bearing such divergent se¬
quences from a heterogeneous in vivo population. Indeed, the
isolation of SI variants from patients progressing to AIDS is
associated with increased virus load and therefore with a
greater likelihood that such extreme variants might by chance
be present in the initial PBMC culture.
Changes in the properties of isolates upon in vitro passaging
are commonly observed. Repeated passaging enables HIV to
adapt to efficient replication in different cell types, including
permanently transformed T-cell lines. It has also been shown
that in vitro culture leads to a rapid loss of sequence variability
in the env gene (39) and often to the replacement of the
predominant in vivo variant with a minor population (37, 39,
50). Indeed, specific outgrowth of SI variants has been found
upon short-term primary lymphocyte culture of PBMCs with
V3 loop sequences that could be predicted to be mainly
NSI/MT (37, 47a, 61). These data are consistent with the
hypothesis that the overrepresentation of SI isolates from
patients with AIDS compared with their frequency in vivo is at
least in part the direct result of their competitive advantage
over NSI/MT variants in certain in vitro culture conditions and
therefore does not necessarily reflect their prevalence in vivo.
Other lentiviruses such as HIV-2 and several of the simian
immunodeficiency viruses (SIV) have envelope proteins with
many structural similarities to HIV-1 gpl60. In particular, it is
possible to identify the homologs of the V1/V2 and V4
hypervariable regions in these different viruses. One puzzling
feature has been the low degree of sequence variability in the
counterpart of the HIV-1 V3 loop in HIV-2 and SIVmac (1, 7,
66). The results in this paper suggest that the designation of V3
as a hypervariable region may have been unduly influenced by
the characteristics of cultured isolates of HIV-1 and may not
reflect the relative homogeneity of sequences in this region in
vivo. The similarities between HIV-1 and other lentiviruses
may be greater than were previously imagined.
In vivo phenotype of HIV. The sensitive and specific detec¬
tion of actively replicating virus in cells by immunocytochem-
ical staining for p24 antigen provided an opportunity to
identify the main target cells of the sequence variants identi¬
fied in this study in vivo and their associated cytopathology.
The only infected cells that could be identified by this tech¬
nique were tissue macrophages in the lung and either macro¬
phages or microglial cells in the CNS. This macrophage
infection was associated with tissue damage and with frequent
giant cell formation.
In contrast, infected cells in the lymph node were not
detected despite the detection of high frequencies of proviral
sequences in DNA extracted from lymphoid tissue in both
presymptomatic patients and those with AIDS. These findings,
however, are consistent with previous reports of extensive but
latent infection in lymphoid tissue (14), which were based upon
the finding that the number of provirus-bearing cells within a
lymph node greatly exceeded the number of those in which
viral RNA sequences could be detected (58). Proviral loads
calculated in this study and in others using similar techniques
(58) range from 102 to 2 X 104 copies per 106 cells. These
figures are not inconsistent with the reported high frequencies
of provirus-bearing cells detected by in situ PCR (14, 15), as
the former figures are for total lymph node DNA, which
includes nucleic acids from cells not susceptible to HIV
infection (B cells, follicular dendritic cells, cells within connec¬
tive tissue, etc.).
The reason why HIV infection is largely latent in lymphoid
tissue remains unclear. One possibility is that the DNA de¬
tected by PCR is partially reverse-transcribed provirus pro¬
duced within extracellular virions (45, 75, 84). Alternatively,
the DNA may be in the form of intracellular (cytoplasmic)
partial transcripts previously observed in vitro upon exposure
of HIV to cells that are nonpermissive for infection (21, 82,
83). As first-strand synthesis of provirus proceeds from the 3'
end of the genomic RNA, transcripts for the 3' long terminal
repeat and env should be relatively more abundant than
transcripts of the pol and gag genes, as has been documented in
vitro (82, 84). However, in this study careful quantitation by
limiting-dilution PCR with nested primers showed no differ¬
ence in the relative frequencies of V3 and pol region se¬
quences, irrespective of whether the samples were from tissue
of lymphoid or nonlymphoid origin (Tables 1 and 2; Fig. 1);
this suggests strongly that the sequences detected and se¬
quenced in this study originated from complete proviruses.
HIV tropism in vivo. We were unable to differentiate
variants in this study in terms of SI/NSI phenotype, as all
showed similar low charge and high degree of sequence
conservation in the V3 loop. However, it was evident that
differences existed in the populations of variants infecting
fluid (X77). (f) High-magnification ( X193) view showing p24 antigen-expressing syncytia in the walls of alveoli, (g) Section of lung from patient
5 showing prominent lymphocytic infiltration (arrow) and containing carbon debris. The lung alveoli are partially filled with edema fluid (X77).
(h) Distribution of p24 antigen within lung lymphoid tissue (arrow), similar to that observed in lymph nodes and spleen tissue.
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different organs. For example, no patient showed equivalent
distributions of variants in the CNS and in lymphoid tissue.
Although it is possible to document rapid turnover of env
sequence variants with time in plasma of FllV-infected indi¬
viduals (69, 79), little if anything is understood about the
dynamics of sequence change outside the peripheral circula¬
tion. In particular, it is not known if separate populations of
HIV develop in isolation from variants in other parts of the
body (local evolution) or whether there is a process of contin¬
uous infection and spread from variants circulating in the
blood (systemic evolution). Local evolution in nonlymphoid
tissues might follow the widespread dissemination of HIV
upon primary infection and persist at a low level (undetectable
by PCR or by immunocytochemical staining) throughout the
asymptomatic phase of infection because of cytotoxic T-cell
activity or other immune effector mechanisms. This restriction
on virus replication would become increasingly ineffective
upon progression; the reactivation of virus replication in
nonlymphoid tissue would form the basis for the previously
observed redistribution of HIV in patients with AIDS (5, 13).
In this model, different populations would develop in different
tissues, through evolutionary drift and possibly through specific
adaptive changes for replication in different cell types.
However, a consistent feature of the sequence distributions
in this study and in others was the dispersed nature of many of
the variants. For example, for many of the study patients, the
major components of populations in brain and other nonlym¬
phoid samples were often found as minor variants in lymphoid
tissue (and vice versa), suggesting repeated traffic of virus
between the two in patients who were severely immunosup-
pressed. These findings are more consistent with the hypoth¬
esis of systemic evolution of HIV, in which virus variants
disseminate freely throughout different tissues in the later
stages of infection and restrict the development of local
populations.
One method of virus spread documented in this paper is by
lymphocyte infiltration of a tissue. In patient 5, the high
proviral load detected by quantitative PCR resulted from the
formation of differentiated lymphoid tissue within the lung and
was associated with the presence of a virus population which
was indistinguishable from that in lymph nodes and spleen
tissue. In contrast, widespread dissemination of infected mac¬
rophages most plausibly accounts for the sequence similarity
between variants infecting lung, colon, and brain tissue in
patient 4, since the sequence identity of the V3 loop would be
unlikely to have arisen by chance at several sites in the body, as
would be necessary in the local model of evolution.
What remains unclear is whether variants associated with
infected macrophages are functionally distinct from those
found in lymphoid tissue. We are currently investigating this
question through further sequence comparisons of different
parts of the env gene, and through in vitro characterization of
isolates derived from lymphocyte- and macrophage-infiltrated
tissues.
This study provides no information on the possible origins or
fate of syncytium-inducing variants of HIV that are frequently
isolated upon disease progression. In this study, not only did
we fail to detect variants with a predicted SI phenotype in the
patients with AIDS, but the observed behavior of HIV in vivo
consistently differed from that observed with cultures. Immu¬
nocytochemical staining for p24 antigen in the CNS (and lung
tissue) of the patients with AIDS revealed cytopathic infection
of macrophage/microglial cells by variants with a predicted NSI
phenotype. These findings suggest that in vivo observations of
giant cell formation are not reproduced by infection of cell
lines such as MT-2. Furthermore, the ability of HIV to infect
macrophages is not lost with disease progression as was
previously suggested (10, 63). Indeed, the findings in this paper
appear more consistent with previous findings that progression
is accompanied by a change in the phenotype of isolates to SI
variants that retain an ability to replicate in primary macro¬
phage culture (8).
Independent evidence for the importance of macrophage
tropism in pathogenesis has been obtained from observations
of a more rapid CD4+ lymphocyte depletion in SCID-Hu mice
infected with an MT variant than in those infected with SF-2
(53). In another animal model, the lack of disease progression,
the stable CD4+ count, and the low circulating virus loads in
chimpanzees infected with HIV-1 were attributed to a species-
specific inability of HIV to infect chimpanzee macrophages
(65). Directly or indirectly, the investigations described in this
communication may contribute to our understanding of the
mechanism by which T cells become depleted, the influence of
macrophage infection, and the role of infection in the lymph
nodes and spleen. These questions are essential for under¬
standing the pathogenesis of HIV infection but are currently
unresolved.
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